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2. Abbreviations 
2-DG 2-Deoxyglucose 
3-MTPPA 3-(4-Methylthiophenyl)propylamine 
4-PBA 4-Phenylbuthylamine 
5'-AMP Adenosine 5'-Monophosphate 
AC Adenyl Cyclase 
ACC Acetyl-CoA Carboxylase 
Acetyl-CoA Acetyl-Coenzyme A 
ACS Acetyl-CoA Synthase 
AGE Advanced Glycation Endproduct 
AMPK AMP-activated Protein Kinase 
AO Amine Oxidase 
AOC3 This gene codes SSAO 
APJ 7 transmembrane domains receptor of apelin 
AR Amplex Red 
ATGL Adipocyte Triglyceride Lipase 
ATP Adonosine Triphosphate 
AUC Area Under the Curve 
B6V10 Benzylamine-Vanadate complex salt by Gene Medica 
BSA Bovine Serum Albumin 
BzA Benzylamine 
cAMP Cyclic Adenosine Monophosphate 
CAO Copper Amine Oxydase 
cd31 Adipocyte differentiation marker 
cd45 Leucocyte marker 
cGMP Cyclic Guanosine Monophosphate 
CRP C-Reactive Protein 
CTRL Control 
DAG Diacyl-glycerol 
DAO Diamine Oxidase 
db -/- Mice having null mutation for db gene 
db -/? Heterozygotes and mice having null mutation 
db -/+ Heterozygote mice for db gene mutation 
DG Diglyceride 
DNA Deoxyribonucleic Acid 
ECD Endothelial Cell Dysfunction 
ECM Extracellular Matrix 
eNOS Endothelial NOS 
ER Endoplasmic Reticulum 
ERK1/2 Extracellular signal-regulating Kinase 
F 4/80 Adipocyte differentiation marker 
FAD Flavin Adenine Dinucleotide 
FAS Fatty Acid Synthase 
FATP FFA transporter 
FFA Free Fatty Acid 
GAPDH Glycerynaldehyde-phosphate Dehydrogenase 
Gi Inhibiting G-protein 
GLUT-1 Glucose Transporter-1 
GLUT-4 Glucose Transporter-4 
GPCR G-protein Coupled Receptor 
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Gs Stimulating G-protein 
H2O2 Hydrogene peroxide 
HbA1c Hemoglobine A 1C 
HFD High Fat Diet 
HOMA index Homeostasis Model Assessment Index 
HSL Hormone Sensitive Lypase 
IKK Inhibitor KappaB Kinase 
IL-6 Interleukine-6 
Ins Insulin 
INWAT Intra-abdominal White Adipose Tissue 
IPGTT Intraperitoneal Glucose Tolerance Test 
IRS-1 Insulin Receptor Substrate 1 
IRS-2 Insulin Receptor Substrate 2 
IRS-3 Insulin Receptor Substrate 3 
Iso Isoprenaline 
JNK Janus Kinase 
Km Michaelis-Menten konstant 
KO AOC3 Knock Out for AOC3 gene 
LO Lysyl Oxidase 
LPL Lipoprotein Lipase 
LTQ Lysine Tyrozylquinone 
Malonyl-CoA Malonyl-Coenzyme A 
MAO Monoamine Oxydase 
MAPK MAP-Kinase 
MG Monoglyceride 
MG Methylglyoxal 
MGL Monoglyceride Lipase 
MRI Magnetic Resonance Imaging 
NC-IUBMB 
Nomenclature Comittee of the International Union of Biochemistry and Molecular 
Biology 
NO Nitric Oxide, Nitrogen Monoxide 
NOS NO Synthase 
NS Not Significant 
OH • Hydroxyl Radical 
PAGE Polyacrlyamide Gel Electrophoresis 
PAI-1 Plasminogen Activator Inhibitor 1 
PAO Polyamine Oxidase (FAD-containing AOs) 
PBS Phosphate Buffer Saline 
PDE-3B Phosphodiestherase 3B 
PGWAT Perigonadal White Adipose Tissue 
PI-3 kinase Phosphatidyl Inositol 3 Kinase 
PKA Protein Kinase A 
PKB Protein Kinase B 
PKC Protein Kinase C 
PRWAT Perirenal White Adipose Tissue 
RNS Reactive Nitrogen Species 
ROS Reactive Oxygen Species 
SCWAT Subcutaneous White Adipose Tissue 
SDS Sodium Disulphide 
SOCS Supressors Of Cytokine Signaling 
SOD Superoxide Dismutase 
SSAO Semicarbazide Sensitive Amine Oxydase 
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STAT Signal Transducers and Activators of Transcription 
STZ Streptozotocin 
TBS TRIS Buffer Saline 
TBST TRIS Buffer Saline Tween 
TE TRIS EDTA Buffer 
TGs Triglycerides 
Tie 2 Endothelial cell differentiation marker 
TNF-α Tumor Necrosis Factor α 
TPQ Topaquinone 
UCP Uncoupling Protein 
GlcNAc N-Acetyle Glucoseamine 
V Vanadate 
VAP-1 Vascular Adhesion Protein 1 
VHFD Very High Fat Diet 
VLDL Very Low Density Lipoprotein 
Vmax Maximal Reaction Velocity 
WAT White Adipose Tissue 
WT Wild Type 
α2-AR α2-Adrenergic Receptor 
β-AR β-Adrenergic Receptor 
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3. Introduction 
The number of obese individuals increases worldwide, leading to consider 
obesity as a global epidemic. It has been estimated that, in 2005, approximately 1.6 
billon adults were overweight and more than 400 million adults were obese. Nowadays, 
around 15 % of the world’s population is overweight or obese, according to the 
International Association for the Study of Obesity (website: http://www.iaso.org). 
Obesity is recognized as a major risk factor for type 2 diabetes, cardiovascular diseases, 
non-alcoholic fatty liver diseases and certain types of cancers. Insulin resistance 
(namely the deficiency of response to insulin, leading to very blunted glucose uptake 
into cardiac or skeletal muscles and adipose tissues) is a metabolic disturbance that 
firmly links excess of white adipose tissue (WAT) with the obesity-related 
complications. 
When considering the number of diabetic patients, type 1 diabetes represents a 
minor part, approximately 10% of all patients with diabetes. However, taking into 
account that these patients suffer from their disease from early on in their lives, they 
also merit serious attention because of late complications. Today's modern lifestyle with 
greatly reduced physical activity resulted in the increasing number of obese and thus 
insulin-resistant subjetcs, also among type 1 diabetic patients. Moreover, diabetic 
patients have very high risk for vascular complications. Therefore new therapeutic 
targets to mimic the effetcs of insulin, but acting independently of insulin are of great 
interest. 
Some biogenic amines are well-established neurotransmitters, having a key role 
in central appetite regulation. Other amines are modulators or pertubators of neuronal 
functions, not only in mammals but also in insects or crustaceans where they are 
naturally present. They are also abundant in plants as products of secondary 
metabolism. Therefore, foods (meat, fish, vegetables), food additives or various 
medicinal plants that are world-wide ingested bring substantial amounts of alimentary 
amines. Once ingested, these dietary amines are mainly metabolised by amine 
oxidation. In spite of a great amount of amines metabolized in the gut, some of them 
may reach the circulation and affect different peripheral or central receptors or may also 
be degraded by different enzymes. 
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Benzylamine (BzA), a synthetic exogenous amine, has never been used in 
clinical studies or proposed as nutraceutic by para-medical companies, but has been 
recently described that it is capable to reduce hyperglycemia in diverse animal models 
of diabetes. The effect of this amine can be extended to diverse amines which are 
substrates of monoamine oxidases (MAO) and mainly of semicarbazide sensitive amine 
oxidases (SSAO). Since the enzymes MAO and SSAO are abundantly expressed in 
adipose tissue, this anatomical location is a key feature in the action of BzA and other 
amine oxidase (AO) substrates. Further studies are necessary before extraplolating to 
man the promising anti-hyperglycemic effects of this family of agents. 
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3.1. Amine oxidases 
AOs are widely used by both autotrophic and heterotrophic life forms. They 
catalyse the metabolism of different mono- and polyamines. Their physiological 
importance is still not entirely understood, though their investigation grew more and 
more intensive in recent years. Their substrates are endogenous or exogenous, both 
decomposing by oxidative deamination that can be described by the following equation: 
R-CH2-NR’R”  +  O2  +  H2O   →   R-CHO  +  H2O2  +  R’R”NH 
During the process aldehyde, hydrogen peroxide and an amine or ammonium (in 
case of a primary amine) are formed. AOs can be classified by the chemical structure of 
their substrates: monoamine oxidases (MAOs), diamine oxidases (DAOs), polyamine 
oxidases (PAOs) and lysyl oxidases (LOs). 
Table 1. Classification of amine oxidases. Adapted from Jalkanen et al., 2001. For abbreviations see the 
text. 
 
Amine oxidases (AOs) 
FAD-containing AOs CAOs 
MAO PAO renalase DAO SSAO RAO LO 
Cofactor FAD FAD FAD TPQ TPQ TPQ LTQ 
Coding 
human 
gene 
MAO-A, 
MAO-B, 
chromosome 
X 
  
AOC1, 
chromo-
some 17 
AOC3, 
chromosome 17 
AOC2, 
chromosome 
17 
LOX1-4, 
chromosome 10 
Presence mitochondria intracell. soluble intracell. extracell., 
soluble 
extracell. extracell. 
Substrates 
noradrenaline
dopamine 
adrenaline 
β-phenylethyl
-amine 
tyramine 
tryptamine 
BzA 
octopamine 
spermine 
spermi-
dine 
nor-
adrenaline 
dopamine 
adrenaline 
putrescine, 
cadeverine 
histamine 
BzA, 
methylamine 
aminoacetone 
β-
phenylethyl-
amine 
tryptamine 
p-tyramine 
lysine 
Inhibitors 
pargyline 
clorgyline 
selegyline 
carbonyl 
reactive 
agents 
not known 
semi-
carbazide, 
hydroxyl-
amine 
semicarbazide, 
hydroxylamine 
semi-
carbazide 
semicarbazide 
hydroxylamine 
Effect 
neuro-
transmission 
cell 
growth 
cardiac 
function, 
blood 
pressure 
Histamine-
degradation 
cell division 
amine 
oxidation, 
glucose uptake, 
leucocyte- 
adhesion 
not known forming of ECM 
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The traditional classification of AOs divides them into two main groups, based 
on the chemical nature of the attached cofactor (Table 1.). The FAD- and topa-quinone 
containing (TPQ) AOs not only differ in their cofactors, but are also distinct in terms of 
their subcellular distribution, substrates, inhibitors and biological functions. A third 
classification based on the enzyme reaction is proposed by the Nomenclature 
Committee of the International Union of Biochemistry and Molecular Biology (NC-
IUBMB). 
The flavin adenine dinucleotide (FAD)-contaning enzymes are also classified as 
amine:oxygen oxidoreductase (deaminating) EC 1.4.3.4 by NC-IUBMB: 
MAO-A and –B are well known mitochondrial enzymes that have firmly 
established roles in the metabolism of neurotranssmitters and other biogenic amines 
(Shih et al., 1999). 
FAD-containing PAOs use secondary amines spermine and spermidine as their 
preferred substrates, and thereby possibly regulate cell growth (Seiler, 1995). 
Renalase is the most recently found FAD-containing AO (Xu et al., 2005). It is 
released by the kidney, oxidises chatecholamines and regulates cardiac function and 
blood pressure, however independently of its enzyme ctivity (Boomsma et al., 2007). 
The TPQ containing enzymes are collectively designated as SSAOs due to their 
characteristic sensitivity of inhibition by a carbonyl-reactive compound, semicarbazide. 
They were also cited as copper amine oxidases (CAOs), however NC-IUBMB has 
recently divided them to EC 1.4.3.21 - primary-amine: oxygen oxidoreductase 
(deaminating) and EC 1.4.3.22 -histamine:oxygen oxidoreductase (deaminating). 
The TPQ-containing enyme DAO prefers diamines putrescine, cadaverine and 
histamine as its substrate. Diamine oxidase is mainly an intracellular enzyme 
preferentially synthetised in the placenta, kidney and intestine. The secreted form binds 
in a heparin-dependent manner to endothelial cells. It is important in regulating 
infammation and allergic reactions. 
The other SSAOs are mostly soluble or expressed on the cell surface, have 
methylamine, aminoaceton, BzA as substrates, are insensitive or only weakly sensitive 
to classical MAO inhibitors, like clorgyline or deprenyl, and mediate different 
biological functions. 
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The retina specific amine oxidase (RAO) is a cell surface enzyme, present in the 
retina. It prefers β- phenylethylamine, tryptamine and p-tyramine as substrates. Its 
proper function is yet to be understood (Imamura et al., 1997; Kaitaniemi et al., 2009). 
LO, another copper containing enzyme is also inhibited by SSAO inhibitors, but 
only to a limited extent, compared to other SSAOs. Its classification is still disputed, 
hence there are several points where it differs from other SSAOs: its structure misses 
some conservative motifs and its cofactor lysine tyrozylquinone (LTQ) is also slightly 
different. The ε-amino groups are its excellent substrates. It is able to establish cross-
links between collagen and elastin during the formation of the extracellular matrix 
(ECM) (Smith-Mungo et al., 1998). It is also classified as EC 1.4.3.13-protein-L-
lysine:oxygen 6-oxidoreductase (deaminating). 
3.1.1. Semicarbazide-sensitive amine oxidases 
SSAOs are widely present in nature: they are expressed by plants, 
microorganisms, animals and men. SSAOs convert primary amines to aldehydes (the 
only exception is histamine). During the process the concomitant hydrogen peroxide 
and ammonium are formed. There are two mammalian isoforms known: the membrane-
bound and soluble (plasma) isoforms. The majority of the tissular SSAOs can be found 
in the vascular walls, particularly in smooth muscle, but endothelial cells, adipocytes, 
chondrocytes, fibroblasts, the retina, the sclera, the kidney, the spleen, the placenta and 
the bone marrow also show membrane-bound SSAO activity. 
TPQ containing SSAOs were discovered some decades ago. The enzyme was 
cloned and its primary structure was determined. The results were surprising: the 
structure was identical with that of another protein, mapped before, the vascular 
adhesion protein (VAP-1) (Smith et al., 1998). The deaminating enzyme activity was 
also proven in case of the VAP-1 and it also turned out that its distribution in the body 
is also similar to other SSAOs. 
Genes and protein structure 
Most SSAOs are dimeric glycoproteins with molecular masses of 140-180 kDa, 
containing two atoms of copper per dimer (Klinman et al., 1994; Lyles, 1996). An 
unknown amino acid 6-hydroxydopa (2,4,5-tridydroxyphenylalanine quinone or TPQ) 
was identified (Janes et al., 1990; Klinman, 1996) being the cofactor. TPQ is generated 
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from an intrinsic tyrosine molecule by a self-processing event that only requires bound 
copper ion and molecular oxygen (Mu et al., 1992). 
SSAO enzyme has been cloned from several species: cow (Klinman et al., 1994; 
Mu et al., 1992), mouse (Bono et al., 1998a; Bono et al., 1998b; Moldes et al., 1999), 
rat (Morris et al., 1997; Ochiai et al., 2005), human (Smith et al., 1998; Zhang et al., 
1996). At the moment full length cDNA sequences are available from seven mammalian 
SSAOs. The human SSAO contains 762 amino acids. 
The products of two genes AOC3 and AOC4 have been identified to be 
responsible for SSAO activity. In man AOC3 and AOC4 are situated in cluster with 
AOC2, the gene coding the RAO, all in the long arm of chromosome 17. AOC3 gene 
codes membrane-bound SSAO. So far it is not clear if soluble SSAO is derived from 
AOC3 or it is encoded by a separate gene. The large extracellular part of the SSAO 
protein was shown to be released by proteolytic cleavage from endothelial (Stolen et al., 
2004b), vascular smooth muscle (Göktürk et al., 2003), liver endothelial cells or 
adipocytes using transgenic and cell culture models (Abella et al., 2004; Stolen et al., 
2004b). At least it is the case in humans and rodents where plasma SSAO activity is 
very low compared to other mammalian species like cow, dog or pig. In pig, the product 
of AOC4 gene, situated in a cluster with AOC3 was found to be responsible for such 
high plasma SSAO activity (Schwelberger, 2006). The mature protein derives from the 
primary translation product by cleavage of a 19 or 22 amino acid signal peptide and 
addition of N-linked carbohydrate residues. However, in human AOC4 a single base 
change converts a codon for a conserved tryptophan at position 225 to a stop codon thus 
leading to a truncated and non-functional protein (Schwelberger et al., 2008). It is 
intriguing that a functional AOC4 gene is also present in cow and dog, which, similary 
to the pig, have a high serum SSAO activity, whereas humans and rodents, which have a 
defective or absent AOC4 gene, respectively, have only a very low serum SSAO 
activity. Proteolytic AOC3 gene product release may also contribute to a minor part of 
plasma SSAO activity in cow, dog and sheep. 
Conserved regions of the protein 
Although we know that SSAOs are not exacly the same depending on the 
species, the isoform (membrane-bound or soluble) and even the age, there are regions 
that are the same regardless of these factors. 
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Figure 1. Conserved regions of SSAO protein. Adapted from Jalkanen 2001. 
It has been proven that the active site of the enzyme remained practically 
unchanged during the evolution (Klinman et al., 1994). Figure 1 shows the conserved 
main caracteritics: 
 The protein consists of 763-765 amino acids, 90 kDA, foming a homodimer 
where the subunits are attached in a bond disulphur. 
 5 amino-acids at N terminal part are positioned intracellular and a 
transmembrane domain, which is a secretion signal is to 5-20 amino acids from 
N terminal part. 
 The carbon atom has been shown to be in the second position of TPQ is situated 
6 Å away from the Cu2+ ion. 
 There is a Asn-TPQ-Asp/Glu-Tyr sequence in the active site of the enzyme. 
 Tyr is situated at 470 or 471 amino acids from N terminal which is post-
trancriptionally modified to TPQ. 
 The protein contains three conserved histidine-binding Cu2+ ion (there is a His-
X-His motif situated approximately 50 residues C-terminal from the cofactor 
and the third one 20-30 residues N-terminal from it). 
 Asp is approximately 100 residues N-terminal from TPQ, the catalytic base of 
the deamination in its reductive half-reaction. 
 6 sites of N-glycosilation (Asn) 
 Arg-Gly-Asp motive for binding with integrines. 
Generally, amino acid identity among SSAOs isolated from different species but 
being of the same cellular origin is higher than that of different isoforms of the same 
species. 
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3D protein structure 
Bovine serum amine oxidase was the first mammalian SSAO characterised 3D 
(Lunelli et al., 2005). The 3D structure of human SSAO has recently been described 
(Jakobsson et al., 2005). The SSAO is a homodimer. The TPQ and the Cu2+ ion are 
situated in the active site. The protein is composed of 4 domains: 
 N terminal D1 domain of each monomer is a transmembrane helix. 
 D2-D4 are located extracellularly. 
 The monomers are bound by the D4 domain. 
 Leucine residue (Leu 469) located adjacent to the active site has been revealed 
to function as a gate controlling its accessibility. 
An Arg-Gly-Asp motif is displayed on the surface, where it could be involved in 
integrin binding and possibly play a role in the shedding of SSAO from the membrane. 
Carbohydrate moieties are observed at five of six potential N-glycosylation sites. 
Carbohydrates attached to Asn 232 flank the active-site entrance and might influence 
substrate specificity. 
SSAO substrates  
SSAOs accept primary amines as substrates, although there may be exceptions 
to this rule (like histamine). Nevertheless, different species show a wide variety of 
substrate preferences. Therefore, some caution must be taken when concluding results 
with SSAOs of different species. In 1996, Lyles summarized that BzA, phenethylamine, 
tyramine, dopamine, which are also MAO substrates, tryptamine and histamine are good 
SSAO substrates in rat or human tissue (Figure 2.) (Lyles, 1996). Generally, it would 
appear that SSAO plays only a small role in metabolizing substrates that are also 
oxidised by MAO, although it could be more important when MAO is inhibited, or in 
the rare genetic condition where the MAO genes are deleted (Fitzgerald et al., 2002). 
Although serotonin is not a substrate for SSAO from most sources, it is a good substrate 
for the enzyme from pig and human dental pulp (O'Sullivan et al., 2002). The enzyme 
may also play a role in the metabolism of some xenobiotics, such as mescaline and 
primaquine (O'Sullivan et al., 2004; Tipton et al., 2004). Among all, BzA has been the 
preferred substrate for most SSAOs for a long time. 
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Methylamine Allylamine Aminoacetone
Benzylamine Phenylethylamine Tyramine
Dopamine Triptamine Histamine
 
Figure 2. Well-caracterized substrates of SSAO. 
SSAO also recognises aliphatic amines. Allylamine, an industrial chemical has 
been described to cause serious vascular and myocardial damage in several species 
(Boor et al., 1982; Boor et al., 1979). Vascular SSAO oxidises allylamine to acrolein, 
acting as a distal toxin, (Boor et al., 1987) responsible for the lesions caused by 
allylamine intoxication (Boor et al., 1980). 
 
Figure 3. Role of endogenous substrates in the development of angiopathy. 
Aminoacetone and methylamine do not have affinity to MAOs (Lizcano et al., 
1998). The major source of methylamine is endogenous with contributions from the 
diet. The role of gut microflora, which varies both within and between individuals, in 
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processing several chemicals or food supplements to methylamine or suitable precursors 
should also be considered. Methylamine is produced in several catabolic reactions, 
including the breakdown of adrenaline (catalysed by MAO) sarcosine, creatine, lecithin 
and choline. It is also a common component of some foods and beverages, and is an 
atmospheric pollutant therefore some sources suggested the high levels of SSAO in the 
lung as a protection against inhaled methylamine and other volatile amines (Lizcano et 
al., 1998). Methylamine is also a constituent of cigarette smoke and is considered as the 
major end product of nicotine metabolism. Smoking or nicotine can induce the release 
of adrenaline, which is in turn deaminated by monoamine oxidase, also producing 
methylamine (Yu, 1998b). Plasma levels of methylamine vary between 11.5 and 123.4 
ng/ml (Li et al., 2004), and may be altered in some pathological conditions such as 
diabetes, typhoid fever, and liver or renal insufficiency or uremia (Baba et al., 1984; 
Mitchell et al., 2001). 
Methylamine has in fact been shown to be converted to formaldehyde in vivo by 
SSAO (Yu et al., 1997): 
CH3NH2  +  O2  +  H2O   →   HCHO  +  H2O2  +  NH3. 
The deaminated product formaldehyde is extremely reactive, forming adducts 
with lysyne side chain of proteins and nucleic acids (Gubisne-Haberle et al., 2004). It is 
potentially carcinogenic and is a subject of major environmental concern. Some reactive 
free radicals can be generated from formaldehyde in the presence of hydrogen peroxide: 
2 HCHO  +  H2O2   -»   2 H-*C=O  +  2 H2O. 
Formaldehyde and hydrogen peroxide simultaneously generated from 
deamination of methylamine may act synergistically causing cellular damage (Yu et al., 
2003b). Yu et al. found that methylamine by itself is relatively nontoxic towards 
cultured endothelial cells obtained from both human umbilical vein and calf pulmonary 
artery. It becomes very toxic, however, in the presence of SSAO. In some pathologies 
there is an increased risk for formaldehyde formation and consequent oxidative stress 
(Yu, 1998a; Yu et al., 1998). 
It has been proposed that excessive deamination of methylamine (e.g. due to 
increased occurrence or impaired disposal of the amine) may become a potential risk 
factor responsible for initiation of endothelial injury of diabetic complications (Yu et 
al., 1993) (see in Figure 3.), and probably disorders associated with stress-related 
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behaviour (Yu et al., 1997). The association of nicotine or disease-mediated increase of 
methylamine can contribute to the potential adverse health effects. Selective SSAO 
inhibitors, e.g. MDL-72974A or aminoguanidine, can effectively protect the cells from 
SSAO-methylamine induced damage (Yu et al., 1993).  
Aminoacetone, which may be formed as a result of threonine or glycine 
metabolism, is oxidised by SSAO to form methylglyoxal:  
CH3COCH2NH2  +  O2  +  H2O   →   CH3COCHO  +  H2O2  +  NH3. 
Methylglyoxal (MG) is cytotoxic and mutagenic. Although there are other 
pathways of aminoacetone breakdown, SSAO makes a significant contribution to the 
process (Mathys et al., 2002). MG is suggested to induce formation of oxygen free 
radicals and chemical modification of essential proteins by reacting with arginine, 
lysyne and cystein residues. MG modifies cell proteins non-enzymatically through the 
Maillard reaction, in which aldehydes and ketones react with ε-amino groups of lysine 
residues and guanidino groups of arginine residues resulting in stable chemical adducts 
in proteins known as advanced glycation end products, or AGEs (Monnier et al., 1992). 
AGEs have been implicated in diverse long-term complications of diabetes, including 
atherosclerosis, retinopathy, nephropathy, and cataract formation. Because MG appears 
to be a major precursor of AGEs in vivo (Brownlee, 2001), any reaction that increases 
MG levels in tissue or plasma could ultimately lead to these complications.  
There is a growing number of evidence proving the existence of in vivo SSAO-
dependent oxidation of amonoacetone and methylamine: 
 Urinary formaldehyde was in correlation with plasma SSAO activity when 
testing different mouse models (Yu et al., 1998). 
 Methylamine and aminoacetone administration resulted in higher urinary 
excretion of formaldehyde and methylglyoxal in diabetic rats (Deng et al., 
1998). 
 Increased urinary levels of methylamine were found following SSAO inhibition 
in different rodent models (Yu et al., 1998). 
 Some studies report an increase of urinary excretion of methylamine following 
administration of nicotine or creatine and the subsequent production of 
formaldehyde and cross-linkage with tissue constituents (Poortmans et al., 2005; 
Yu, 1998b). 
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Figure 4. Novel subtrates identified after Dunkel et al., 2008 and Yraola et al., 2009. 
The characterisation of the 3 D structure of the protein promoted the chemical 
design of new SSAO substrates. Homology modeling of the catalytic site of the mouse 
SSAO was performed by the group of Marti and pharmacophoric motif based on BzA 
was constructed (Marti et al., 2004). Their model resulted in 5 substrates having 
arylalkylamine or aminomethyl-pyrrolidine structure. Yraola has then published 
structure-activity relationship of arylalkylamines in human and mouse enzyme 
preparations (Yraola et al., 2006), the best substrates of the screening are illustrated in 
Figure 4. Unzeta and coworkers synthesised 3-(4-methyltiophenyl) propylamine 
(Gallardo-Godoy et al., 2004). 
SSAO inhibitors  
The enzyme is characterised by its sensitivity towards semicarbazide, however, 
this hydrazine derivative has a relatively weak inhibitor capacity. Inhibitors can be 
conveniently subdivided into the main groups of hydrazine derivatives, arylalkylamines, 
propenyl- and propargylamines, oxazolidinones, and haloalkylamines. 
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Table 2. Some important inhibitors of SSAO. 
Pharmacons having SSAO-inhibiting capacity 
chemical 
structure/group Compounds 
SSAO 
inhibition 
MAO 
inhibition other characteristics 
Hydrazine 
Derivatives semicarbazide 
weak (1mM), 
irreversible no inhibits LO and DAO 
aminoguanidine potent, irreversible weak weak NOS inhibitor 
isoniazid Weak (1mM) weak antituberculoticum 
hydralazine 
(neprezole) 
irreversible 
(μM) reversible antihypertensive drug 
phenelzine  irreversible MAO antidepressant 
carbidopa   anti-Parkinson drug 
benserazide   anti-Parkinson drug 
procarbazine 
selective 
reversible 
strong 
no anticancer drug 
LJP-1207 
potent (nM) 
competitive, 
irreversible 
  
Arylalkylamine 
Derivatives 
B24 potent (μM), reversible no  
mexiletine   antiarrythmic drug 
Propenylamines 
MDL 72974A potent (10 nM)   
MDL 72145 potent (10 nM) 
MAO-B 
irreversible, 
competitive 
MAO-A 
anti-Parkinson drug 
candidate 
Propargylamine 
Derivatives 
propargylamine potent (μM), irreversible weak  
β-aminopropionitrile weak (200 μM), competitive reversible LO inhibitor at μM 
Haloalkylamine 
Derivatives 2-bromoethylamine 
potent, 
irreversible no  
Oxazolidinone 
Derivatives MDL 220662 potent (μM)   
Antidepressants 
with different 
chemical 
structures 
imipramine   antidepressant 
maprotiline   antidepressant 
zimeldine   antidepressant 
nomi fensine   antidepressant 
Hydrazinoalcohols 
BTT-2052 potent   
amikacin 
tobramycin 
puromycin 
gentamicin 
  aminoglycoside antibiotic 
 
Of them, aryl(alkyl)hydrazines, and 3-halo-2-phenylallylamines are generally very 
strong SSAO inhibitors. Most of these inhibitors of SSAO have been originally 
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developed for other purposes, or they are simple chemical reagents with highly reactive 
structural element(s); these compounds have not been able to fulfil all criteria of high 
potency, selectivity, and acceptable toxicity. New potent compounds have recently been 
developed with the structures: oxazolidinone; hydrazinoalcohols; 4,5,6,7-
tetrahydroimidazo[4,5-c]pyridines; thiocarbamoyl derivatives; carboxamides and 
sulfonamides; tetraphenylphosphonium analogues; 1,3,4-oxadiazines. There are also 
alternative ways to inhibit SSAO. Some biomolecules with a free NH2 group, such as 
peptides with lysine side-chain, aminohexoses or aminoglycoside antibiotics can 
interact with the enzyme. Function-blocking antibodies to hVAP-1, as well as small 
interfering RNAs could be applied for modulation of the adhesion molecule. There is a 
demand for novel selective and non-toxic inhibitors, which may be useful tools for 
further understanding the roles and function of SSAO. SSAO inhibitors may even be 
valuable substances for the treatment of various diseases (Dunkel et al., 2008; Matyus et 
al., 2004). Table 2. presents the most important SSAO inhibitors. 
The physiological and pathophysiological role of 
semicarbazide sensitive amine oxidases 
The physiological role of SSAOs is not fully understood yet. Until recently it was 
assumed that their most important effect is to decrease the level of monoamines by 
oxidative deamination. The elevated level of the known endogenous substrates, 
methylamine and aminoacetone, is harmful, therefore it seems reasonable to keep them 
under control. Some novel functions of SSAO have been characterised: they may play a 
role in inflammatory processes, in the regulation of the glucose transport of adipocytes 
and in the maturation of collagen and elastin. 
3.1.2. The oxidative deamination  
SSAOs catalyse oxidative deamination of mainly primary amines. The reaction 
consists of two parts. In the first step the enzyme is reduced by the substrate, itself being 
oxidated to the corresponding aldehyde (Figure 5, 1-4). In the second half-reaction the 
enzyme is reoxidated by molecular oxygen with conformant release of hydrogen 
peroxide and ammonium (Figure 5, 5-6). 
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During the reductive half-reaction multiple transition stages exist among others a 
transient but covalent Schiff base is formed, thus substrate is ad interim trapped in a 
covalent bond. During the oxidative half-reaction, the reduced cofactor returns in its 
former oxidised TPQ form, and hydrogen peroxide and ammonium are released.  
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Figure 5. The oxidative deamination catalysed by SSAO. After Matyus et al., 2004. 
Membrane-bound SSAOs  
The biological role of SSAOs, with the exception of LO, has remained enigmatic 
for decades in mammals. In bacteria and yeast, the SSAO reaction provides a source of 
nitrogen (and carbon) when growing. On the other hand the hydrogen peroxide is used 
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for wound healing in plants. In mammals novel functions of SSAO has been revealed 
besides amine oxidation. Although the significance of all SSAO mediated biological 
effects is far from clear. 
Mammals express SSAO in a wide variety of tissues (Jaakkola et al., 1999; 
Lewinsohn, 1984; Lyles, 1996; Salmi et al., 1993). The most prominent synthesis takes 
place in smooth muscle (both vascular and non-vascular) and adipocytes, endothelial 
cells and follicular dendritic cells. Leucocytes, epithelial and fibroblastoid cells lack 
SSAO. Brain is also devoid of SSAO (except microvessels). Unlike in other mammals, 
in man, the protein is also absent from chondrocytes and odontoblasts.  
Membrane-bound SSAOs may be involved in the regulation of glucose 
metabolism in adipose cells, in the regulation of leucocyte trafficking in endothelial 
cells as well as vascular elasticity. 
Glucose metabolism 
SSAO is involved in glucose metabolism in adipocytes and smooth muscle cells, 
with H2O2 being responsible for the effect. The mechanism involves insulin-responsive 
glucose transporter (GLUT-4) translocation to the plasma membrane in fat cells, while 
GLUT-1 accumulation on the surface of smooth muscle cells (El Hadri et al., 2002). 
The involvment of adipocyte SSAO in the glucose metabolism is a major topic of this 
thesis. For more details see chapter 3.2. 
The role of SSAO/VAP-1 in the regulation of leucocyte adhesion  
As mentioned previously, SSAO has been found identical to VAP-1 adhesion 
molecule. SSAO induces cell adhesion and regulates leucocyte trafficking through the 
endothelial barrier. Circulating leucocytes reversibly tether to and roll on the endothelial 
cells under conditions of blood flow as a first step of a well-orchestrated cascade (Salmi 
et al., 1997a). Reception of appropriate activation signals is followed by firm adhesion 
to the vessel wall and transmigration into the tissue by leucocytes. Multiple adhesion 
and activation molecules on the leucocytes and endothelial cells regulate the molecular 
execution of the process (Figure 6.) (Jalkanen et al., 2001). 
SSAO is constitutively present in intracellular granules within endothelial cells 
(Salmi et al., 1993). However, with in vivo inflammation models, SSAO seems to be 
translocated lumenally from intracellular storage granules only upon elicitation of 
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inflammation (Salmi et al., 1997b). SSAO mediates leucocyte subtype specific adhesion 
of CD8+ T-cells, NK-cells and granulocytes. SSAO is also present on sinusoidal 
endothelial cells in liver (McNab et al., 1996). The SSAO molecule seems to be 
important for the rolling phase and most likely later at the transmigration step of 
leucocyte extravasation/transmigration (Tohka et al., 2001). 
 
Figure 6. Role of VAP-1 and other molecules in the extravasation of leucocytes. Adapted from 
Jalkanen 2001. 
The protein was also shown to oxidise BzA and methylamine. Moreover, the 
reactions catalysed by SSAO have been shown to be important in the leucocyte 
adhesion (Salmi et al., 2001b). It is interesting that artificial SSAO inhibitors decrease 
rolling and adhesion of leucocytes by about 50% and anti-VAP-1 antibodies inhibit 
lymphocyte rolling but do not affect enzyme activity. On the other hand products of the 
catalytic reactions, like aldehydes or hydrogen peroxide do not alter the lymphocyte-
endothelium adhesion. Leucocyte adhesion can also be decreased by SSAO substrate 
pretreatment suggesting that during the multistep extravasation cascade there is a 
transitional covalent bond between the enzyme (the endothelial VAP-1) and a 
membrane-bound substrate of leucocyte origin. It is therefore the membrane-bound 
isoform and not the soluble one that plays the important role in the adhesion to the 
endothelial cells. This hypothesis was substantiated by an experiment using a synthetic 
peptide blocking the catalytic cavity of VAP-1. It is possible that surface bound amines 
(like N-termini of proteins, NH2-containing amino acid side chains, amino sugars etc.) 
may be SSAO substrates in addition to soluble amines (Salmi et al., 2001b). Moreover, 
aminosugars, also promoting the adhesion, bind reversibly to SSAO in the presence of 
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H2O2. The enzyme catalysed oxidation of substrates may thus considerably contribute to 
leucocyte binding to the endothelial cell (O'Sullivan et al., 2003; O'Sullivan et al., 
2004). SSAO, in this case an endothelial ectoenzyme, can directly and indirectly 
regulate the leucocyte extravasation. VAP-1 is a dual function molecule: it binds 
lymphocytes to the endothelium and utilises the catalytic reaction between the surface-
bound amine and VAP-1 to transiently link the interacting cells. The VAP-1-catalysed 
reaction may further contribute to cross-linking if the protein-bound aldehydes formed 
on lymphocytes interact with molecules on the endothelial cell surface (Jalkanen et al., 
2001). 
Organisation of the arterial wall 
SSAO may be involved in vascular smooth muscle cell differentiation (El Hadri 
et al., 2002), organization of the extracellular matrix (Vidrio, 2003) and regulation of 
vascular tone (Langford et al., 1999; Langford et al., 2002; Vidrio, 2003). Langford and 
his coworkers have shown that pharmacological inhibition of SSAO induced by 
semicarbazide in a growing rat model led to striking elastic fiber disorganisation. 
Semicarbazide, however, inhibits both SSAO and LO and its effect on collagen cross-
linking is mainly attributed to LO inhibition (Mercier et al., 2007; Mercier et al., 2006). 
Alternatively, it has been suggested that SSAO could influence arterial vascular tone, 
although contradictory results have been reported: Vidrio and his group have proposed 
that SSAO-mediated H2O2 production could increase vascular tone and enhance 
hydralazine-induced vasodilation (Vidrio et al., 2003); In contrast, Conklin et al. have 
recently suggested that SSAO activation by methylamine mediated vasorelaxation in 
isolated human arteries (Conklin et al., 2004). At a molecular level, it is conceivable, in 
view of previous results using molecular modeling (Salmi et al., 2001a) that in addition 
to soluble primary amines, such as methylamine or aminoacetone, SSAO may act on 
amino acids, including matrix proteins. SSAO may, thus, contribute to physiological 
cross-linking of elastic and collagen fibers. Formaldehyde-induced protein cross linkage 
(Gubisne-Haberle et al., 2004) might also be involved in the process. Nevertheless, 
SSAO-deficient mice have normal elastic fiber network, elastin cross-linking processes, 
and vascular endothelial or smooth muscle function (Mercier et al., 2006). These results 
do not support a major role of SSAO in the rodent arterial wall, even if unknown 
compensatory mechanisms may contribute to the phenotype in this model. However, the 
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only detectable alteration in KO AOC3 mice was an increase in carotid diameter, in line 
with a potential involvement of SSAO in arterial growth and/or the pathophysiology of 
aneurysms, as suggested (Langford et al., 1999; Sibon et al., 2004). 
Soluble SSAOs 
Soluble SSAOs may have an important function in several biological 
mechanisms. First of all, increased levels of soluble serum SSAO were found in specific 
diseases, for instance in diabetes and liver diseases. Soluble SSAO may also be 
involved in the production of non-enzymatic addition of oligosaccharides to proteins 
during formation of advanced AGEs, typical of diabetic lesions. Finally, it has been 
proven, that soluble SSAOs also modulate lymphocyte adhesion to endothelial cells, 
presumably by triggering positive signals on the lymphocyte (Kurkijarvi et al., 1998). 
Plasma SSAO activity varies considerably in mammals (Boomsma et al., 
2000b). It is high in species with a functional AOC4 gene and low in humans and 
rodents that lack a functional AOC4 gene. Despite that human plasma amine oxidase 
activity is lower than in tissues, the easier plasma accessibility has resulted in a 
substantial number of clinical reports in various pathologies (Boomsma et al., 2003). 
In healthy adults with BMI ≤ 25, SSAO activity varies in a narrow range. It is 
interesting, that the activity is much higher in children, with a sharp decrease at the age 
of 16 to finally settle at the adult values. There is a slight increase in the activity from 
the age of 50. Enzyme activity is independent from gender, posture (standing, sitting, 
lying) or circadian rhythm. A higher activity can be measured during pregnancy 
(Boomsma et al., 2003). 
Obesity, diabetes and atherosclerosis 
Obesity is not a condition associated with clear-cut increase in plasma SSAO, 
despite adipose tissue has been proposed as a source of soluble SSAO, essentially in 
diabetes (Stolen et al., 2004b). While plasma SSAO clearly increases in diabetic 
conditions, its association with obesity is less consistent (Carpéné, 2009). Therefore, the 
correlation found between plasma SSAO activity and BMI in type 2 diabetic patients 
(Mészáros et al., 1999b) might be the consequence of a parallel increase in insulin 
resistance and adiposity. An elevation in SSAO activity has been found in non-diabetic, 
obese patients and has been proposed as a cardiovascular risk factor (Weiss et al., 
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2003). However, such an association between plasma SSAO and BMI was not 
confirmed by other studies conducted with non-diabetic (Dullaart et al., 2006) or young 
obese (Visentin et al., 2004) subjects. When morbidly obese patients (BMI of 38.8) 
received vertical banded gastroplasty and lost weight after the surgery (BMI lowering to 
30.8), there was only a weak tendency to correlate the individual changes in plasma 
SSAO with the decrease in different anthropometric measurements of adiposity (Li et 
al., 2005). A more substantial increase in plasma SSAO than those reported in the above 
mentioned studies should be expected in obese subjects, regarding to the dramatic 
increase in TNF-α in obesity and owing to in vitro TNF-α stimulation of SSAO 
shedding from adipocytes (Abella et al., 2004).  
High plasma SSAO level was measured in type 1 (Boomsma et al., 1995), type 2 
(Mészáros et al., 1999b), and type 1 juvenile diabetes. This phenomenon has also been 
observed in animal models of diabetes (Hayes et al., 1990). It has been proven that 
oxidative stress is important in the development of diabetic complications. It is assumed 
that diabetic vascular complications are caused partially by elevated blood level of the 
toxic formaldehyde, MG and hydrogen peroxide, all deriving from the SSAO mediated 
oxidative deamination of methylamine and aminoacetone. SSAO activity is elevated in 
patients with diabetic complications such as retinopathy (Garpenstrand et al., 1999; 
Gronvall-Nordquist et al., 2001), hypertension and atherosclerosis (Mészáros et al., 
1999a), therefore plasma SSAO has been suggested to be a possible clinical marker of 
diabetic complications.  
Serum SSAO levels correlate with Crouse score and intima media thickness, 
both reliably marking the progression of atherosclerosis (Mészáros et al., 1999a). 
Experiments done on human umbilical vein showed that SSAO catalyses LDL oxidation 
by endothelial cells (Exner et al., 2001). A more intensive oxidative stress can help to 
progress the disease. Oxidation of LDL increases the atherogenity of the lipoprotein and 
this can hasten the formation of atherosclerotic plaques. 
Other diseases  
Since there is a significant amount of SSAO in the vascular wall, great interest 
has been given to patients suffering from all types of vascular diseases. In patients with 
congestive heart failure plasma SSAO has been found considerably increased 
(Boomsma et al., 2000a) and was in correlation with severity of the disease. According 
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to certain observations, SSAO activity of individuals with essential and renovascular 
hypertension is normal (Lyles, 1996), SSAO levels of patients with chronic renal 
insufficiency are lower compared to controls. There is a very high level in stroke and 
malignant hypertension, which can be a consequence of the cardiac insufficiency. 
SSAO activity is increased in pre-eclampsia (Boomsma et al., 2003) or in cerebral 
autosomal dominant arteriopathy with subcortical infarcts as well as in 
leukoencephalopathy (Ferrer et al., 2002), inflammatory liver diseases (Kurkijarvi et al., 
1998), multiple sclerosis with ongoing inflammatory activity (Airas et al., 2006), 
psoriasis (Madej et al., 2007), atopic eczema (Madej et al., 2006), Alzheimer’s disease 
(del Mar Hernandez et al., 2005), myopathies (Olive et al., 2004) and also bone cancer 
with skeletal metastases (Ekblom et al., 1999). 
SSAO activity is unchanged in Sjögren syndrome or colitis ulcerosa. Decreased 
levels are rare, e.g. in children born with hernia diaphragmatica, in cases of severe 
burns, in different malignomes and in lung cancer, and decreased serum levels have also 
recently been reported in highly depressed (Roessner et al., 2006) and schizophrenic 
patients treated with second-generation “diabetogenic” antipsychotics (a possible link to 
the role of SSAO in glucose metabolism was suggested) (Roessner et al., 2007). 
In pathologies with high plasma SSAO activity some of the enzyme substrates 
are also elevated: methylamine and aminoacetone in diabetes, creatinine in uremia and 
adrenaline in stress-related diseases. It is possible that the substrates mentioned above 
cause the increase of SSAO activity. 
It is not clear how a moderate increase of SSAO activity observed in a number 
of human diseases could possibly cause any damage (Boomsma et al., 2003; Yu et al., 
2003b). However, the increase in released SSAO could just be indicative of an increase 
of the membrane-associated SSAO at the cell surface where the actual damage is done. 
The regulation of plasma SSAO levels is yet to be defined. Although several 
correlations have been set up between plasma SSAO activity and other clinical markers 
like ACE activity (Boomsma et al., 2005b), thyroid hormone (Boomsma et al., 2005a), 
TNF-α, insulin and blood glucose levels, glycated haemoglobin (Dullaart et al., 2006; 
Salmi et al., 2002) etc, only TNF-α and insulin seems to be involved in the regulation of 
plasma SSAO activity. TNF-α promoting insulin resistance, causes an increase in the 
release of SSAO by adipocytes (Abella et al., 2004; Garcia-Vicente et al., 2005). On the 
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other hand insulin appears to hamper shedding from tissues or increase the clearance of 
plasma SSAO levels. Finally, some recent trials showed that acute glucose load itself 
may increase plasma SSAO activity in non-diabetic individuals (Li et al., 2009a; Li et 
al., 2009b). 
3.2. Adipose tissue 
In vertebrates white adipose tissue (WAT) is the primary site of energy storage. 
The lipid droplets of the adipocytes contain mostly triglycerides (TG). When energy 
expenditure exceeds energy intake WAT releases free fatty acids (FFA). WAT is also a 
secretory organ as it produces several adipocytokines permitting self-regulation 
(autocrine effect), a cross-talk with local (paracrine effect) and distant adipocytes and 
other cells in the brain, the liver, the muscles, the pancreas, etc. (endocrine effect) (Kim 
et al., 2000). 
WAT contains different cell types. Only one third of the cells are adipocytes and 
the rest is a mixture of stromal vascular fraction: fibroblasts, macrophages, stromal 
cells, monocytes and preadipocytes. Adipose tissue seems to derive from an embryonic 
stem cell precursor (Pittenger et al., 1999). The development of white adipose tissue 
begins early during embryogenesis and continues throughout life resulting in an 
increase in fat cell size (hypertrophy) as well as in fat cell number (hyperplasia) 
depending on the energy status and the storage needs of the body.  
Fat develops in many different sites and has different functions: subcutaneous 
adipose tissue (SCWAT) is an effective insulating layer located between the muscles 
and dermis while visceral adipose tissue fills in space gaps between organs, like gonads 
(PGWAT), heart, kidneys (PRWAT), or gut, protecting them against mechanical 
impacts and maintaining them in the adequate position. 
3.2.1. Metabolic function 
Lipogenesis 
Figure 7 shows the lipogenic processes grouped on the left hand side. In 
postprandial state adipocytes produce TG. Lipid accumulation in adipose tissue depends 
on circulating FFA and glucose uptake. Fatty acids may be synthesised from 
carbohydrate precursors (de novo lipogenesis). Insulin stimulates glucose uptake by 
30 
stimulating the translocation of GLUT-4 to the plasma membrane. Glucose undergoes 
glycolysis resulting in acetyl-coenzyme A (acetyl-CoA). Acetyl-CoA is transformed to 
Malonyl-CoA by the Acetyl-CoA carboxylase (ACC). Further chain prolongation is 
catalysed by the fatty acid synthase (FAS). In human, only a fraction of the TG stock is 
formed by de novo lipogenesis. Insulin also favours fatty acid uptake from circulating 
lipoproteins by stimulating lipoprotein lipase (LPL) activity. FFAs are released by 
lipoprotein lipase hydrolysing TGs from chylomicrons or VLDLs and are finally taken 
up by FFA transporters (FATP). Be the source of FFAs carbohydrates or TGs, 
reesterification is necessary to form TGs suitable for lipid storage (Vazquez-Vela et al., 
2008). 
 
Figure 7. Major biochemical pathways involved in the regulation of energy homeostasis in the 
adipocyte (Vazquez-Vela et al., 2008). For abbreviations see the text. 
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Lipolysis 
During fasting WAT hydrolyses TGs to supply other organs with FFAs (Figure 
7. right hand side). TGs stored in the lipid droplet are first hydrolysed by the adipose 
triglyceride lipase (ATGL), resulting in diacylglycerol moiety and FFA, then further 
hydrolysed sequentially by the hormone-sensitive lipase (HSL) and monoglyceride 
lipase (MGL) producing FFAs and glycerol. Receptors enhancing cyclic adenosine 
monophosphate (cAMP) formation stimulate lipolysis. β-adrenergic stimulation (Gs) of 
adipocytes and the subsequent protein kinase A-dependent (PKA) phosphorylation of 
HSL and perilipin trigger the translocation of HSL from the cytoplasm to the lipid 
droplet and induce neutral lipid hydrolysis. Opposingly, molecules decreasing 
intracellular cAMP inhibit lipolysis. Insulin induces PDE-3B (phosphodiesterase 3B) 
which degrades cAMP. α2-adrenergic agonists are also anti-lipolytic, as they inhibit 
adenyl cyclase (AC) enzyme activity. 
3.2.2. Endocrine function 
Beyond its essential function in lipid storage and the supply of free fatty acids, 
WAT produces numerous bioactive molecules (lipids or peptides). Among these 
molecules, we can find hormones, like leptin, adiponectin, resistin and apelin (Table 3.). 
Leptin is considered as a metabolic signal for energy sufficiency by directly acting on 
the hypothalamus. Adiponectin enhances insulin-sensitivity, decreases FFA influx, 
increases β-oxidation in liver and muscle. Adiponectin decreases atherogenic risk via 
depressing the expression of adhesion molecules within the vascular wall, as well. 
Resistin acts on skeletal muscle and WAT and its high plasma levels are associated with 
insulin resistance. Apelin increases cardiac contractility, decreases blood pressure and 
hyperglycemia (Dray et al., 2008; Vazquez-Vela et al., 2008). Obesity might reduce 
physiological response of some adipokines (resistance). 
In addition to the above mentioned molecules, adipose tissue also produces and 
secretes a variety of other peptides, cytokines and complement factors, including 
tumour necrosis factor α (TNF-α), interleukine 6 (IL-6), plasminogen activator inhibitor 
1 (PAI-1), angiotensinogen, etc. TNF-α is involved in the pathophysiology of insulin 
resistance via modifying insulin sensitivity which induces abnormal phosphorylation of 
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insulin receptor substrate (IRS)-1. IL-6 comes from the stromal vascular fraction and it 
controls the hepatic production of inflammatory proteins (Antuna-Puente et al., 2008). 
Table 3. Some biologically active molecules of WAT. See abbreviations in chapter 2. 
  Source Receptors Pathway Main effects In obesity 
TNF-α 
adipocytes membrane 
bound and 
soluble 
cytokine 
receptors 
JNK, IKK 
block insulin's action (IRS-
1) 
↑ 
macrophages 
lymphocytes 
IL-6 
fibroblasts 
cytokine 
receptor 
JNK 
induce liver inflammatory 
protein production (CRP) 
↑ 
endothelial 
cells alters tyr phosphatase 
activity and SOCS 
monocytes   
Leptin adipocytes 
long, 
short, 
soluble 
cytokine 
receptors 
JNK/ STAT 
β-oxidation ↑ 
↑ 
RESISTANCE 
UCP expression↑ 
hypothalamus-food intake↓ 
insulin secretion↑ 
Resistin 
adipocytes 
not 
known 
not known 
WAT, skeletal muscle- 
insulin resistance (IRS-2↓) ↑ 
macrophages liver-glycogen synthesis ↑ 
Adiponectin adipocytes GPCR AMPK/MAPK 
liver and skeletal muscle-
insulin sensitivity, β-
oxidation ↑ 
↑ 
RESISTANCE 
hypothalamus-food intake↑ 
Apelin adipocytes GPCR AMPK/PKB 
blood pressure↓ ↑ 
RESISTANCE? blood glucose↓ 
3.2.3. Obesity 
The abundance of nutrients and the decreased physical activity coupled with 
modern western life, result in excessive accumulation of adipose mass. Obesity, the 
excessive storage of energy as fat caused by the imbalance between energy intake and 
expenditure, has become a prevalent health hazard in industrialised countries. 
Disturbed energy balance alters WAT activity especially that of adipocytes or 
macrophages, inducing low-grade chronic inflammation which is supposed to play a 
central role in obesity-linked insulin resistance. Insulin resistance may be featured in 
many pathologies complications such as hypertension, hyperlipidemia, atherosclerosis, 
metabolic syndrome, polycystic ovarian disease, certain cancers, and type 2 diabetes 
mellitus. Especially, increase in visceral fat mass seems to contribute to such 
complications. 
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3.2.4. Hydrogen peroxide 
The majority of the bioactive H2O2 is derived from spontaneous or superoxide 
dismutase-catalyzed (SOD) dismutation of superoxide, a side product of several enzyme 
reactions: mitochondrial electron transport chain, lipoxygenase, cycloxygenase, 
cytochrome P450s, xanthine oxidase, NADPH oxidases, uncoupled eNOS, etc. Some 
other enzymes, like xantine oxidase, glucose oxidase or amine oxidases produce H2O2 
directly. 
H2O2 has long been known to mimic several of insulin’s actions in adipocytes 
(Czech et al., 1974; May et al., 1979). H2O2 acts through insulin signaling: it enhances 
insulin receptor phosphorylation and kinase activity (Hayes et al., 1987) and subsequent 
tyrosine phosphorylation of intracellular proteins. Insulin can induce NADPH oxidase-
dependent H2O2 release, H2O2 thus can be regarded as a second messenger of insulin 
(Mukherjee et al., 1977). The membrane-bound NADPH oxidase is coupled to the 
insulin receptor via a Gi/Go heterotrimeric G protein (Krieger-Brauer et al., 1997) 
regulating insulin action (Moxham et al., 1996).  
Despite its unquestionable biological function, it cannot be denied that H2O2, as 
a reactive oxygen species (ROS), may also have deleterious effects on the cells. As a 
matter of fact, H2O2 is poorly reactive in chemical terms. Its danger comes mainly from 
its conversion into hydroxyl radical (OH•) either in the Fenton or the Haber-Weiss 
reaction. Insulin resistance, as well as its complications have also been associated with 
high levels of H2O2. This might be the consequence of impaired antioxidant systems 
(catalase, glutathione peroxidase) and/or increased ROS production (Eriksson, 2007). 
3.2.5. Expression of SSAO in adipocytes and in white 
adipose tissue 
An increase of SSAO during adipocyte differentiation in rodents has been 
described as early as 1990 by Raimondi and co-workers on cells isolated from the 
stroma-vascular fraction of rat adipose tissue and cultured under adipogenic conditions 
(Raimondi et al., 1990). Afterwards, an impressive increase of SSAO mRNA, protein 
and activity was detected during adipocyte differentiation in the murine lineages 3T3-
F442A and 3T3-L1 (Moldes et al., 1999). More recently, it has been evidenced that the 
product of the AOC3 gene dramatically increases during adipogenesis of human 
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preadipocytes (Bour et al., 2007a) resulting in high SSAO activity in mature adipocytes 
(Bour et al., 2007a; Morin et al., 2001). The increase in SSAO activity found during 
adipogenesis has still a poorly defined role. 
In human adipose tissue, there is no doubt that fat cells exhibit higher levels of 
SSAO than any other cells belonging to the stromal vascular fraction (Bour et al., 
2007a). This observation confirms previous findings made on rat brown adipose tissue 
(Barrand et al., 1984). The very high expression of SSAO in adipocytes has been 
confirmed by independent approaches studying protein expression profile in different 
subcelullar compartments: SSAO has been detected in plasma membrane (Barrand et 
al., 1984), glucose transporter-containing vesicles (Enrique-Tarancon et al., 2000), 
caveolae (Souto et al., 2003) and in diverse microvesicles of adipocytes (Morris et al., 
1997). 
The variations of obesity-induced changes in SSAO expression of WAT are still 
unknown and need further investigation. In the subcutaneous adipose tissue, no change 
in SSAO was found when comparing young obese subjects with age-matched controls. 
(Visentin et al., 2004). Since the visceral, intra-abdominal adipose depots are especially 
involved in the serious complications of massively obese patients, it would be worth to 
obtain information on pathology-related SSAO expression in these tissues, as well. 
Our limited knowledge about the regulation of SSAO in human obesity is hardly 
compensated by animal studies (Carpéné, 2009). An upregulation of the protein has 
been detected in omental adipose tissue of dogs after 9 weeks of high-fat feeding: both 
SSAO mRNA and activity increased. Intriguingly simultaneous upregulation in 
subcutaneous WAT has not been observed (Wanecq et al., 2006). On the contrary, high-
fat diet did not induce changes of SSAO activity or expression in mice (Visentin et al., 
2005). To further complicating the puzzle, a decrease in SCWAT was showed in obese 
Zucker rats (activity and mRNA) (Moldes et al., 1999), as well as a decreased SSAO 
mRNA and increased SSAO activity were found in PGWAT of db-/- animals when 
compared to lean littermates (Cioni et al., 2006). Although, some in vitro experiments 
proposed TNF-α, forskolin and isoproterenol to decrease SSAO activity of adipocytes 
by releasing the protein to the culture medium (Abella et al., 2004; Garcia-Vicente et 
al., 2005; Mercier et al., 2003; Moldes et al., 1999). Among all, only TNF-α has been 
proven in vivo to downregulate SSAO activity in WAT (Mercier et al., 2003). Despite 
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of the proposed regulation by TNF-α, it is still a very hard task to clarify changes in 
WAT SSAO activity in different animal models of obesity. 
3.2.6. Insulin-like actions of SSAO substrates 
The two first papers reporting the insulin-like action of tyramine (Marti et al., 
1998) and BzA (Enrique-Tarancon et al., 1998) in rat adipocytes clearly showed that 
SSAO and MAO activity was responsible for promoting glucose transporter 
translocation and glucose uptake: the synergistic action between SSAO substrates and 
vanadate is due to either extracellularly or intracellularly generated active compounds, 
possibly peroxovanadate. Such active compounds may activate a protein-tyrosine kinase 
or inhibit a protein-tyrosine phosphatase, which in turn causes tyrosine phosphorylation 
of IRS-1 and IRS-3, rapidly interacting with the p85 subunit of PI 3-kinase, crucial in 
insulin-signal transduction. The p85–p110 PI 3-kinase activity is also stimulated 
resulting in GLUT-4 recruitment to the cell surface (Figure 8.). Such activation of a 
protein-tyrosine kinase or inhibition of a protein-tyrosine phosphatase causes a weak 
activation of insulin-receptor kinase (Zorzano et al., 2003). 
Diverse in vitro insulin-like actions were reported for the combination of 0.1-1 
mM SSAO substrates and 0.1 mM vanadate while these agents were without clear effect 
when tested separately (Enrique-Tarancon et al., 2000; Enrique-Tarancon et al., 1998; 
Visentin et al., 2003a; Yu et al., 2004). Enzyme-dependent generation of H2O2 was 
proven to be responsible for such effects. Insuline-like effect of SSAO substrates and 
vanadate was also investigated in vivo: acute injection improved glucose tolerance in 
non-diabetic or diabetic animals, and chronic injection reduced hyperglycemia of 
diabetic animals (Abella et al., 2003a; Marti et al., 2001). 
In some other experiments, effects of BzA were observed even in the absence of 
vanadium. First, in human adipocytes, the insulin stimulation of glucose transport was 
partially reproduced by 0.1-1 mM BzA and methylamine in a manner that was not 
potentiated by vanadate (Iglesias-Osma et al., 2005; Morin et al., 2001). Second, SSAO 
substrates alone induced adipogenesis of the murine preadipocyte 3T3-F442A or 3T3-
L1 cell lines (Carpéné et al., 2006; Fontana et al., 2001). Lastly, lipolysis inhibition, 
another insulin-like action, was observed with methylamine and BzA in human, rabbit 
and mouse fat cells or murine preadipocyte cells without any need for vanadate 
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(Carpéné et al., 2006; Iglesias-Osma et al., 2005; Iglesias-Osma et al., 2004; Morin et 
al., 2001). 
 
Figure 8. The role of SSAO in the regulation of glucose uptake in adipocytes. Adapted from Zorzano, 
2003. 
Most importantly, SSAO substrates exhibited insulin-like actions even when 
responses were studied in vivo. In the conscious rabbit and mice, the single infusion or 
injection of 7 µmol/kg BzA (without vanadate) before a glucose challenge is sufficient 
to lower the hyperglycaemic response, in an SSAO-dependent manner (Iglesias-Osma et 
al., 2004). Furthermore, chronic oral administration of BzA improved glucose-tolerance 
in Wistar rats (Bour et al., 2005). 
3.3. Diabetes induced oxidative stress and 
vasculopathy 
Vascular complications are the main causes of morbidity and mortality in 
diabetic patients (Head et al., 1990; Ruderman et al., 1992). The pathophysiology of 
diabetic angiopathy is complex. Chronic hyperglycemia, characteristic feature of the 
disease, initiates processes responsible for the early functional impairment of the blood 
vessels, the endothelial cell dysfunction (ECD). ECD is characterised by reduced 
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endothelium-dependent vasodilatation, as well as altered anti-coagulant, anti-
inflammatory properties and disturbed barrier function of the endothelium, and is 
recognized as the common initial pathophysiological change in the development of 
diabetic microangiopathy and macroangiopathy. Decreased availability of the 
vasodilator nitric oxide (NO), as well as increased production and action of 
vasoconstrictor agents, such as ROS are suggested to be responsible for ECD 
(Cosentino et al., 1998; Santilli et al., 2004). 
 
Figure 9. Mechanism by which hyperglycemia-induced mitochondrial superoxide overproduction 
activates four pathways of hyperglycaemic damage. After Brownlee, 2001. 
The key event in hyperglycemia-induced oxidative stress is the increased 
oxidative metabolism of glucose, resulting in the overproduction of superoxide anions 
in the mitochondria (Nishikawa et al., 2000), and activation of biochemical pathways 
responsible for the elevated formation of ROS, as well as decreased antioxidant defense 
mechanisms. Excess superoxide partially inhibits the glycolytic enzyme 
glyceraldahyde-phophate dehydrogenase (GAPDH), thereby diverting upstream 
metabolites from glycolysis into pathways of glucose overutilization (Figure 9.). 
Increased glucose flux activates the polyol pathway and excess of fructose-6-phosphate 
transforms to N-acetylglucosamine (hexoseamine pathway). Triose phosphates are 
converted to either diacyl-glycerol (DAG) an activator of protein kinase C (PKC), or to 
methylglyoxal (MG), the main intracellular AGE precursor (Brownlee, 2001; Ceriello, 
2003; Sheetz et al., 2002). 
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The impaired biological effects of NO can be the consequence of its 1.) reduced 
production by NO synthase (NOS), 2.) increased inactivation related mainly to 
oxidative stress, or 3.) decreased responsiveness to its cellular actions. There are 
conflicting data in the literature about the alteration of the expression of NOS isoforms 
and their activity to produce NO in tissues of experimentally induced diabetic animals 
(Honing et al., 1998; Santilli et al., 2004). 
H2O2 causes endothelium-dependent and independent vasodilation of vessels. 
Endothelium-dependent dilatory mechanisms include enhanced eNOS expression via 
PKB or ERK1/2 activation or potassium channel-induced hyperpolarization. Of note, 
endothelium-independent vasorelaxation may involve cGMP activation or other 
currently unknown pathways. H2O2 strongly upregulates eNOS expression in vitro and 
in vivo. On the other hand H2O2 may derive from uncoupled eNOS (Drouin et al., 2007; 
Matoba et al., 2000). The strong interplay between eNOS and H2O2 is involved in the 
physiological adaptation to exercise (Lauer et al., 2005) but may have detrimental 
pathophysiological consequences, as well. 
Some authors propose that ROS production down-regulates endothelial NOS 
(eNOS) expression and activity (Brownlee, 2001; Srinivasan et al., 2004). However, it 
is well established, that metabolic transformation of NO is accelerated during oxidative 
stress. Oxidative stress leads to NOS uncoupling and NO-quenching by excess 
superoxide resulting in peroxynitrite and further reactive nitrogen species (RNS) 
production. These compounds do not have vasoactive properties, but are strong oxidant 
and nitrating agents, thus may damage endothelial cells (Beckman et al., 1990; Pacher 
et al., 2005; Soriano et al., 2001). 
Direct measurement of NO and peroxynitrite production in the tissues is difficult 
because of their reactivity and short half-life. However, the biological availability and 
oxidative metabolism of NO can be estimated by the measurement of its stable 
end-products. Under physiological conditions, nitrite is the primary decomposition 
product of NO, which is further oxidised only in the presence of oxidizing species such 
as oxyhaemoglobin and superoxide (Ignarro et al., 1993). Contrary to NO, peroxynitrite 
and other RNS decompose directly to nitrate (van der Vliet et al., 1995). Tissue level of 
nitrite thus indicates the effectiveness of NO, while the ratio of nitrate to nitrite can be 
used to assess the oxidative metabolism of NO (Kobayashi et al., 2001).  
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The complex interplay of these mechanisms results in a perturbation of the 
physiological properties of NO in the maintenance of endothelial homeostasis, such as 
vasodilation, anticoagulation, leucocyte adhesion, smooth muscle cell proliferation, and 
antioxidant capacity. 
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4. Research Objectives 
My work aimed at studying the insulin-like effect of semicarbazide-sensitive 
amine oxidase (SSAO) substrates on adipocyte metabolism (glucose uptake, lipolysis), 
on in vivo glucose homeostasis and on certain markers of vascular complications 
developing during obesity and diabetes. 
Semicarbazide-sensitive amine oxidase activity is very high in white adipose 
tissue (WAT). It is present at the surface of fat cells and independent approaches have 
evidenced its impressive increase during adipogenesis. However, the factors that might 
regulate the expression of SSAO in adipose tissue are still poorly defined. 
 The first part of my thesis thus investigates the link between adipose tissue 
extension (increased in obesity or reduced during fasting) and SSAO activity 
in the adipose depots of different anatomical location. 
Insulin-like effect of amine oxidase substrates has already been reported in vitro 
as well as in vivo. BzA, a very good substrate of the enzyme, was used for further 
experimental approaches aiming at the better understanding the role of SSAO in adipose 
tissue physiology and in regulation of energy balance. Our questions were: 
 Could the effect of BzA be abolished in adipocytes by the pharmacological 
inhibition or the genetic invalidation of SSAO protein? 
 Is a single injection of BzA able to improve glucose tolerance in mice in 
vivo? 
 How does chronic BzA injection influence markers of vascular complication 
in streptozotocin-induced diabetes? 
 Could the chronic oral BzA administration restore the defective glucose 
handling and vascular complication markers in different mouse models of 
insulin resistance? 
On the basis of previous experiments with BzA on human adipocytes, and owing 
to the anti-hyperglycemic properties of BzA evidenced on the above mentioned models, 
we propose SSAO substrates as possible drug candidates to restore glucose homeostasis 
in adipose tissue. 
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 In this context, we wanted to know whether recently synthesised amines can 
act more efficiently to produce insulin-like effects such as anti-lipolysis or 
glucose uptake stimulation on human fat cells. 
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5. Materials and Methods 
5.1. Chemicals 
Benzylamine hydrochloride (BzA), semicarbazide, pargyline, collagenase, 
bovine insulin, fatty-acid-free bovine serum albumin, and other reagents were obtained 
from Sigma-Aldrich (Saint Quentin Fallavier, France and Budapest, Hungary). Enzymes 
for glycerol assay and liberase blendzyme 3 were from Roche Diagnostics 
(Indianapolis, USA). 2-[1,2-3H]-deoxyglucose (2-DG, 29.7 Ci/mmol) and [3-3H]-
glucose were purchased from Perkin Elmer Life Science Products (Boston, USA). 
[14C]-benzylamine (57 mCi/mmol) came from Amersham Biosciences 
(Buckinghamshire, UK). Amplex red fluorescent dye was from Flouoprobes/Interchim 
(Montlucon, France). 
Antibodies for immunoblot analysis (TK-1079) and for immunohistochemistry 
(7-88) were a very kind gift of Professor Sirpa Jalkanen (Turku University, Finland). 
Hexaquis (benzylamonium) decavanadate (B6V10) salt was synthesised at 
GenMedica Therapeutics (Barcelona, Spain) and provided by Dr. Alec Mian. 
4-phenylbuthylamine hydrochloride (4-PBA), 3-(4-methylthiophenyl)-
propylamine hydrochloride (3-MTPPA) and substrates A-D were synthesised at 
Semmelweis University, Department of Organic Chemistry. The latter are presented 
without complete chemical description in order to keep the confidentiality until 
complete data acquisition and patent application. 
5.2. Animals 
5.2.1. Housing 
All of the mice (C57BL/6 or transgenic) or rats (Wistar) used for our studies 
were handled in accordance with the European Communities Council Directives for 
experimental animal care with the principles and guidelines established by the French 
National Institute of Medical Research (INSERM) or by Semmelweis University. They 
were housed under specific pathogen-free/conventional conditions with constant 
temperature (20 to 22°C) and with a 12-hour light-dark cycle. All mice and rats had free 
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access to food and water. Normal and special diet compositions are presented in Table 
4. 
Table 4. Diet compositions 
 % of energy 
 Fat Protein Carbohydrate 
Normal diet (ND): 
3.85 kcal/g
   (Gannat, France) 
11 19 70 
High fat diet (HFD): 
4.73 kcal/g
    (UAR, France) 
45 20 35 
Very high fat diet (VHFD): 
5.24 kcal/g
    (Safe, France) 
72 
(Corn oil 14.6, 
lard 46.5%) 
28 <1 
5.2.2. Rat models 
Streptozotocin-induced diabetes model 
Diabetes was evoked by a single i.p. injection of 75 mg/kg streptozotocin (STZ) 
in citrate-buffered saline, pH 5.0. Diabetes induction was verified by the measurement 
of blood glucose; animals with blood glucose higher than 20 mmol/L were considered 
being diabetic. The animals were assigned in five groups and were treated for four 
weeks, starting four days after the induction of the disease. One group of diabetic 
animals was treated with s.c. insulin ultralente 15 IU/animal/day, one group was given 
BzA 10 mg/kg/day s.c., one group received BzA 10 mg/kg/day s.c. and sodium 
orthovanadate (V) in the drinking water 50 mg/L, the control group received 0.9 % 
sodium chloride s.c. injection (CTRL). 
Fasting conditions  
Five groups of male Wistar rats were constituted according to their age (7 
weeks) and similar initial body weight. They were sacrificed under fed condition or 
after 1 to 4 days of starvation. None of the rats died during prolonged starvation. 
5.2.3. Mouse models 
VHFD model 
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C57BL/6 male mice were purchased from Charles River (l’Arbresle, France) and 
were housed at 4-6 animals per cage. For one descriptive experiment, one group of 15 
mice received standard rodent chow while the other group of 45 mice was fed on VHFD 
(see Table 4.). As previously reported, VHFD can produce in C57BL/6 mice diverse 
states of obesity and/or diabetes (Burcelin et al., 2002). For studies on chronic effect of 
BzA on glycemic control and oxidative stress, mice turned on VHFD for at least three 
months were screened by intraperitoneal glucose tolerance test (IPGTT) and only those 
presenting glucose intolerance were used for further studies. These VHFD-fed mice 
were separated in two groups of equivalent body weight and hyperglycemic response to 
IPGTT. 16 mice were fed VHFD without any additional treatment (control group), and 
their water consumption was determined weekly. 16 other mice fed VHFD were given 
BzA 4000 µmoles/kg/day in the drinking water for 12 weeks (BzA-treated). BzA 
amount (in mg) to be dissolved in 400 ml drinking solution was weekly adjusted 
according to mouse body mass (in g) and daily water intake (in ml). Lastly, two other 
groups of VHFD were constituted in a similar manner: 12 VHFD and 12 VHFD 
drinking 2000 µmoles of BzA/kg/day (Figure 10.). 
 
Figure 10. Protocol of VHFD model 
Characteristics of the VHFD model 
Mice were fed VHFD for three months before receiving BzA injection or 
chronic per os treatment. At this stage they were 17-week old, hyperglycemic, 
hyperlipidemic, and mildly obese when compared to standard diet-fed control mice. 
However, they were not hyperinsulinemic since they ingested only very limited amount 
of carbohydrates, practically absent in the VHFD. Nevertheless, the glucose intolerant 
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state of VHFD mice was readily evidenced during IPGTT: their hyperglycemic 
response was exaggerated when compared to controls (respective AUC was 920 ± 28 vs 
628 ± 17 arbitrary units, p < 0.001). Once installed, glucose intolerance remained 
constant for at least 3 months (Table 5.). 
Table 5. Main characteristics of the VHFD model. 15 C57BL/6 male mice received standard rodent 
chow (ND) and 15 mice very high fat chow (VHFD).VHFD was statistically different from ND: * p < 
0.05; *** p < 0.001. 
 ND VHFD 
Body weight (g) 24.8 ± 0.3 27.8 ± 0.3 *** 
Glucose (mmol/l) 6.60 ± 0.22 8.27 ± 0.33 *** 
Insulin (μIU/ml) 19.2 ± 2.6 22.7 ± 1.5 Ns 
Cholesterol (mmol/l) 2.92 ± 0.20 4.54 ± 0.36 * 
FFA (mmol/l) 0.23 ± 0.02 0.57 ± 0.09 * 
 
HFD model 
HFD (diet composition in Table 4.) was purchased from UAR (UAR, Lyon, 
France) or Research Diets Inc (New Brunswick, USA) and replaced the standard rodent 
chow (ND) at the age of 8 weeks for a group of 36 C57BL/6 mice housed at 3 animals 
per cage with free access to food and water. 
 
Figure 11. Protocol of HFD model 
Three weeks after the nutritional switch, one group of 12 mice was kept 
untreated (control), while another group of 12 weight-matched mice received BzA in 
the drinking water for a 17-week period in order to ingest approximately 3600 
µmol/kg/day (BzA-treated). For that, the amount of BzA (in mg) to be dissolved in 400 
ml of the drinking solution was adjusted taking into account body mass (in g) and daily 
46 
water intake (in ml); this resulted in an approx. 0.4 % BzA solution that was changed 
weekly (Figure 11.). 
Characteristics of the HFD model 
Mice were fed HFD for three weeks before receiving BzA per os. At sacrifice, 
mice were 27-week old, hyperglycemic, hypercholesterolemic, and mildly obese when 
compared to control mice fed a standard diet. However, they were not hyperinsulinemic 
(Table 6.). 
Table 6. Main characteristics of the HFD model. 12 C57BL/6 male mice received standard rodent 
chow (ND) and 12 mice high fat chow (HFD). HFD was stratistically different from ND: * p < 0.05; *** 
p < 0.001. 
 ND HFD 
Body weight (g) 30.4 ± 1.3 36.0 ± 1.8 * 
Glucose (mmol/l) 8.00 ± 1.10 15.90 ± 1.00 *** 
Insulin (μIU/ml) 19.0 ± 3.0 23.0 ± 6.0 Ns 
Cholesterol (mmol/l) 2.92 ± 0.20 5.63 ± 0.26 *** 
FFA (mmol/l) 0.70 ± 0.07 0.61 ± 0.06 Ns 
db-/? mice 
Mice that develop a severe hyperglycemia and insulin resistance have been 
shown to have a recessive inheritance (db-/-) of the gene encoding for the leptin 
receptor leading to the loss of leptin signaling and altered food consumption. Among 
many other disturbances, these mice have a lot of reproductive problems therefore the 
reproduction consisted in using heterozygotes db-/+ (Table 7.). 
Table 7. Representation of the reproduction of db-/? mice. 
  db-/ db /+ 
db-/  db-/- db-/+ 
db /+ db-/+ db+/+ 
 
After weaning, the littermates (3-15) were separated by gender at four weeks of 
age and the litters were further divided in two groups, one receiving BzA in the drinking 
water (2 g BzA hydrochloride in 400 ml drinking water, changed weekly). The protocol 
was conducted on db-/- and their db-/+ littermates as their controls. db+/+ were 
discarded from the experiment based on their smaller body weight and their grey fur. 
At the age of 6 weeks, the db-/- animals, phenotyped on their overweight, were 
separated from their lean db-/+ littermates to facilitate the follow-up of food and liquid 
consumption. It means that during a while parameters were collected without knowing 
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if they would become obese or not. We could thus reconstitute post hoc the body weight 
and non-fasting glycemia of the complete groups as soon as week 4 (Figure 12.). 
 
Figure 12. Protocol of db-/? model 
Characteristics of the db-/? model 
At sacrifice db-/- mice were 11 week old, hyperglycemic, hyperlipidemic, 
hyperinsulinemic and obese when compared to db-/+ ones. Since the diabetes and 
obesity observed in this model were of genetic origin, standard diet (ND) was served ad 
libitum to the animals (Table 8.). 
Table 8. Main characteristics of the db-/? model. n = 21 (both genders) for db-/+ and 
n = 28 (both genders). Statistically different from heterozygotes: * p < 0.05; *** p < 0.001. 
 db -/+ db -/- 
Body weight (g) 21.8 ± 0.8 32.9 ± 1.0 *** 
Glucose (mmol/l) 6.09 ± 1.42 31.47 ± 2.70 *** 
Insulin (μIU/ml) 9.7 ± 1.2 69.3 ± 7.6 *** 
Cholesterol (mmol/l) 1.94 ± 0.13 2.29 ± 0.22 * 
FFA (mmol/l) 0.64 ± 0.05 0.90 ± 0.05 *** 
 
Mice invalidated for the AOC3 gene 
Mice deficient in SSAO/VAP-1 (KO AOC3) were produced by the group of 
Prof. S. Jalkanen (Turku Univ., Finland) on a pure 129 background by replacing a 
portion of the first exon of the mouse AOC3 gene with a neomycin-resistance cassette. 
KO AOC3 mice, homozygous for the null mutation, were backcrossed onto C57BL/6 
for eight generations and compared with wild-type mice with a C57BL/6 background. 
Mouse VAP-1 mutant allele (null), and endogenous mouse VAP-1 allele (WT) were all 
identified by polymerase chain reaction (PCR) screening of purified genomic DNA with 
specific primers and verified immunohistochemically with human and mouse 
SSAO/VAP-1 antibodies and enzymatic assays (Amplex Red-based fluorometric 
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detection). Comparisons between genotypes were made on mice sacrificed after 
overnight fasting, at the age of 6 months, unless stated otherwise. 
As for db-/? mice, problems in reproduction prompted us to breed heterozygous 
animals and after genotyping, the homozygous offsprings bearing two copies of the 
invalidated gene were compared to homozygous wild type littermates, when possible or, 
when precised to WT of the same strain. 
Characteristics of the model 
At sacrifice mice were 27-week old, normoglycemic, normolipidemic, not 
hyperinsulinemic and not obese when compared to WT littermates. Note that, in several 
mature females, an overweight occurred lately as already observed during the 
preliminary work of Bour and colleagues (Bour et al., 2009) (Table 9.). 
Table 9. Main characteristics of the KO AOC3 model. Data for 10 male mice. 
 WT KO AOC3 
Body weight (g) 31.5 ± 1.8 29.3 ± 1.2 
Glucose (mmol/l) 6.11 ± 0.39 6.83 ± 0.17 
Insulin (μIU/ml) 13.4 ± 4.3 10.3 ± 1.9 
Cholesterol (mmol/l) 3.29 ± 0.28 3.00 ± 0.33 
FFA (mmol/l) 0.70 ± 0.09 0.61 ± 0.08 
 
5.3. In vivo non invasive studies 
5.3.1. Intraperitoneal glucose tolerance tests (IPGTT) 
Fasted mice (5 h) were i.p. injected with saline or BzA (0.7 to 700 µmol/kg), 
BzA (7 µmol/kg) + vanadate (22 µmol/kg), B6V6 (7 umol/kg) 15 min before i.p. glucose 
(1 g/kg) load. Blood was collected from the tail vein of conscious mice after 0, 15, 30, 
45, 60, 90 and 120 min for determination of glucose levels with a glucosemeter (Roche 
Diagnostic, Mannheim, D). Blood was also collected before any i.p. injection to 
determine basal glycemia. Area under the curve (AUC) of hyperglycemic excursion was 
calculated and expressed in arbitrary units as previously detailed (Morin et al., 2002). 
5.3.2. In vivo metabolic follow up 
In many protocols unfasted blood glucose, body weight, water consumption and 
food intake were determined weekly, except in HFD and VHFD conditions due to the 
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sticky nature of the pellets. Some db-/? mice were chosen randomly and put in 
individual metabolic cages for 24 hours to collect urine. 
5.3.3. Determination of fat and lean mass  
To measure total body fat and lean mass by nuclear magnetic resonance, living 
mice were placed into a Plexiglass tubular holder inserted into an Echo MRI NMR 
machine (100TM3; Echo Medical Systems, Houston, TX) and measured during less 
than 1 minute. 
5.4. Blood and tissue sampling 
Most comparisons between genotypes or between untreated and treated animals 
were made on mice/rats sacrificed after overnight fasting by cervical dislocation, at the 
stated age. When rodents were sacrificed at the end of treatment, tissues and 
plasma/serum were immediately frozen until determination of diagnostic parameters 
using the described kits and methods. 
5.4.1. Plasma/serum markers 
Ultrasensitive Insulin Elisa kit was obtained from Mercodia (Uppsala, Sweden), 
NEFA C Wako Free fatty acid kit was from Oxoid (Dardilly, France). Plasma glucose 
was measured using the glucose oxidase method (Biomériux, France). Analyses of 
circulating fructosamine (using a colometric assay based on nitrotetrazolium blue 
reduction) and of uric acid (using a uricase-peroxidase method) were adapted to 96-well 
microplates for use in the multi-analyser. Plasma total cholesterol, HDL, LDL and TGs 
were determined using a Cobas-Mira+ multi-analyser, according to the manufacturer’ 
instructions (Roche, Neuilly, France). AGE levels in the sera/plasma were measured by 
their native fluorescence (370/440 nm) (Wu et al., 1996). Serum samples were diluted 
30 times with pH 7.4 phosphate buffered saline (PBS), mixed with chloroform to 
remove lipoproteins, and centrifuged (15 000 g, 4°C, 5 min). The aqueous phase was 
used for the fluorimetric analysis. Glycated hemoglobin levels (HbA1C) were 
determined by a commercially available laboratory assay using immunoturbidimetry. 
50 
5.4.2. RNA Extraction, Reverse Transcription, and Real-
Time PCR 
400 mg of WAT/liver were homogenised in 2 ml of a highly denaturing 
guanidine-thiocyanate-containing buffer supplied by the RNeasy mini kit (Qiagen, 
Courtaboeuf, France) plus 20 μl of β-mercaptoethanol. After lipid elimination by 
chloroform extraction, total RNA was extracted according to the supplier’s instructions. 
Then, 0.5 μg of total RNA was reverse-transcribed using random hexamers and 
Superscript II reverse transcriptase (Invitrogen, Cergy Pontoise, France). The same 
reaction was performed in parallel without reverse transcriptase (RT-) to estimate 
genomic DNA contamination. Real-time PCR was performed starting with 6.25 ng of 
cDNA and both sense and antisense oligonucleotides in a final volume of 20 μl using 
the SYBR Green TaqMan Universal PCR Mastermix (Eurogentec, Angers, France). 
Fluorescence was monitored in GeneAmp 7500 detection system instrument (Applied 
Biosystems, Foster City, CA). Oligonucleotide primers were designed using Primer 
Express (Perkin- Elmer Life Sciences, Courtaboeuf, France) and verified on Blast 
Nucleotide software. Primer specificity was checked by the occurrence of a single peak 
of expected size during dissociation experiments. Analysis of the 18S ribosomal RNA 
was performed using the Ribosomal RNA Control TaqMan assay kit (Applied 
Biosystems) to normalize gene expression. Results were expressed as arbitrary units 
relative to 18S expression, as reported (Bour et al., 2007a) using the following equation:  
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where Ct corresponds to the number of cycles needed to generate a fluorescence 
threshold. 
5.4.3. Human adipose tissue 
Samples of subcutaneous adipose tissue were obtained from a total of 6 healthy 
nonobese women: mean body mass index (BMI) was 28.0 ± 1.2 kg/m2, and age ranged 
from 30 to 48 years. Mammary or abdominal adipose tissue was obtained from patients 
undergoing dermolipectomy (not suction lipectomy) of localized fat depots for cosmetic 
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reasons in the Department of Plastic Surgery of Toulouse Rangueil Hospital. All 
patients had fasted overnight, and the operations were performed in the morning under 
general anesthesia. The study was approved by the Ethical Committee of Toulouse 
University Hospital. Samples of subcutaneous tissues were transported to the laboratory 
in less than 15 min and were promptly subjected to homogenisation or adipocyte 
preparation through collagenase digestion. 
5.5. Ex vivo and in vitro determinations 
5.5.1. Determination of DNA content from adipose tissue 
30-50 mg of adipose tissue (SCWAT or PGWAT) was digested in 1 ml 
preheated (30 min at 55°C) TBS (50 mM TRIS-HCl + 150 mM NaCl, pH 7.5) 
containing 0.1 mg/ml proteinase K (Macherey-Nagel GmbH, Düren, Germany) shaked 
overnight at 55°C. 10 μl of DNA samples were diluted in 90 μl TE buffer (10 mM 
TRIS-HCl + 1 mM EDTA, pH 8). 10 μl of the diluted samples and 90 μl of TE were put 
in wells. 100 μl of mouse genomic DNA (Bioline, London, UK) were used for 
calibration (0-500 ng/ml). 100 μl of PicoGreen (Invitrogen Life Technologies, Glasgow, 
UK) solution was used once 200-fold diluted as reagent. After 2 minutes the 
fluorescence (excitation: 460 nm, emission: 530 nm) was detected in 96-well dark plates 
by a Fluoroscan Ascent FL plate reader (Thermo Electron Corporation, Vantaa, 
Finland). 
5.5.2. Immunohistochemistry 
For immunohistological analysis, WAT was fixed in PBS containing 4% 
paraformaldehyde. The sections were first incubated in PBS 2% bovine serum albumin 
(BSA) for 30 minutes, then with PBS 2% BSA 50 μg/ml rat anti-VAP-1 (7-88 mAb 
recognizing mouse VAP-1) for 90 minutes. Sustained lavages were performed in PBS 
2% Tween (4x10 min) and PBS (5 min). Further incubation in PBS 2% BSA for 30 
minutes then in PBS + 2% BSA containing peroxidise-coupled anti-rat IgG (Vector 
Laboratories, Peterborough, UK) was used as secondary antibody. Samples were 
exposed to another wash block of PBS 2% Tween (4x) and PBS (1x) then incubate in 
DAPI 1X (Invitrogen) to mark nuclei. Whole tissue parts were then analysed using 
fluorescence microscopy (inversed microscop Eclipse TE2000-U, Nikon). 
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5.5.3. Immunoblotting assays 
WAT was homogenised in sample buffer (Tris-HCl 62,5 mM, pH 6.8, SDS, 10 
% w/v, glycerol 0,01 % v/v, bromophenol blue), then kept at 95°C for 5 min. SDS-
PAGE electrophoresis was performed using BioRad polyacrylamide gels (acrylamide 
gradient 4-12 %). After loading 20 μg of protein per lane, the electrophoretic separation 
in 25 mM TBS + 20% SDS was allowed to proceed at 100 V/gel during 1 hour then 125 
V during 2 hours. 
Separated proteins were transferred to a nitrocellulose membrane in TBS + 20% 
methanol using an electric field of 60 V during 1 h then 80 V for 30 minutes. The 
nitrocellulose membranes were then incubated for 60 minutes under gentle shaking in 
blocking solution. The blocking solutions used were TBST (25 mM Tris Base, 140 mM 
NaCl, 0.1% v/v Tween 20) containing 5% w/v non-fat dry milk. The saturated 
membranes were subsequently incubated overnight, at 4°C with the corresponding 
primary antibodies against (4.8 ug/ml TK 10-79: rat antibody against mouse SSAO; or 
β-actine rabbit) mouse in TBST containing 5% of the corresponding blocking solution. 
After repeated washing in TBST, membranes were incubated with the secondary 
antibody monoclonal anti-rabbit (for β-actin) or anti-rat IgG coupled to horseradish 
peroxidase (for SSAO) (2 h, at 4°C, gentle shaking), Sigma Detection was performed 
using enhanced chemoluminescence (ECL, Amersham Pharmacia Biotech.). Blots were 
subsequently scanned and quantified using Image’Quant TL (Molecular Dynamics, 
Sunnyvale, CA, USA). 
5.5.4. Isolation of adipocytes  
Samples of adipose tissue were dissected and digested by 60 µg/ml liberase 
(rodents) or 40 µg/ml liberase (human) (Blendzyme3, Roche Diagnostics, Mannheim, 
Germany) in Krebs-Ringer solution, pregassed with 95% O2 / 5% CO2, containing 
bovine serum albumin (35 mg/ml), 15 mM sodium bicarbonate, 10 mM Hepes (pH 7.4), 
and 2 mM pyruvate or 5 mM glucose. After digestion for 35 to 45 min at 37°C under 
agitation, isolated fat cells were filtered and washed three times in the same buffer 
without liberase. Freshly isolated adipocytes were adjusted to a suitable dilution and 
immediately dispensed in plastic vials for the determination of lipogenesis, glucose 
transport, or lipolytic activities in intact cells. 
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5.5.5. Lipolysis 
After being washed, the floating fat cells were diluted in around 10-fold their 
volume of Krebs-Ringer containing 15 mM sodium bicarbonate, 10 mM HEPES, and 
bovine serum albumin, and 400 μl of the cell suspension was immediately distributed 
under shaking into plastic incubation vials containing 4 μl of drug dilutions at 100-fold 
the final concentration to be tested. After a 90-min incubation, the glycerol released into 
the medium was enzymatically assayed as described (Morin et al., 2001). The results 
were expressed as percentage of responses to 10 nM isoprenaline, which is independent 
of fat cell size and basal triglyceride breakdown (Prévot et al., 2007). 
5.5.6. Hexose Transport 
Isolated adipocytes were diluted 10-fold in Krebs-Ringer buffer and 400 μl of 
cell suspension were distributed in vials containing the tested agents and incubated for 
45 min at 37°C. The addition of 2 mM pyruvate replaced the removal of glucose in 
order to avoid any competition with its non-metabolisable analogue added under the 
form of an isotopic dilution of [3H] 2-Deoxyglucose (2-DG, 26.5 Ci/mmol, PerkinElmer 
Life Sci.,Boston, MA). Thus, 2-DG was added in 100 µl portions for an exact period of 
10 min at a final concentration of 0.1 mM (0.6 mCi/100 ml). Assays were then stopped 
by 100 μl of 100 μM cytochalasin B and aliquots were centrifuged in microtubes 
containing dinonyl-phthalate to separate adipocytes from buffer by flotation. 
Intracellular radioactive 2-DG was counted as described. After centrifugation, the fat 
cells (upper part of the tubes) were placed in scintillation vials, and the intracellular 
radioactivity was counted as described. Extracellular 2-DG present in the cell fraction, 
which was determined using adipocytes whose transport activity had been previously 
blocked by cytochalasin B, did not exceed 1% of the maximum 2-DG transport in the 
presence of insulin. 
5.5.7. Lipogenesis 
Isolated adipocytes were diluted 10-fold in Krebs-Ringer buffer and 400 μl of 
cell suspension were distributed in vials containing the tested agents and [3H]-glucose 
(400 000 dpm/tube), and were incubated for 120 min at 37°C. Again, to better detect the 
glucose incorporation into lipids, the labelled hexose was present at 0.55 mM final 
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instead of 5.5 mM for lipolysis measurements. Reaction was stopped by a cocktail for 
liquid scintillation that is non miscible in aqueous solutions, allowing extraction into an 
organic phase and the measurement of [3H]-glucose incorporated and metabolized into 
lipids. Since the radiolabelling element is tritium, the radioactive glucose which was not 
metabolized remained in the aqueous phase and was not in contact with the scintillation 
organic mixture, present in the upper phase and the only detected during radioactivity 
counting as already described (Moody et al., 1974). 
5.5.8. Measurement of SSAO activity and H2O2 production 
Radioactive method 
SSAO activity was measured based on the conversion of radiolabelled substrate 
[14C]-benzylamine to [14C]-benzaldehyde according to the method of (Yu et al., 1992). 
Tissue homogenates were used for the enzyme activity measurements. The 
concentration of substrate used in the assay was 0.01-1 mM. Enzyme activity was 
expressed as pmol [14C]-benzaldehyde produced/mg protein/min, since only the 
benzaldehyde was extracted in the toluene/ethyl acetate-based extraction medium while 
the BzA that escaped from oxidation remained in the lower aqueous phase and was not 
counted. 
Amplex Red method 
Amplex Red (10-acetyl-3,7-dihydrophenoxazine) was used as a fluorescent 
probe for the detection of hydrogen peroxide. 50 μl tissue homogenate was preincubated 
in 50 μl 0.2 M pH 7.4 phosphate buffer with or without inhibitors (1 mM semicarbazide 
or 0.1 mM pargyline) for 10 minutes at 37○C. The reaction was started by adding 50 μl 
substrate/buffer and 50 μl reaction mixture containing 40 μM Amplex Red, 4 U/ml 
horseradish peroxidase. After 30 minutes of incubation at 37○C in 96-well dark plates 
the fluorescence (excitation: 530 nm, emission: 590 nm) was detected by a Fluoroscan 
Ascent FL plate reader (Thermo Electron Corporation, Vantaa, Finland). A standard 
H2O2 curve was built in a concentration range of 0–10 μM and used for calibration. 
Enzyme activity or H2O2 release was given as pmol H2O2/mg protein/min. 
Approximately 20 mg of WAT pieces were put in 580 μl phosphate buffer for 10 
minutes. 200 μl fluorogenic mixture (same as for honogenates) was added at time 0. 
Plastic tubes protected from light were incubated for 30 minutes at 37○C. 200 μl of the 
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solution was placed to 96-well dark plates for the detection of fluorescence signal using 
reactives and calibration as described above. 
5.5.9. Measurement of tissue nitrite and nitrate 
concentration 
Tissue nitrate and nitrite concentrations were measured by a capillary 
electrophoresis method (Szökő et al., 2004). Briefly, samples were sonicated in 5 
volumes of 0.1 M NaOH to immediately destroy proteins. pH was adjusted to about 7 
by an equal volume of 0.09 M acetic acid. Samples were then placed in boiling water 
for 3 minutes, then cooled on ice and proteins were removed by centrifugation (20 000 g 
for 10 minutes at 4 °C). Supernatant was used for injection (100 mbar for 0.75 min). 
Electrophoretic separation was performed by Prince capillary electrophoresis system 
(PrinceTechnology, Emmen, The Netherlands). Separations were carried out in 
uncoated fused silica capillaries (75 μm i.d., 365 μm o.d., 70 cm total length, 55 cm to 
the detector, Polymicro Technology, Phoenix, AZ, USA) using 30 mM sulfate-β-alanine 
pH 3.8 buffer, constant current: -110 μA. Appartus was equipped with a UV detector, 
set at 214 nm. Calibration curve was fitted for 0-100 μM KNO3 and NaNO2, 100 μM 
KBrO3 was used as internal standard. 
5.6. Statistical analysis 
Results are given as means ± SEM and were compared using Student’s t test. NS 
means no significant difference between the compared samples. We used the Splus 6.1 
software version (Insightful , WA) for statistical computations of the parameters of db-
/? animals. A linear mixed statistical model was fitted to the data collected 
constitutively during the treatment period. For end-point analysis (mostly parameters at 
sacrifice) 2x2 ANOVA or student’s t test was used. 
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6. Results 
6.1. Investigation of SSAO activity in adipose tissue 
6.1.1. Determination of SSAO activity in subcutaneous 
adipose tissue 
We measured SSAO activity using BzA as a substrate, and basal SSAO-
dependent H2O2 production in SCWAT of C57BL/6 mice.  
 
Figure 13. Benzylamine oxidation in SCWAT. Total, SSAO and MAO-dependent benzylamine 
oxidation was determined in SCWAT homogenate of 4 adult (15-week old) male C57BL/6 mice. H2O2 
production was measured by Amplex Red method, data are presented as mean ± SEM. 
As shown in Figure 13, BzA oxidation in SCWAT, in the concentration range of 
0.02-1 mM, is very sensitive to 1 mM semicarbazide (SSAO-dependent oxidation), 
while a very little part of its oxidation is sensitive to 0.1 mM pargyline (MAO-
dependent oxidation). Maximum amine oxidation capacities have been reached already 
at 0.1 mM BzA concentration. As it can be seen on the Figure 11, a detectable H2O2 
production in the mouse SCWAT in the absence of exogenous BzA was found, which 
could be inhibited by semicarbazide. It was decided to verify whether this hydrogen 
peroxide production, detected without any addition of exogenous amine, was really 
related to a basal, spontaneous SSAO activity.  
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Figure 14. SSAO-dependent H2O2 production. Basal SSAO-dependent H2O2 release is measured in the 
absence and in the presence of 0.1 mM benzylamine (BzA) in SCWAT homogenate of 3 WT and 5 KO 
AOC3 27 week-old mice. Data are presented as mean ± SEM, difference between genotypes is marked: 
*** p < 0.001. 
The basal SSAO-dependent hydrogen-peroxide production was totally abolished 
in KO AOC3 mice (Figure 14.). 
 
Figure 15. Effect of genetic invalidation of AOC3 on immunoreactive SSAO in white adipose tissue. 
AOC3 protein (SSAO) is not present at the surface of adipocytes of KO AOC3 mice while it is 
aboundantly expressed in wild type mice (WT). Semicarbazide-sensitive amine oxidase protein labelled 
in subcutaneous mouse fat cells by the anti SSAO-VAP-1 antibody 7-88 (Merinen 2005)+ DAPI 
(Magnification: 20x). 
Since the KO AOC3 mice are totally lacking SSAO-dependent BzA oxidation 
(Figure 14.) and SSAO protein (Figure 15.) in their adipocytes, one could exclude the 
possibility that another amine oxidase, sensitive to semicarbazide (DAO or LO), would 
be responsible for such semicarbazide-inhibitable basal hydrogen peroxide production. 
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6.1.2. Influence of the adipose mass on the SSAO activity in 
different adipose tissues 
High fat diet induced obesity 
The effect of high fat diet-induced obesity (see characteristics in chapter 5.2.3) 
on SSAO activity and basal SSAO-dependent H2O2 release was investigated in PGWAT 
and SCWAT of C57BL/6 mice. Mice eating normal chow served as controls in the 
experiment. 
Table 10 shows that BzA oxidation was more intensive in PGWAT than in 
SCWAT in control, as well as in obese mice. Obesity caused an increase in SSAO 
activity in SCWAT but not in PGWAT. This difference was also seen in basal SSAO-
dependent H2O2 release (in absence of BzA).  
Table 10. H2O2 production of SC and PGWAT homogenates. SSAO activity was assessed as 1 mM 
semicarbazide inhibitable hydrogen peroxide release. Results are expressed in mean ± SEM, n=5, 
statistically different from normal diet at:  * p < 0.05; ** p < 0.01. 
 HFD ND 
Basal SSAO-dependent H2O2 release (pmol/mg 
prot/min) in PGWAT 25 ± 2 29 ± 6 ns 
Basal SSAO-dependent H2O2 release (pmol/mg 
prot/min) in SCWAT 48 ± 8 18 ± 5 ** 
SSAO activity of PGWAT 
(0.1 mM BzA used-pmol H2O2/mg prot/min) 
210 ± 26 152 ± 35 ns 
SSAO activity of SCWAT 
(0.1 mM BzA used-pmol H2O2/mg prot/min) 
100 ± 17 43 ± 14 * 
 
Genetic obesity  
Effect of obesity on SSAO activity and basal SSAO-dependent H2O2 release was 
investigated in different white adipose tissue depots, namely PGWAT, PRWAT and 
SCWAT in genetically obese mice owing to the use of the db-/? strain (Table 11.). To 
assess SSAO activity BzA, was added in different concentrations between 0.02-0.5 mM. 
Lineweaver-Burk plot was used for Km and Vmax determination. Mice with a naturally 
occurring mutation of db gene with loss of function became obese and diabetic (see 
Materials and Methods for further information). Heterozygotes for the mutation were 
used as controls in the protocol. 
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Table 11. H2O2 production of SC, PG and PR WAT tissue homogenates. Results are expressed in 
mean±SEM, n=6 for PG and PR ,7 for SCWAT, statistically different from db-/+ * p < 0.05. 
 db-/- db-/+ 
Basal SSAO-dependent H2O2 release 
(pmol/mg prot/min) in PGWAT 28 ± 9 29 ± 5 ns 
Basal SSAO-dependent H2O2 release 
(pmol/mg prot/min) in PRWAT 31 ± 9 39 ± 9 ns 
Basal SSAO-dependent H2O2 release 
(pmol/mg prot/min) in SCWAT 92 ± 18 68 ± 14 ns 
SSAO activity of PGWAT 
(0.1 mM BzA used-pmol H2O2/mg prot/min) 
356 ± 63 252 ± 37 ns 
SSAO activity of PRWAT 
(0.1 mM BzA used-pmol H2O2/mg prot/min) 
273 ± 41 294 ± 55 ns 
SSAO activity of SCWAT 
(0.1 mM BzA used-pmol H2O2/mg prot/min) 
299 ± 47 152 ± 10 * 
Km PGWAT (μM) 23 ± 1 28 ± 4 ns 
Km PRWAT (μM) 28 ± 3 24 ± 1 ns 
Km SCWAT (μM) 33 ± 4 22 ± 5 ns 
Vmax PGWAT (pmol H2O2/protein/min) 413 ± 75 306 ± 41 ns 
Vmax PRWAT (pmol H2O2/protein/min) 339 ± 38 345 ± 61 ns 
Vmax SCWAT (pmol H2O2/protein/min) 440 ± 72 212 ± 22 * 
 
Based on our measurements, db-/- mice had increased SSAO activity in SCWAT 
(Table 11.). Both calculated Vmax and the measured H2O2 production during oxidation 
of 0.1 mM BzA were increased in the obese mice. PGWAT and PRWAT SSAO 
activities were not affected by the recessive mutation of db gene. Increased SSAO 
activity in SCWAT was in line with both the enhanced expression of AOC3 mRNA 
(db-/- 78.22 ± 7.58 vs db+/- 30.68 ± 3.37 arbitrary units, n = 9, p < 0.001, not shown) 
and enriched content in immunoreactive SSAO proteins detected by Western Blot 
analysis : (2.65 ± 0.06 vs 2.04 ± 0.11 arbitrary units normalized for β-actin, n = 6, p < 
0.001) (Figure 16.). 
 
Figure 16. Immunoblot analysis of SSAO protein in SCWAT of female db -/- and db -/+ mice, 
representative for 6 cases. 
Influence of fasting on INWAT SSAO activity 
Influence of 1-4 days of fasting on SSAO activity was investigated in INWAT of 
Wistar rats. 
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Figure 17. Influence of fasting duration on body mass (A), blood glucose (B), mass of intra-
abdominal white adipose tissues (INWAT) (C), and SSAO activiy in INWAT (D). Seven-week old 
rats were sacrificed under fed state (day 0) or after the indicated days of fasting. Semicarbazide sensitive 
amine oxidase activity was determined on crude INWAT homogenates and are expressed as oxidised (14C 
benzaldehyde) product formed in nmol/mg protein /min. Mean ± SEM of 6 animals in fed state (day 0) 
and of 3 for each fasting duration. Statistically different from fed control at:  * p < 0.05; ** p < 0.01; *** 
p < 0.001. 
Fasting-induced slimming (Figure 17. A) and glucose lowering (Figure 17. B) 
effects were statistically significant even after the first day of starvation. As expected, 
longer fasting periods provoked a continuous fall in body and dissectible INWAT mass 
(Figure 17. A, C) while blood glucose level remained stable (Figure 17. B). Under these 
conditions, no change in SSAO activity was observed in the INWAT of male rats 
(Figure 17. D). 
6.2. In vitro insulin-like effect of benzylamine 
In adipocytes, several amines may exert insulinomimetic effects (see 3.2.6) 
when oxidised. BzA-induced in vitro insulin-like effects were thus investigated in 
mouse adipocytes. To see the role of SSAO in these processes adipocytes of AOC3 null 
mice were also tested. 
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Lipolysis in rodent fat cells 
Effect of insulin, BzA, vanadate and their combination on lipolytic response of 
isolated adipocytes was investigated. 10 nM isoprenaline was used for stimulation of 
lipolysis. 
 
Figure 18. Inhibition of 10 nM isoprenaline-induced lipolysis (Iso) by 100 nM insulin (Ins), 0.1 mM 
benzylamine (BzA), 0.1 mM vanadate (V) and their combination (BzA + V) in mouse adipocytes (n 
= 10 WT and 7 KO AOC3, age 27 weeks). Data are expressed as mean ± SEM in % of 10 nM 
isoprenaline (Iso) stimulation above the basal lipolysis (which was 0.67 ± 0.07 and 0.44 ± 0.04 µmol 
glycerol released/100 mg lipid/90 min in WT and KO AOC3, mean ± SEM, n = 29 and 25, respectively, P 
< 0.01) , Statistically different (t test) from 10 nM isoprenaline’s effect: ++ p < 0.01;and different from 
WT * p < 0.05. 
Figure 18. shows that BzA or vanadate alone could not inhibit β-adrenergic-
stimulated lipolysis, while the anti-lipolytic effect of BzA + vanadate was abolished in 
KO AOC3 mice. The anti-lipolytic effect of 100 nM insulin was identical in both 
genotypes. 
Glucose uptake in rodent adipocytes 
Impact of insulin, BzA, vanadate and their combination on glucose uptake of 
isolated adipocytes was studied. 
BzA or vanadate alone exerted only 20-30 % of 100 nM insulin’s effect on 
glucose uptake. When they are used in combination, glucose uptake stimulation reached 
85% of that of 100 nM insulin (Figure 19.). Such stimulation of glucose uptake by 
amines was found to be abolished in KO AOC3 mice (Bour et al., 2007b). 
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Figure 19. Effect of 0.1 mM benzylamine (BzA) and 0.1 mM vanadate (V) on glucose uptake in 
isolated mouse adipocytes from INWAT of HFD mice (n = 12, age 28 weeks). Data are expressed as 
mean  ± SEM in % of 100 nM insulin’s (Ins) effect. 
Lipogenesis in rodent adipocytes 
 
Figure 20. Lipogenic effect of benzylamine (BzA) and vanadate (V) and their combination  
(BzA + V) in isolated mouse adipocytes from INWAT of C57BL/6 mice (n = 10, age 27 weeks). Data 
are expressed as mean ± SEM in % of 100 nM insulin’s effect. 
Lipogenesis measurements were performed in adipocytes isolated from mouse 
INWAT to study the effect of BzA. BzA or vanadate alone had partial effect on 
lipogenesis compared to that of their combination. BzA + V, which reached 89 ± 17% 
of 100 nM insulin’s effect (Figure 20.). 100 nM insulin stimulation was similar in KO 
AOC3 and WT mice adipocytes (1.9 ± 0.2 vs 2.0 ± 0.1 fold increase over basal 3H 
glucose incorporation). In KO AOC3 mice, the lipogenic effect of BzA + vanadate was 
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compared to WT animals, and reached only the 37 ± 13% of the insulin’s effect. 
Stimulatory effect of vanadate was 20 ± 6% of that of insulin in SSAO invalidated mice, 
while 53 ± 13% of that of insulin in WT animals. 
Together, these results show that the absence of SSAO alters the in vitro 
insulinomimetic effects of BzA + vanadate, thus these effects are at least partly due to 
BzA’s oxidation. 
6.3. In vivo insulin-like effect of benzylamine 
6.3.1. Effect of single injection of benzylamine on glucose 
handling 
We have observed in adult normoglycemic mice that, when injected 15 min 
before a glucose load of 1 g/kg, 70 µmol/kg i.p. BzA was able to lower the 
hyperglycemic response (area under the curve of the hyperglycaemic excursion was : 
2375 ± 295 arbitrary units in BzA treated vs 3386 ± 252 arbitrary units in controls, n = 6 
and 12, p < 0.05).  
 
Figure 21. Dose-dependent effect of benzylamine (BzA) on provoked hyperglycemic responses in 
VHFD mice. After 5 hour fasting, mice i.p. received saline (0) or the indicated dose of BzA 15 min 
before IPGTT consisting of a load of glucose at time 0 (1 g/kg, i.p.). Blood samples were collected from 
the tail vein of conscious animals for immediate blood glucose assay. Areas under the curve (AUC) of the 
hyperglycemic responses were expressed in arbitrary units. Means ± SEM of 4 to 8 mice per group, age 
17 weeks. Different from control at: * p < 0.05, ** p < 0.01. 
The dose-response of the anti-hyperglycemic action of BzA was studied in mice 
rendered glucose intolerant by 3 months of VHFD. Bolus i.p. injection of BzA did not 
lower blood glucose in overnight fasted mice which was 9.2 ± 0.5 mM 15 min after 
saline bolus, and remained at 8.7 ± 0.3, 9.5 ± 0.5, 8.5 ± 0.5 and 9.1 ± 0.2 mM after 
receiving 0.7, 7, 70 or 700 µmol/kg BzA, respectively (ns). However, BzA improved 
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the somewhat altered glucose tolerance of these mice adapted to a calory intake almost 
devoid of carbohydrates. In fact, BzA dose-dependently reduced the hyperglycemic 
response following an i.p. glucose load (Figure 21.). The anti-hyperglycemic action of 
BzA occurred without a detectable change in plasma insulin level. Stimulation of 
insulin secretion thus was not the mechanism by which BzA exerted its anti-
hyperglycemic effect. 
 
Figure 22. Glucose tolerance test after single injection of hexakis (benzylammonium) decavanadate 
(B6V10) or saline (control) in WT (A) and KO AOC3 (B) mice. B6V10 (7 µmol/kg) or NaCl 0.9% were 
i.p. injected 15 min before glucose load (1 g/kg, i.p.) at time 0. Mean ± SEM of 12 mice per group. 
Different from corresponding control at : **  p < 0.01. 
It was also tested whether the response to 7 µmol/kg BzA could be potentiated 
by simultaneous administration of vanadate. No greater anti-hyperglycemic effect was 
found when BzA 7 µmol/kg was combined with vanadate 22 µmol/kg (respective AUC 
of IPGTT were 469 ± 38 and 441 ± 35 arbitrary units, n = 10-14, ns). 
Since a benzylamine-vanadate complex salt synthesised by GenMedica 
Therapeutics (Barcelona, Spain) named hexaquis (benzylamonium) decavanadate 
(B6V10) has been shown to exert similar or even improved insulinomimetic effect than 
the combination of benzylamine and vanadium (Garcia-Vicente et al., 2007; Yraola et 
al., 2007), we took advantage of the availability of this compound to further verify 
whether its mechanism of action was really dependent on amine oxidase activity. 7 
μmoles of B6V10 were injected to WT and KO AOC3 mice. As Figure 22 shows the 
compound improved glucose tolerance in WT but not in KO AOC3 mice. The presence 
of SSAO is thus crucial for the in vivo effect of the benzylamine compound. Insulin 
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levels measured at 15 minutes after glucose load were similar in all studied groups (WT 
control: 0.74 ± 0.10, WT B6V10: 0.59 ± 0.08, KO AOC3 control: 0.72 ± 0.05, KO 
AOC3 B6V10: 0.71 ± 0.07 μg/l, n=9-11), thus the effect is not the consequence of an 
increased insulin release. 
Our studies have shown that BzA can directly interact with adipose tissue, by 
increasing the hydrogen peroxide production, and by activating glucose transport and 
lipogenesis. Moreover, BzA improves glucose tolerance in vivo. We supposed that 
chronic BzA treatment might affect not only hyperglycemia but also hyperglycemia 
related vascular complications. 
6.3.2. Effect of chronic benzylamine injection in 
streptozotocin-induced diabetes in rats 
Diabetes was evoked by streptozotocin in rats. Effect of 4 weeks’ treatment with 
s.c. 15 IU/animal/day insulin (Ins), s.c. 10 mg/kg/day benzylamine (BzA) and s.c. 
10 mg/kg/day benzylamine combined with 50 mg/L vanadate in the drinking water 
(BzA+V) was investigated in streptozotocin-induced diabetic rats (STZ). Blood glucose, 
glycated haemoglobin, serum AGE and NO bioavailability in the kidney were measured 
to clarify whether the anti-hyperglycemic or the potential cytotoxic effects of the SSAO 
substrate - through the production of H2O2 - have greater impact on diabetic vascular 
complications. 
Blood glucose, HbA1C and serum AGE levels 
Four weeks treatment with Ins or BzA reduced but did not normalize the 
elevated blood glucose in diabetic rats. HbA1C level was significantly reduced only by 
the insulin treatment. The amount of the serum AGEs in the diabetic animals was higher 
compared to the controls. Ins and BzA + V treatments were found to decrease the 
elevated serum AGE levels, whereas BzA alone was ineffective (Table 12). 
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Table 12. Diagnostic parameters of control, diabetic and treated rats. CTRL: control animals, STZ: 
diabetic animals, STZ + Ins: diabetic animals having insulin treatment, STZ + BzA: diabetic animals 
having benzylamine treatment, STZ + BzA + V: diabetic animals having benzylamine and vanadate 
treatment. Mean ± S.E.M of five groups. * p < 0.05 vs Control group, † p < 0.05 vs STZ group. 
Group Glucose (mM) HbA1C(%) AGE(RFU) 
CTRL 9.00 ± 0.75 3.80 ± 0.30 280.89 ± 6.94 
STZ 38.10 ± 2.40 * 9.25 ± 0.53 * 408.00 ± 16.74 * 
STZ + Ins 27.90 ± 4.70 † 6.86 ± 0.99 † 296.00 ± 21.93 † 
STZ + BzA 27.50 ± 5.87 † 9.69 ± 1.50 * 384.63 ± 19.60 * 
STZ + BzA + V 28.40 ± 1.61 † 9.12 ± 0.63 * 331.67 ± 14.53 † 
 
NO availability in diabetic animals 
Impaired NO bioavailability and increased formation of RNS were indicated by 
the measurements of the stable metabolic end products of NO, nitrite and nitrate in 
kidney tissue of the diabetic animals. The nitrite concentration was found to be reduced, 
while the ratio of nitrate/nitrite was elevated in diabetic rats compared to controls (Table 
13.). 
Table 13. Nitrite level and nitrate/nitrite ratio in kidney tissue of control, diabetic and treated rats. 
STZ: diabetic animals, STZ + Ins: diabetic animals having insulin treatment, STZ + BzA: diabetic 
animals having benzylamine treatment, STZ + BzA + V: diabetic animals having benzylamine-vanadate 
treatment. Mean ± S.E.M of five animals per group. * p < 0.05 vs Control group, † p < 0.05 vs STZ 
group. 
Group Nitrite nmol/g kidney Nitrate/nitrite ratio 
Control 10.72 ± 0.94 2.35 ± 0.28 
STZ 6.51 ± 1.14 * 4.90 ± 1.00 * 
STZ + Ins 5.67 ± 1.09 * 3.74 ± 0.51 † 
STZ + BzA 7.48 ± 1.12 * 4.82 ± 0.92 * 
STZ + BzA + V 9.80 ± 0.54 † 3.67 ± 0.50 † 
 
Although insulin treatment failed to restore the kidney nitrite concentration, it 
was effective in reducing the elevated nitrate/nitrite ratio in the diabetic animals. 
Similarly, four week BzA+V treatment enhanced NO bioavailability in the kidney of 
diabetic rats. The nitrite level was markedly increased in these animals, compared to the 
untreated diabetic controls. BzA treatment alone caused no significant change in the 
nitrite and nitrate levels of the diabetic rats (Table 13.).  
In conclusion, BzA + V treatment, similarly to Ins, lowered blood glucose and 
improved NO bioavailability, the impairement of which is contributing to endothelial 
dysfunction and vascular complications. 
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6.3.3. Effect of oral benzylamine treatment in various 
animal models of insulin resistance  
We have shown that BzA alone has anti-hyperglycemic properties in vivo, 
although for in vitro insulin-like effects, the presence of vanadate is crucial in rodents. 
As we intended to study the effect of orally administered BzA, we have performed some 
initial experiments which have shown that a remarkable amount of BzA could cross the 
intestinal barrier without being oxidised by the amine oxidases expressed in the gut wall 
protecting the body against dietary amines (Bour, 2006). BzA was also detected in urine 
of BzA-drinking animals (measured in collaboration with Dr. Marianna Budai who 
performed HPLC-MS determinations; data not shown). 
Oral administration of benzylamine in VHFD-fed mice 
In this first model of insulin resistance mice were fed a very high fat diet for 
three months (see chapter 5.2.3 for model caracteristics) before they were given BzA 
(2000 or 4000 μmol/kg/day) in their drinking water for 12 weeks. BzA was supposed to 
improve glucose handling in these glucose-intolerant mice. 
Glucose handling in VHFD mice 
After three weeks of treatment, mice treated or not with BzA were fasted for 5 
hours and submitted to IPGTT (Figure 23. A). 
The overall hyperglycemic excursion was reduced after prolonged treatment 
with BzA at 2000 μmol/kg/day, since the area under the curve presented in Figure 23. B 
was reduced in BzA-treated mice. This modest improvement of glucose tolerance was 
apparently not the consequence of increased insulin sensitivity since injection of insulin 
at 0.75 IU/kg lowered blood glucose similarly in control and BzA-treated mice, 
reaching a minimum concentration of 6.0 ± 0.2 and 6.7 ± 0.3 mM within 30 min (n = 9, 
NS). In the VHFD animals, glycemia was lower in fed than in fasted state, and a 
significant glucose lowering effect of BzA-treatment could be evidenced under fed 
conditions at several time points of the treatment. For instance, four weeks after the start 
of treatment, non-fasting blood glucose was 8.27 ± 0.33 mM in untreated VHFD mice, 
which was lowered to 7.32 ± 0.22 mM in mice having daily 2000 µmol/kg BzA (n = 12, 
p < 0.02). However, no decrease in non-fasting blood glucose was detected in BzA 
treated animals, with the 4000 µmol/kg/day dose given during 12 weeks (not shown). 
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Figure 23. Influence of benzylamine (BzA) oral treatment on glucose tolerance. A panel: After three 
weeks of oral BzA administration, mice were fasted for 5 hours before a glucose load (1 g/kg, i.p. at 
time 0). Blood glucose values were determined on conscious animals at the indicated times. B panel: Area 
under the curve of the hyperglycemic excursion (AUC). Means ± SEM of 11 mice per group. Different 
from control at: * p < 0.05, ** p < 0.01. 
Water intake and body weight gain  
The average daily water intake was 4.4 ± 0.1 g in mice receiving 4000 
μmol/kg/day dose of BzA (BzA-treated) in drinking water, while it was 4.8 ± 0.1 g in 
mice drinking only water (n = 16, p < 0.05). Such reduction of water intake persisted 
along the entire 12-week treatment. It was difficult to assess whether this reduction of 
water intake was concomitant with change in calorie intake, because the very high fat 
chow was peculiarly sticky and did not facilitate accurate determination of food 
consumption. Nevertheless, after 12 weeks of treatment, there was no difference in body 
mass between the control and the BzA-treated groups, whatever the BzA dose tested 
(2000 or 4000 μmol/kg/day). Similarly, there was no change in adipose tissue, liver, or 
heart mass. 
Plasma markers of metabolic disturbances 
BzA treatment did not modify plasma triglycerides (1.32 ± 0.05 vs 1.37 ± 0.05 
mmol/l, NS), cholesterol (4.86 ± 0.18 vs 4.55 ± 0.36 mmol/l, NS) or non-esterified fatty 
acids (0.38 ± 0.04 vs 0.37 ± 0.01 mmol/l, NS) in VHFD mice. The treatment did not 
modify the amount of circulating AGEs (3.58 ± 0.55 vs 4.24 ± 0.25 relative units of 
fluorescence, NS), which were lower in both groups of VHFD mice than in animals fed 
a standard chow (6.05 ± 0.48, n = 5-6, p < 0.001), probably because of the low 
carbohydrate content of the diet. In adipocytes, the expression of genes encoding for 
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proinflammatory adipokines like TNFα, IL-6, leptin, resistin, PAI-1 was unaltered by 
BzA-treatment (not shown).  
Lipolytic and glucose uptake activities in adipocytes 
In order to test whether the sustained presence of the substrate administered to 
the treated mice was altering the in vitro insulin-like effects of BzA described above, we 
measured the glucose uptake and lipolysis activities in adipocytes from control and 
BzA-treated mice fed a VHFD. 
The dose-dependent stimulation of lipolysis by isoprenaline was identical in 
mouse adipocytes from VHFD control and BzA-treated mice. Maximal stimulation was 
reached at using 100 nM beta-adrenergic agonist (not shown). The insulin-evoked 
inhibition of lipolysis was also unaltered by BzA-treatment (treated: 62 ± 12 vs 
untreated: 72 ± 13% inhibition of 10 nM isoprenaline’s effect, n = 5, NS). The 
inhibition of lipolysis by 0.1 mM BzA plus 0.1 mM vanadate was also equivalent in the 
two groups, leading to 60 ± 10 and 57 ± 15% inhibition of the lipolytic response to 10 
nM isoprenaline (NS). 
GLUT-1 and GLUT-4 expressions, basal and insulin-stimulated glucose 
transport activities were also unchanged by BzA-treatment. Insulin 10 nM 
submaximally stimulated hexose uptake, and the combination of 0.1 mM BzA plus 0.1 
mM vanadate clearly reproduced insulin activation of hexose transport in both VHFD 
control and BzA-treated mice. Therefore, no alteration of the adipocyte responses to 
insulin or insulin mimicking agents could be detected after chronic oral administration 
of BzA, ruling out a putative desensitisation of the pathways activated by sustained 
activation of SSAO. 
Oxidative stress and aorta NO bioavailability 
No alteration of nitrite content could be detected in the aorta even after 12-week 
treatment with the higher dose of BzA (55.5 ± 6.5 vs 52.4 ± 4.4 nmol/g tissue, n = 6, 
NS). Similarly, nitrate to nitrite ratio remained unchanged in the aortas of BzA-treated 
mice (2.47 ± 0.33 vs 2.68 ± 0.27 nmol/g tissue, n = 6, NS), indicating that BzA 
administration probably did not provoke oxidative stress in the vasculature. In liver, the 
gene expression of catalase or manganese superoxide dismutase was unaltered by BzA 
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administration. Catalase gene expression in adipocytes was also similar in BzA-treated 
and non-treated mice. 
Taken together, VHFD mice clearly responded to BzA challenges by limiting 
their hyperglycemic response during IPGTT. However, the chronic oral administration 
did not reduce their slightly increased fasting glycemia. This was probably the 
consequence of the lack of carbohydrates in their special diet. As chronic BzA ingestion 
was devoid of adverse effects on nitric oxide bioavailability in the vasculature or on 
markers of inflammation in the adipose depots, our team decided to investigate this 
amine’s effect in a mouse model of insulin resistance having more carbohydrates in the 
diet.  
Oral administration of benzylamine in HFD-fed mice  
In this second model of insulin resistance HFD mice were given 3600 
μmol/kg/day BzA in their drinking water during 17 weeks (detailed in chapter 5.2.3).  
Glucose handling in HFD mice  
Blood glucose was followed weekly under non-fasting conditions. BzA-treated 
mice had significantly reduced glycemic levels on only three occasions out of 17 sample 
points, but the mean values of the 204 determinations made for each group during the 
treatment period showed significantly decreased blood glucose from 8.18 ± 0.07 mM in 
control to 7.71 ± 0.08 in BzA-treated mice. 
Two weeks before the end of the treatment, mice were subjected to a glucose 
tolerance test. They were fasted for 5 hours and then received an i.p. glucose challenge 
(1 g/kg). The overall hyperglycemia was lower in BzA-treated mice as shown by Figure 
24. A: the more rapid return of blood glucose to basal levels at almost all the check 
points tested, resulted in lower area under the curve (n = 12, p < 0.05) (Figure 24. B). 
Alongside the improvement in glucose tolerance it induced, BzA treatment also lowered 
fasting blood glucose level based on two measurements (t-15 and t-0), since the BzA-
treated mice had lower values than controls before the glucose load: 8.9 ± 0.7 mM and 
10.2 ± 0.7 mM vs 11.8 ± 0.3 mM and 12.9 ± 0.7 mM, respectively (n = 12, p < 0.01) 
(Figure 24. A).  
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Figure 24. Influence of benzylamine (BzA) oral treatment on glucose tolerance. After 15 weeks of 
oral amine administration, mice were fasted for 5 hours prior to glucose load (1 g/kg, i.p. at time 0, 
arrow). A panel: glucose was determined in blood collected from the tail of conscious animals at the 
indicated times before and after the glucose load. B panel: Area under the curve of the hyperglycemic 
excursion (AUC). Mean ± SEM of 12 mice per group. Statistically different from control at: * p < 0.05; 
**, p < 0.01; *** p < 0.001. 
Further analysis of plasma samples obtained at sacrifice showed that glucose 
levels were clearly lower in the treated mice: they were equivalent to only 76 ± 6% of 
that of untreated animals (n = 12, p < 0.02). Immunoreactive insulin levels also showed 
a tendency to diminish but, due to high intra-group variability, there was no statistically 
significant effect of the treatment. Consequently, the observed decrease in HOMA, an 
index of insulin resistance, was at the limit of significance (7.79 ± 2.25 vs 18.76 ± 5.07 
n = 8, p < 0.07). Therefore, the glycemic control appeared to be improved in BzA-
treated animals, at least when considering the lowered non-fasting and fasting glycemia 
and the reduced hyperglycemic response to glucose load. 
Water intake and body weight gain 
The water consumption was followed weekly and exhibited small variations. 
There were only two instances when water intake was lower in the BzA-treated group 
than in the controls (6 and 10 weeks after starting treatment, p < 0.02). Nonetheless, the 
mean daily water consumption calculated over the entire 17-week treatment period was 
significantly lower in mice with the BzA treatment: average values were 3.9 ± 0.1 
g/mouse/day for the controls and 3.5 ± 0.1 for the treated animals (p < 0.001, n = 68). 
BzA-treated mice thus limited their water consumption by approximately 10%. 
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Figure 25. Body weight of mice fed a high-fat diet (HFD) and treated or not with orally 
administered benzylamine (BzA). Two groups of age- and weight-matched mice were constituted (4 
cages of 3 animals per group) three weeks before oral administration of BzA (arrow). The amine was 
given as a drinking solution in order to achieve an intake of 3600 µmol/kg/day for 17 weeks. Mice had 
free access to water and HFD. A) Weekly body weight changes and cumulative body weight gain during 
the treatment (B). Each point/column is the mean ± SEM of 12 determinations. Statistically different from 
corresponding value in HFD control at * p < 0.05; ** p < 0.01. 
Although both groups had the same initial body mass (BzA + HFD: 25.1 ± 0.6 vs 
HFD: 25.3 ± 0.6 g, n = 12, NS), BzA-treated mice weighed significantly less than the 
untreated age-matched controls after one week of treatment and until the end of 
experiment (Figure 25. A). Consequently, the overall body weight gain was clearly 
limited by the BzA-treatment (Figure 25. B). 
Plasma markers of metabolic disturbances 
At the end of the treatment, it became evident that the reduced body weight of 
BzA-treated mice was accompanied by a reduced lipid accumulation since the 
adiposomatic index, which is estimated as the percentage of dissected intra-abdominal 
(perirenal, retroperitoneal and epididymal) and subcutaneous fat depots relative to final 
body weight, was significantly lower than in the untreated animals (BzA + HFD: 
6.6 ± 1.1 vs HFD: 11.6 ± 0.9%, n = 12, p < 0.01). This was due to a reduction in both 
intra-abdominal WAT and SCWAT. For instance, the latter weighed 1.72 ± 0.22 g in 
the HFD-control and 0.82 ± 0.17 g in the HFD-mice drinking BzA (n = 12, p < 0.01). 
The liver was also smaller in the BzA-treated animals than in control mice but no 
significant reduction could be detected when hepatic mass was expressed as a 
percentage of body weight (3.4 ± 0.1 vs 3.6 ± 0.1%, n = 12, NS). 
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Table 14. Effect of chronic benzylamine ingestion on plasma metabolites and cytokines. Mice fed a 
high-fat diet (HFD) and drinking benzylamine (HFD + BzA) were sacrificed after overnight fasting. Data 
are presented as Mean ± SEM of 12 mice. Significantly different from HFD at: * p < 0.05; *** p < 0.001. 
Experimental group: 
   (plasma levels) HFD HFD + BzA 
FFA (mM) 0.61 ± 0.06 0.64 ± 0.07 
TG (mg/dl) 69.2 ± 5.9 58.0 ± 3.2 
Total cholesterol (mg/dl) 218.2 ± 10.2 131.0 ± 15.7  *** 
Fructosamine (µmol/l ) 200.4 ± 11.2 193.5 ± 6.9 
Uric acid (µmol/l) 365.9 ± 32.4 234.1 ± 13.6 *** 
Leptin (ng/ml) 9.78 ± 2.46 9.31 ± 2.35 
Adiponectin (µg/ml) 12.92 ± 1.16 12.64 ± 1.03 
Resistin (ng/ml) 5.93 ± 0.51 4.45 ± 0.29 * 
 
The circulating levels of free fatty acids were also measured. Under fed 
conditions, no difference was detected between untreated and BzA-treated groups 
(respective values found after 15 weeks of treatment were 0.70 ± 0.07 and 0.67 ± 0.07 
mM, NS). Under the fasting condition at the time of sacrifice, neither free fatty acids or 
triglycerides (Table 14.) were reduced in the plasma of treated mice. However, a 
decrease in total cholesterol was unexpectedly observed in the plasma from the BzA-
treated mice. Such a clear-cut anti-hypercholesterolemic effect of BzA, leading to a 
reduction of 40% in the levels found in the hyperlipidemic mice was not accompanied 
by a significant decrease of the beneficial HDL-cholesterol: 171 ± 21 and 121 ± 18 
mg/dl in HFD and HFD+BzA, respectively (n = 5, NS). The natural antioxidant 
compound uric acid showed increased plasma levels in HFD mice when compared with 
age-matched controls fed a standard chow (365.9 ± 32.4 vs 250.2 ± 22.7 µmol/l, n = 10-
12, p < 0.01). BzA-treatment significantly lowered this parameter. Fructosamine levels 
were not modified in the BzA-treated group, suggesting that BzA treatment did not 
affect plasma protein glycation. Among the three adipokines measured, only resistin 
showed a significant decrease while adiponectin and leptin plasma levels remained 
unaltered in BzA-treated mice. 
Lipolytic and glucose uptake activities in adipocytes 
The dose-dependent stimulation of lipolysis by isoprenaline was similar in 
mouse adipocytes from HFD control and BzA-treated mice, in terms of increase over 
basal values (2.5 ± 0.2 vs 2 ± 0.1, n = 9 and 12, NS for 10 nM isoprenaline). 
Submaximal stimulation by 10 nM isoprenaline was chosen to study the anti-lipolytic 
actions of insulin and BzA alone or in combination with vanadium. Insulin-dependent 
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inhibition of lipolysis was unaltered in BzA-treated animals. BzA or vanadate alone 
were practically not anti-lipolytic, but the simultaneous presence of 0.1 mM BzA plus 
0.1 mM vanadate mimicked insulin anti-lipolytic action and clearly reduced the effect 
of isoprenaline stimulation. This effect was not modified after chronic ingestion of BzA 
since the inhibition of lipolysis was equivalent in both groups (54 ± 4 vs 62 ± 7 in % 
inhibition of 10 nM isoprenaline action, n = 9 and 12, NS).  
Dose-dependent stimulation of glucose transport by insulin was unaltered by 
chronic BzA-treatment (2.2 ± 0.5; 4.9 ± 0.7; 5.1 ± 0.4; vs 2.2 ± 0.3; 4.6 ± 0.5; 5.9 ± 0.7 
fold increase over basal transport for 1; 10; 100 nM insulin, n = 9 and 12, NS). When 
tested separately, neither vanadium nor BzA exceeded 25% of the maximal insulin 
activation on hexose transport, whatever the group studied. Again, the synergism 
between BzA and vanadate totally reproduced insulin action in both HFD control and 
BzA-treated mice. Therefore, no alteration of the adipocyte responses to insulin, BzA 
and vanadate could be detected after prolonged oral administration of BzA. 
Oxidative stress and aorta NO bioavailability 
High fat diet reduced nitrite concentration in the aorta 125.08 ± 18.10 nmol/g in 
mice fed a normal chow vs 53.55 ± 2.72 nmol/g in HFD-fed mice. Table 15 shows that 
nitrite concentration was increased in the aortas of BzA-treated mice, indicating that 
BzA administration slightly improved the reduced NO bioavailability found in the 
vasculature of HFD-mice. Chronic BzA treatment did not modify the nitrate to nitrite 
ratio in aortic tissue (Table 15.). This finding argued against a putative exaggerated 
oxidative conversion of NO induced by hydrogen peroxide production accompanying 
sustained BzA ingestion and oxidation. 
Table 15. Effect of chronic benzylamine ingestion on the concentration of stable end-products of 
NO metabolism. Mean ± SEM of 8-9 aortae per group. Statistical difference between mice fed a high-fat 
diet (HFD) and drinking benzylamine (HFD + BzA) at: * p < 0.05. 
  HFD HFD+BzA 
Nitrite nmol/g aorta  53.55 ± 2.72 66.23 ± 4.49 * 
Nitrate/nitrite ratio  1.91 ± 0.22 1.59 ± 0.14 
 
Accordingly, no detectable change in the expression of SOD was found in the 
liver (not shown).  
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In HFD animals receiving BzA treatment we could observe improved glucose 
tolerance. Moreover, the amine also lowered fasting blood glucose, body weight and the 
high circulating cholesterol without causing excessive oxidative stress. 
Further inverstigations aimed at studying oral BzA administration in a more 
drastic animal model of diabetes during the set-up of hyperglycemia. 
Oral administration of benzylamine in db-/- mice 
This third set of experiments on the effect of oral BzA was conducted on young 
littermates. After weaning mice were immediately distributed into two groups: on 0.5% 
BzA and tap water drinking groups and were investigated during 8 weeks. 
A linear mixed statistical model was fitted to the data (blood glucose, water 
consumption, body weight) to describe the temporal pattern change. The initial model 
contained sex, treatment (BzA or not) and genotype (db-/- or db-/+) as fixed factors and 
it was assumed that these factors modify the individual slopes and intercepts of the 
changing parameter-age curve of the animals. Initial analysis revealed that sex is a 
clearly non-significant factor but at the same time there is a highly significant triple 
interaction between time (age), treatment and genotype. Independent factors were 
always the same, regardless what the dependent variable (water consumption, body 
weight or blood glucose) was. To reveal the reason of this interaction we split the data 
into two parts by genotype and dropped sex as a factor from the model. 
Glucose handling in db-/- mice 
Non fasted glycemia was monitored twice a week during the whole protocol 
(between week 4 and 11). 
Initial fed glycemia was higher in db-/- and remained above the level of db-/+ 
mice throughout the entire experiment. While the glucose level of db-/+ did not change 
with age, non-fasted glycemia of db-/- mice continuously increased (p < 0.0001 for age 
dependence). BzA did not alter normoglycemia of db-/+, but significantly lowered the 
non-fasting blood glucose level of db-/- animals (Figure 26.). Applying the linear mixed 
statistical model, the slope for BzA db-/-: 33.81 ± 3.14 vs db-/-: 52.61 ± 3.90, mean ± 
SE, p < 0.0005). 
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Figure 26. Non-fasted glycemia of db-/? mice at the age of 4-11 weeks. Mean ± S.E.M of experimental 
points. Statistical analysis: linear mixed model was fitted for 1027 observations and 89 groups, difference 
is indicated between slopes. Data collection db-/-: 27 (17/10); BzA db-/-: 18 (9/9); db-/+: 21 (12/9); BzA 
db-/+: 14 (7/7) animals (males/females) used respectively. 
The daily urine excretion was increasing with age in db-/-, concomitantly with 
the diabetes onset, while this parameter remained at a lower level in db-/+ mice (Figure 
27. A). The increase in the daily urine production was prevented by BzA treatment 
(Figure 27. A). Although the BzA-treated db-/- animals excreted more urine than the 
normoglycemic db-/+ ones, they produced significantly less than the untreated 
hyperglycemic mice during the last two weeks of treatment. Accordingly, the glucosuria 
was significantly reduced in db-/- mice drinking BzA solution, but was not normalized 
to a complete disappearance of glucose in urinary output (Figure 27. B). 
 
Figure 27. Urine emission (A) and daily glucose urinary output (B) of db-/- and db-/+ mice at the 
age of 8-11 weeks. Mean ± S.E.M for experimental points of db-/-: 11 (5/6); BzA db-/-: 9 (5/4); db-/+: 10 
(5/5) animals (males/females) isolated in metabolic cages, 103 determinations altogether. * p < 0.05 (vs 
db-/+); ** p < 0.01 (vs db-/+); + p < 0.05 (vs db-/- mice). 
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Elevated fasting plasma glucose of db-/- mice at sacrifice was accompanied with 
increased plasma immunoreactive insulin levels (Table 17.), which is totally in 
agreement with the type 2 diabetes mellitus that takes place in this model. BzA did not 
modify fasted glycemia of heterozygotes but lowered that of db-/- animals by 42%. 
Circulating immunoreactive insulin was not altered by the treatment regardless of the 
genotype. 
Water and food intake, body weight gain 
Water consumption increased with age in the db-/- group (p < 0.0001 for age 
dependence) while it showed small variations but not age-dependence in the db-/+ 
littermates. BzA treatment did not affect water intake of db-/+ while it changed this 
parameter dramatically in db-/- mice (slope for BzA db-/-: 0.96 ± 0.26 vs db-/-: 
3.72 ± 0.64, mean±SE, p < 0.0005 Figure 28.). 
The food consumption was followed weekly (week 6-11) and exhibited small 
variations. The db gene invalidation resulted in two-fold increase in food intake (Figure 
29.). BzA limited the average food intake by 13% in db-/+ and by 15% in db-/- mice. 
 
Figure 28. Influence of benzylamine supplementation (BzA) on liquid consumption of db-/? mice 
between the ages of 6 and 11 weeks. Mean ± S.E.M of experimental points. Data collection from db-/-: 
12 (7/5); BzA db-/-: 8 (4/4); db-/+: 9 (6/3); BzA db-/+: 5 (2/3) cages (males/females). For statistical 
analysis raw data (141 points, 35 groups) was fitted into linear mixed model, difference is indicated 
between slopes of each group. 
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Figure 29. Daily food intake between the ages of 6 and 11 weeks in db-/- and db-/+  mice (A) and 
overall average of food intake (B) during the complete experimental period. Mean ± S.E.M of 
experimental points. Data collection from db-/-: 12 (7/5); BzA db-/-: 8 (4/4); db-/+: 9 (6/4); BzA db-/+: 5 
(2/3) cages (males/females) (A). N is given between parentheses in B. Different (t test) from db-/+ at:  * p 
< 0.05; ** p < 0.01; *** p < 0.001. or from db-/- : + p < 0.05; ++ p < 0.01; +++ p <0.001. 
 
 
Figure 30. Body weight evolution of db-/? mice at the age of 4-11 weeks. Mean ± S.E.M of 
experimental pionts. For statistical analysis linear mixed model was fitted for 562 observations, 88 
groups, difference is indicated between slopes. Data collection db-/-: 27 (17/10); BzA db-/-: 18 (9/9); db-
/+: 21 (12/9); BzA db-/+: 14 (7/7) animals (males/females) used respectively. 
Although separation of obese and lean animals according to their body weight at 
the age of 4 weeks was not at all evident, body mass of db-/- mice was higher than that 
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of the animals in the db-/+ group throughout the whole experiment/measured period. 
Body weight increased with age in db-/+ (p < 0.0001) as well as in db-/- (p < 0.0001), 
however body weight of db-/- mice reached a plateau between 9-10 weeks and even 
decreased slightly by the end of the experiment (Figure 30.). 
Body mass at 4 weeks of age was similar in treated and untreated groups. BzA 
did not influence body mass of db-/+ mice (slope for BzA db-/+: 1.09 ± 0.07 vs db-
/+ :1.09 ± 0.07, NS). db-/- BzA treated mice kept their maximum body weight between 
9-11th weeks differentiating the slopes and values at the 11th week from that of BzA-
treated mice (slope for BzA db-/-: 2.92 ± 0.18 vs db-/-: 1.84 ± 0.15, mean±SE, 
p < 0.0005). Body weight gain also confirms BzA’s action (db-/- BzA: 19.7 ± 1.1 vs db-
/-: 14.6 ± 1.1 g, n = 9+9 and 11+12 males and females, p < 0.01). When adiposity was 
assessed by Echo MRI, an increased % fat mass was found in obese mice 1 day before 
sacrifice (BzA db-/-: 49.6 ± 1.6 vs db-/-: 44.3 ± 1.4, n =  3+6 and 6+7 males and 
females, p < 0.03.) 
At sacrifice, INWAT and SCWAT mass was at least 10-fold increased in db-/- 
vs db-/+ (Table 16.). As described above, BzA did not change any of these parameters 
in db-/+ animals. In db-/- mice, increased body weight of BzA-treated mice was 
accompanied by an increased lipid accumulation according to the changes in 
adiposomatic index, which is estimated as the percentage of dissected fat depots relative 
to final body weight. The adiposomatic index was significantly higher in the db-/- BzA-
treated mice (BzA db-/-: 15.3 ± 0.5 vs db-/-: 13.7 ± 0.4%, n = 18 and 28, p < 0.02). This 
was mainly due to a 25% increase of subcutaneous white adipose tissue mass compared 
to the non-treated db-/- animals ( Table 16). 
Table 16. Effect of benzylamine supplementation (BzA) on some clinical parameters in db-/+ and 
db-/- at sacrifice. Statistical analysis was made by two-way ANOVA. Number of animals 
(males/females)/group db-/-: 28 (18/10); BzA db-/-: 18 (9/9); db-/+: 21 (12/9); BzA db-/+: 14 (7/7) used 
respectively. Different from db-/+ at:  * p < 0.05; ** p < 0.01; *** p < 0.001, or from db-/-: + p < 0.05; 
++ p < 0.01, no difference found between db-/+ and BzA db-/+. 
 db-/+ BzA db-/+ db-/- BzA db-/- 
body weight (g) 21.74 ± 0.82 21.52 ± 0.70 ns 32.94 ± 0.96 *** 36.19 ± 0.95 + 
Fasting blood glucose 
(mg/dL) 85.00 ± 5.58 76.41 ± 4.20 ns 375.00 ± 22.94 *** 245.39 ± 23.77 +++ 
total mass of  INWAT (g) 0.45 ± 0.02 0.42 ± 0.06 ns 1.93 ± 0.10 *** 2.24 ± 0.11 ns 
SCWAT mass (g) 0.35 ± 0.03 0.29 ± 0.04 ns 2.66 ± 0.18 *** 3.31 ± 0.16 + 
liver total mass (g) 0.89 ± 0.03 0.91 ± 0.04 ns 1.71 ± 0.07 *** 1.87 ± 0.07 ns 
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Plasma markers of metabolic disturbances 
Diabetes onset increased cholesterol (total and HDL), free fatty acid, uric acid 
and fructosamine in plasma. BzA-treatment did not affect any of the above mentioned 
parameters in db-/+ mice, albeit BzA reduced triglyceridemia but not FFA. The lowered 
TG is in accordance with increased SCWAT permitting a better storage of lipids in that 
tissue. BzA also lowered uric acid levels (Table 17.) as observed before in other animal 
model of insulin resistance (Oral administration of benzylamine in HFD-fed mice). 
As BzA had no effect on glycemia, body weight, plasma metabolic parameters 
of db-/+ mice, but it clearly improved diabetic state of db-/- animals, further 
investigations aimed at studying BzA’s effect in only db-/- mice. 
Table 17. Plasma metabolic parameters after overnight fasting at sacrifice. Number of animals 
(males/females)/group db-/-: 28 (18/10); BzA db-/-: 18 (9/9); db-/+: 21 (12/9); BzA db-/+: 14 (7/7) used 
respectively. Statistical analysis was made by two-way ANOVA. Different from db-/+ at:  * p < 0.05; ** 
p < 0.01; *** p < 0.001, or from db-/-: + p < 0.05; ++ p < 0.01, no difference found between db-/+ and 
BzA db-/+. 
 db-/+ BzA db-/+ db-/- BzA db-/- 
Glucose (g/l) 1.10 ± 0.08 1.07 ± 0.13 ns 5.67 ± 0.49 *** 3.30 ± 0.43 ++ 
Insulin (μg/l) 0.40 ± 0.05 0.38 ± 0.05 ns 2.89 ± 0.32 *** 2.62 ± 0.51 ns 
Cholesterol 
(mmol/l) 1.94 ± 0.13 2.00 ± 0.13 ns 2.29 ± 0.22 * 2.46 ± 0.19 ns 
Cholesterol LDL 
(mmol/l) 0.18 ± 0.04 0.20 ± 0.04 ns 0.28 ± 0.12 ns 0.23 ± 0.10 ns 
Cholesterol HDL 
(mmol/l) 1.62 ± 0.11 1.69 ± 0.11 ns 2.01 ± 0.16 ** 2.08 ± 0.15 ns 
FFA (mmol/l) 0.64 ± 0.05 0.78 ± 0.07 ns 0.90 ± 0.05 *** 0.94 ± 0.06 ns 
TG (g/l) 0.97 ± 0.07 1.13 ± 0.09 ns 1.27 ± 0.10 ns 0.87 ± 0.06 + 
Uric acid (µmol/l) 279.31 ± 17.99 272.63 ± 17.94 ns 406.70 ± 23.54 *** 330.60 ± 24.55 + 
Fructosamine 
(µmol/l) 204.46 ± 4.66 189.07 ± 7.69 ns 291.84 ± 11.23 *** 262.73 ± 14.28 ns 
Lipolytic and glucose uptake activities in adipocytes 
The influence of diabetes and oral BzA on lipolysis and glucose uptake, was 
studied in adipocytes freshly isolated from perigonadal WAT of db-/- mice. 
Basal lipolysis was similar in db+/- and db-/- mice (not shown). Isoprenaline 
exerted maximal effect at 100 nM in db-/+ (not shown) while at 10 μM concentration in 
db-/- littermates. The basal lipolytic activity was unaltered after oral BzA treatment 
(0.63 ± 0.05 vs 0.55 ± 0.11 µmol glycerol/100 mg lipid/90 min, n = 3, NS). The dose-
dependent stimulation of lipolysis by isoprenaline remained also unaffected (Figure 31. 
A). 
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Figure 31. Isoprenaline-induced lipolysis in db-/- mice expressed as the increase over basal output 
(A). Anti-lipolysis of different agents on 10 nM isoprenaline’s stimulated effect (B). Means ± SEM of 
4 mice. Statistical analysis is made by t test. Different from 10 nM isoprenaline in db-/- at:  + p < 0.05; 
different from 10 nM isoprenaline in BzA-treated db-/- at:  # p < 0.05 and difference between db-/- vs 
BzA-treated db-/-: * p < 0.05. 
When the anti-lipolytic effect of insulin was tested on the submaximal 
stimulation promoted by 10 nM isoprenaline, BzA-treated mice exhibited a greater 
response to 100 nM insulin than untreated db-/- mice, although insulin could only 
partially inhibit the β-adrenergic agonist-evoked lipolysis in both groups (Figure 31. B). 
BzA itself was also anti-lipolytic, since only 60 ± 12 and 46 ± 9% of the 10 nM 
isoprenaline-induced lipolysis remained in the presence of 1 mM BzA in db-/- and BzA-
treated db-/- mice, respectively. BzA effect was not greater in the presence of vanadate. 
In accordance with the well-known insulin-resistant state of db-/- mice, the 2-
deoxyglucose transport was poorly activated by insulin in adipocytes of young db-/-
obese mice, since 100 nM insulin induced only 2.2 ± 0.2 fold increase over basal values 
while in lean heterozygotes the maximal response to the hormone was 4.9 ± 0.4 fold 
(n = 6, p < 0.001, not shown). In fact, oral BzA treatment modified neither basal 
(0.47 ± 0.09 vs 0.35 ± 0.05 nmol 2-DG/100 mg lipid/10 min, n = 3, NS) nor maximal 
insulin-stimulated hexose uptake (2.7 ± 0.4 vs 2.2 ± 0.1 increase over basal 2-DG 
uptake, n = 4, NS). By contrast, BzA treatment tended to improve the adipocyte 
sensitivity to insulin since 10 nM insulin’s effect was equivalent to 56 ± 2% of maximal 
insulin’s effect in treated vs 37 ± 7% in untreated obese mice (n = 3, p < 0.07). Again, 
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BzA was able to partially mimic insulin action on adipocytes, since at 1 mM, it 
stimulated uptake up to 52 ± 3% of maximal insulin effect in db-/- mice. Taken 
together, these data show that BzA behaved in vitro as an insulin mimicking agent, 
while it was unable to totally prevent in vivo the setup of insulin resistance in adipocytes 
of INWAT. 
As SCWAT was more affected by BzA-treatment, the gene expression in 
SCWAT was investigated to further explore BzA’s actions. Table 18. shows that 
expression of HSL a protein related to adipocyte metabolism was higher in diabetic 
animals. FAS, Adiponectin, apelin, some adipocyte hormones, as well as inflammation 
(PAI-1, Il-6, F4/80) or endothelial markers (cd31, Tie2) were also overexpressed in 
diabetic animals. 
Table 18. Gene expression in SCWAT in lean and obese mice receiving or not oral benzylamine 
(BzA). Mean  ± SEM of 9 mice. Different from db-/+ at:  * p < 0.05; ** p < 0.01; *** p < 0.001, no 
difference found between db-/- and BzA db-/-. 
Function  db-/+ db-/- BzA db-/- 
Adipocyte 
secretion 
Adiponectin 207.03 ± 16.36 298.20 ± 32.30 * 302.33 ± 21.49 ns 
Apelin 0.27 ± 0.05 0.93 ± 0.15 *** 0.70 ± 0.08 ns 
Fatty acid 
metabolism 
FAS 220.40 ± 43.23 77.47 ± 48.93 * 41.57 ± 4.88 ns 
HSL 55.39 ± 4.06 86.08 ± 8.57 ** 88.26 ± 6.16 ns 
Inflammation 
PAI-1 2.04 ± 0.66 20.43 ± 4.14 *** 26.59 ± 4.21 ns 
IL-6 0.01 ± 0.00 0.04 ± 0.02 ns 0.05 ± 0.01 ns 
F 4/80 0.49 ± 0.08 4.51 ± 1.60 * 2.74 ± 0.68 ns 
Endothelial 
markers 
cd31 31.52 ± 3.25 43.85 ± 4.78 * 41.22 ± 3.09 ns 
Tie 2 5.37 ± 0.62 8.06 ± 0.99 * 6.08 ± 0.85 ns 
Adipocyte 
differentiatio
n markers 
APJ 2.06 ± 0.35 2.44 ± 0.52 ns 2.28 ± 0.46 ns 
SSAO 30.68 ± 3.37 78.22 ± 7.58 *** 84.64 ± 7.10 ns 
 
Oxidative stress and aorta NO bioavailability 
Basal hydrogen peroxide production, without any added exogenous substrate 
was increased in db-/- vs db-/+ mice when expressed on a per mg protein basis 
(113.4 ± 19.1 vs 65.3 ± 13.2 pmol H2O2/mg protein/min, n = 7, p < 0.06) in SCWAT 
tissue homogenates. BzA treatment did not change hydrogen-peroxyde release neither 
in homogenates (BzA db-/-: 103.1 ± 9.2 vs db-/-: 113.4 ± 19.1 pmol H2O2/mg 
protein/min, n=7, NS), nor in fresh pieces of WAT: (BzA db-/- 0.45 ± 0.19 vs db-/- 
0.46 ± 0.21 pmol H2O2/mg wet tissue/min, n = 4-5, NS).  
Nitrite concentration was decreased, while nitrate to nitrite ratio was increased in 
the aortas of db-/- compared to db-/+ (Table 19.). These data are in accordance with 
those collected on previously reported models (HFD- and streptozotocin-induced 
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diabetes), indicating a decreased NO formation of the endothelial cells during the set-up 
of insulin resistance accompanied by an increased relative oxidative conversion of this 
vasoactive agent. BzA restored aortic nitrite levels (as was also seen in HFD-fed mice), 
and reduced nitrate/nitrite ratio, however this reduction was at the limit of significance 
(p < 0.06). BzA administration is thus suggested to improve the reduced NO 
bioavailability found in the vasculature of db-/- mice. 
To sum up, we could show that oral BzA is able to delay the onset of 
hyperglycemia in db-/- mice. BzA reduced food and water intake and increased body 
weight gain. This latter is in accordance with the effect of the amine on insulin 
resistance in adipocytes. Furthermore BzA improved NO bioavailability in aorta and did 
not cause any excessive oxidative stress or inflammation in SCWAT. 
Table 19. Nitrite concentrations and nitrate to nitrite ratio in aorta of db-/? mice. Mean  ± SEM of 
db-/-: 14 (8/6); BzA db-/-: 11 (7/4); db-/+: 13 (7/6) mice (males/females) used respectively. Statistical 
analysis is made by t-test. Different from db-/+ at: * p < 0.05; ** p < 0.01 or from db-/-:  ++ p < 0.01. 
 db-/+ db-/- BzA db-/- 
Nitrite nmol/g aorta  181.21 ± 25.45 108.24 ± 11.00 * 179.36 ± 24.64 ++ 
Nitrate/nitrite ratio  1.97 ± 0.22 3.48 ± 0.48 ** 2.28 ± 0.34 Ns 
 
6.4. In vitro tests for screening SSAO substrate drug 
candidates 
It has been described several decades earlier that inter-species variations and 
even inter-tissular variations exist regarding the selectivity of SSAO towards its 
substrates because SSAO and other copper-containig amine oxidases have been studied 
in numerous animal models, rat, mouse, cow, pigs, etc on different tissues (Boomsma et 
al., 2000b). Curiously, less evident were the changes of inhibitor capacities between 
rodents and human forms of SSAO (Callingham et al., 1990). In this context and with 
our objective to search for novel substrates of SSAO, we focused our attention in 
comparing biochemical and pharmacological properties of human and rodent SSAOs. 
We have found that human SCWAT has greater capacity to oxidise BzA even at 1 mM 
concentration than mouse fat depots. In both species, BzA was prominently oxidised by 
SSAO. Mouse SSAO Vmax is one third of human’s. Km of SSAO in human SCWAT is 
40 fold higher than that of mouse SCWAT (Table 20.). Another difference is that 
human adipocytes do not need vanadate for glucose transport stimulaton or anti-
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lipolysis by SSAO substrates. Human adipose SSAO, thus can be a promising drug 
target. 
Table 20. Comparison of enzyme kinetic parameters of murine and human SCWAT. SSAO-
dependent H2O2 production was assessed by Amplex Red method. Mean ± SEM of  n = 3-5 
determinations. 
 Vmax (pmol/mg protein/min) Km μM 
Human SCWAT H2O2 detection  1184 ± 243 469 ± 44 
Mouse SCWAT H2O2 detection  411 ± 11 14 ± 2 
 
Until recently, BzA was the best substrate for SSAO. Four novel (Substrate A-
D) and two already known (4-phenylbuthylamine (4-PBA) (Marti et al., 2004), 3-(4-
methylthiophenyl)propylamine (3-MTPPA) (Gallardo-Godoy et al., 2004)) SSAO 
substrates were designed and synthesised at the Organic Chemistry Department of 
Semmelweis University. Chemical structures of the new compounds are not allowed to 
be published because of patentship. We developed screening methods to test these 6 
SSAO substrates as potential drug candidates in diabetes, in all protocols we used BzA 
as a reference.  
First, hydrogen peroxide production in human SCWAT homogenates was tested 
at 0.1 and 1 mM amine concentrations. 
 
Figure 32. Effect of amines on hydrogen peroxide release of SCWAT homogenate of 6 women 
patiens undergoing abdominal dermolipectomy. 
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Most substrates were able to increase H2O2 production and their action depended 
on the used concentration (Figure 32.). Substrate-A, substrate-B and 4-PBA 
hydrochloride produced more hydrogen peroxyde in human fat preparations at 1 mM 
concentration when compared to 1 mM BzA. 4-PBA has been previously reported a 
better substrate of SSAO than BzA (Yraola et al., 2006) . 
Next, in vitro insulinomimetic effects of amines were measured in isolated 
human adipocytes. 
Lipolysis in human adipocytes 
 
 
Figure 33. Anti-lipolytic effect of SSAO-interacting agents(A). Adipocytes were isolated human from 
SCWAT of 5 women undergoing abdominal dermolipectomy. Correlation between antilipolitic effect and 
SSAO-dependent H2O2 release in the presence of 1 mM amine concentration (B). 4-PBA and 3-MTPPA 
are excluded from correlation. 
BzA at 1 mM inhibited the isoprenaline-stimulated lipolysis in human 
adipocytes by 50%. Under the same conditions, 4-PBA and 3-MTPPA totally abolished 
the lipolytic activation. Their anti-lipolytic effect was dose-dependent and the 
stimulation induced by 10 nM isoprenaline was inhibited by 100 µM of amines (Figure 
33.). 4-PBA and 3-MTPPA were also anti-lipolytic in mouse adipocytes (not shown). In 
order to verify the involvement of SSAO in their anti-lipolytic effect, the agents were 
further tested in KO AOC3 mice. 3-MTPPA and 4-PBA were still anti-lipolytic at 1 
mM in adipocytes fom KO AOC3 mice (the former inhibiting 22.3 ± 4.9, the latter 61.7 
± 6.2 % of 10 nM isoprenaline stimulation), while BzA (+vanadate) did not show effect. 
These agents may behave as MAO or other AO substrates or can hamper isoprenaline-
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lipolytic response through other possible ways (β-antagonist, α2-agonist). As both 
compounds inhibit the effect of the direct adenyl cyclase activator forskolin (3-MTPPA: 
32.7 ± 16 and 4-PBA: 33.9 ± 15.9 in % of the effect of 10 μM forskolin, n=2) in human 
adipocytes, they do not interact with β-adrenoceptors. Actually, the SSAO-independent 
anti-lipolytic action of these two molecules is under current investigation. 
In most cases hydrogen peroxyde production correlates with the anti-lipolytic 
effect. Substrate-A and substrate-B seems to have greater effect than BzA. 3-MTPPA 
and 4-PBA are excluded from the correlation as they apparently do not behave only as 
SSAO-interacting agents. 
Glucose uptake in human adipocytes 
4-PBA, but not 3-MTPPA, was as efficient as BzA regarding glucose transport 
activation in human adipocytes. At 100 µM, both amines promoted a glucose uptake 
activation that was equivalent to 27% of the maximal response to insulin. 
 
Figure 34. Effect of SSAO-interacting agents on glucose uptake(A). Adipocytes were isolaletd from 
SCWAT of 6 women. Correlation between glocose uptake stimulation and H2O2 production at 1 mM 
substrate concentration (B). Substrate-A does not match in correlation. 
Figure 34 shows that only substrate-B has better capacity to stimulate glucose 
uptake than BzA. 
Taking together anti-lipolysis and glucose transport, this screening method has 
succeeded in detecting Substrate-B as better substrate for SSAO than BzA. Ongoing 
research on a larger number of compounds will ascertain whether other molecules can 
be considered as better substrates for human SSAO than BzA. 
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7. Discussion 
7.1. Investigation of SSAO activity in adipose tissue 
High SSAO activity and subsequent H2O2 production has already been described 
in WAT (Raimondi et al., 2000; Raimondi et al., 1991). Our results showing that the 
oxidation of BzA in SCWAT is highly dependent on SSAO are in accordance with these 
previous reports. The maximal H2O2 release which is slightly diminished at higher 
substrate concentrations reflects the very complicated enzyme kinetics of SSAO (Holt, 
2009; Holt et al., 2008). Nevertheless this work reports first that the WAT SSAO 
produces H2O2 in vitro without any addition of exogenous amines. This finding 
deserves further investigations. First, the endogenous substrates present in WAT 
responsible for the small but detectable hydrogen peroxide production should be 
identified. The concentrations of two such candidates, namely aminoacetone and 
methylamine, have been recently determined in adipose tissue (1.9±0.9 for 
methylamine, 0.1±0.0 aminoacetone nmol/g tissue) (Xiao et al., 2009). However 
because of their very small amounts, they can hardly be responsible for the basal H2O2 
production found in our experiments. Second, it should be verified if the intact, adipose 
tissue shares the same spontaneous activity with the homogenate or the homogenisation 
process and the cell rupture are responsible for the release of a substrate (for example 
histamine (Fredholm et al., 1971), noradrenaline from WAT nerves (Dodt et al., 2003) 
or lysine) prone to be catabolized by the SSAO enzyme. 
The soluble form of SSAO circulating in the plasma has been extensively 
studied in diverse pathologies, including diabetes (Obata, 2006) and obesity (Dullaart et 
al., 2006; Li et al., 2005; Mészáros et al., 1999b; Visentin et al., 2004) while changes in 
tissue-bound SSAO activity in such pathologies are less described. 
The present work clearly shows that the SSAO activity is increased in SCWAT 
in two models of obesity and insulin resistance: the HFD-fed and the db-/- mice. The 
higher activity was due to an enhanced expression of the gene encoding for the copper-
containing amine oxidase and to increased protein abundance as was confirmed by RT-
PCR and Western Blot analysis, respectively. Enzyme activity was not changed in 
PGWAT and in PRWAT, indicating a complex anatomical-dependent mechanism of 
regulation. The fact that the basal SSAO-dependent H2O2 release is also increased in 
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SCWAT of HFD-diabetic animals but not in that of db-/- mice may be a result of the 
different diet composition or genetic background leading to a difference in endogenous 
SSAO substrate amines present in WAT. 
Fasting did not alter enzyme activity in INWAT depots in rats. The lack of 
detectable change in SCWAT SSAO activity in adipose tissue during fasting was also 
observed (Iffiú-Soltész et al., 2009). This preservation of SSAO capacity in fat stores 
during weight loss is likely the consequence of: 1) persistent SSAO expression in spite 
of fasting-induced metabolic disturbances, and 2) maintained total protein content in 
INWAT. Fasting-induced depletion of fat cell stores thus is not accompanied by 
SSAO/VAP-1 down-regulation, while the circulating level of insulin was found to be 
decreased (not shown). 
These observations improve our current knowledge about amine oxidase 
regulation in adipocytes, which was limited so far to the repeatedly reported increase of 
SSAO activity and mRNA expression during adipocyte differentiation (Bour et al., 
2007a; Mercier et al., 2001; Moldes et al., 1999; Subra et al., 2003). 
Increased SSAO activity in SCWAT of obese mice is probably due to an 
enhanced expression of SSAO in the mature adipocytes, since they have higher activity 
and express much more mRNAs of the AOC3 gene encoding for SSAO than the other 
cell types found in adipose tissue (Bour et al., 2007a). The SSAO enrichment that 
occurs in hypertrophied fat cells resembles to the SSAO emergence that takes place 
during adipocyte differentiation (Bour et al., 2007a; Mercier et al., 2001; Moldes et al., 
1999; Subra et al., 2003). However, the overexpression of SSAO in WAT does not 
contribute to obese phenotype (Iffiú-Soltész et al. unpublished data). 
Increased SSAO activity in SCWAT of obese mice can also be related to low 
grade inflammation of the tissue. This latter idea is supported by the enhanced mRNA 
expression of PAI-1 and F 4/80 in SCWAT of db-/- vs db-/+ mice (Table 18.) and by 
the fact that KO AOC3 mice possess reduced low-grade inflammation of WAT (Bour et 
al., 2009). 
Nevertheless, the relationship between fat depot extension and SSAO expression 
could be more complicated than it appears since PGWAT and PRWAT, which also 
enlarge with obesity, did not exhibit any increase in SSAO activity. However, higher 
SSAO activity in intra-abdominal - but not subcutaneous - fat depots has been reported 
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in dogs fed a high-fat diet (Wanecq et al., 2006) and PGWAT of adult db-/- mice (Cioni 
et al., 2006). Another investigation on mice rendered obese by high-fat diet feeding 
described no alteration in adipose SSAO activity (Visentin et al., 2005) and obese 
Zucker rats seem to express less adipose SSAO than their lean controls (Moldes et al., 
1999). In SCWAT, no change in SSAO activity was found when comparing young 
obese subjects (Body mass index >30) with age-matched controls (Visentin et al., 
2004). Therefore, our observations can be regarded as one more among the numerous 
interspecies differences (Al-Wabel, 2008) related to SSAO. 
Two distinct causes of increased SSAO may coexist: one is the upregulated 
expression of AOC3 gene encoding for SSAO and the other merely depends on the 
adipose tissue enlargement that characterises obesity. As a consequence of its 
hypertrophied mass, the adipose tissue of an obese individual contains much more 
SSAO activity than the same anatomical fat depot in a lean control, even without an 
increase in enzyme expression at cellular level. Obviously, this quantitative aspect must 
be considered for a tissue that can increase its mass 10-fold in obesity. There are no 
other organs capable of a change of this magnitude except for growing tumors and 
placenta (Carpéné, 2009). 
Even if the enzyme activity does not change when expressed on a per mg protein 
basis, in obesity the overall capacity of WAT to oxidise BzA is higher compared to lean 
controls. At this point, the need for further determination of age- and adiposity- 
dependent changes in adipose SSAO becomes evident, especially for clinical 
investigations. Indeed, the numerous variations of plasma SSAO found in patients 
suffering from a broad variety of metabolic diseases (Boomsma et al., 2003) warrant the 
extension of the investigations to the adipose tissue-bound form. 
7.2. In vitro insulin-like effect of benzylamine 
Since amine oxidation may influence adipocyte functions, there is a need to 
increase our knowledge on the regulation and the physiological role of amine oxidases 
and their substrates in adipose tissue.  
In our in vitro rodent models, assessing anti-lipolysis, glucose transport and 
lipogenesis, we have evidenced that beside the SSAO-mediated oxidation of our 
reference amine substrate (BzA), the presence of the protein tyrosin phosphatase 
inhibitor vanadate was also needed to observe insulinomimetic effects. These data are in 
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line with previous reports about the synergism between vanadate and amines due to the 
formation of peroxovanadate complexes (Abella et al., 2003a). We have also shown that 
anti-lipolysis and lipogenesis induced by BzA + V were significantly less in KO AOC3 
mice. Similar difference was found on glucose uptake in adipocytes of KO AOC3 and 
WT mice (Bour et al., 2007b), evidencing that the insulinomimetic effects were 
dependent on SSAO. The targeted invalidation of the AOC3 gene leads to SSAO-
deficient mice that otherwise possess functional adipocytes: the β-adrenergic 
isoprenaline response is unaltered as well as insulin responsiveness. 
Albeit several insulin-like effects of exogenous amines have been described in in 
vitro studies there is not at the present time any indication supporting the spontaneous in 
vivo occurrence or the physiological relevance of the amine-dependent H2O2 
production. Further studies on the adipose tissue development and on the metabolic 
control of mice with null mutation of the AOC3 gene appear to be of first importance, 
especially because, under some conditions, this model can be considered as mildly 
obese (Bour et al., 2009). Disturbances in cholesterol and methylamine metabolism, 
adipokine production are under current investigation (Carpéné et al., unpublished 
observations) and may help to unravel novel role of AOs in adipocyte physiology. 
7.3. In vivo insulin-like effect of benzylamine 
7.3.1. Effect of a single injection of benzylamine on glucose 
handling 
Although the in vitro experiments have demonstrated the insulin-like actions of 
BzA in combination with vanadate, it seemed to be worth to clarify whether BzA alone 
is also effective in vivo, for at least two reasons: On the one hand vanadium potentiates 
BzA’s insulin-like actions but it is potently toxic and it may alter overall phosphorus 
metabolism (a serious adverse effect that has limited its development as an antidiabetic 
drug). On the other hand the presence of vanadate does not improve the insulin-like 
effects of BzA in murine preadipocytes (Carpéné et al., 2006) and in human adipocytes 
(Morin et al., 2001). It might thus be suspected that the synergism observed between the 
amine and the transition metal in the rodent diabetic models studied so far could not be 
easily extrapolated to diabetic patients. In this context, it was justified to test whether a 
diabetic model shown in vivo to be responsive to arylalkylamine vanadium salts 
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(Garcia-Vicente et al., 2007; Yraola et al., 2007) could be influenced similarly by BzA 
alone. 
Non-diabetic and VHFD mice clearly responded to BzA challenges by limiting 
their hyperglycemic response during IPGTT. BzA administration did not change fasting 
plasma glucose levels in VHFD mice (Figure 21. A). Therefore, the synthetic amine was 
devoid of a strong hypoglycemic activity, while it provoked a dose-dependent clear-cut 
anti-hyperglycemic response at 7-700 μmol/kg doses (Figure 21. B). These results are 
completely in line with previous findings where 7 μmol/kg BzA improved glucose 
tolerance in diabetic mice or non-diabetic rabbits when injected or infused (Iglesias-
Osma et al., 2004). In such conditions the in vivo insulinomimetic effect of BzA was 
totally abolished by pre-treatment with semicarbazide. 
In our model the simultaneous presence of vanadate did not further improve the 
anti-hyperglycemic response to BzA. The presence of vanadate thus was not crucial for 
the in vivo insulin-like effect of the tested SSAO substrate. Moreover, BzA was equally 
efficient alone or when associated with vanadium in reducing the hyperglycemic 
response of mice subjected to a glucose load.  
SSAO is the protein being involved in the anti-hyperglycemic effect of the 
benzylamine-vanadate complex B6V10 (Figure 22.), as supported by previous reports 
(Garcia-Vicente et al., 2007). The immunoreactive insulin levels clearly showed that 
beneficial effect of B6V10 on glucose tolerance is not the consequence of a stimulated 
insulin secretion. This was in line with previous in vitro experiments where BzA was 
unable to stimulate insulin secretion in pancreatic islets from VHFD-fed mice (Iglesias-
Osma et al., 2004). 
Glucose tolerance of KO AOC3 and WT mice was similar (Figure 22.), as was 
insulin secretion in our experiments at 0-5-15-30 minutes after glucose load. However 
Garcia-Vicente and coworkers experienced a delay in early insulin secretion (5 min 
after glucose load) in female KO AOC3 mice vs WT (Garcia-Vicente, 2007). 
Some observations suggest that SSAO inhibitors could impair a putative action 
of biogenic amines and may predispose to insulin resistance, therefore explaining the 
hyperinsulinism observed in treated rabbits (Iglesias-Osma et al., 2004), or are capable 
to provoke glucose intolerance, as evidenced in another model of obese diabetic mice 
(Yu et al., 2004). It should be taken into account that SSAO substrate amines escaping 
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from oxidation may activate other receptors like H2 receptors in adipocytes (Berlan et 
al., 1981) or ion channels (Banchelli et al., 2001; Pirisino et al., 2001). The lack of 
inhibitor selectivity might be responsible for such contradictions between these models 
and genetic invalidation of SSAO. We should not forget that even semicarbazide 
inhibits DAO, LO, etc. 
7.3.2. Effect of chronic benzylamine injection in 
streptozotocin-induced diabetic rats 
As SSAO is present on the surface of endothelial cells, besides adipose SSAO 
(Abella et al., 2004), endothelial SSAO can be a possible source of the excessive 
plasma SSAO found in diabetes (Stolen et al., 2004b). While SSAO activity can have 
beneficial effect in adipocytes because of the insulin-mimicking properties described 
above, the activation of plasma or endothelial SSAO can be hazardous, because it 
increases the local production of ROS, aldehydes, and ammonium, which products can 
damage the blood vessels. These cytotoxic compounds thus may contribute to the 
cardiovascular and renal complications of diabetes (Yu et al., 2003a). Considering the 
deleterious vascular effects of methylamine administration reported in mice 
overexpressing vascular SSAO (Stolen et al., 2004a), SSAO substrates might induce 
oxidative stress or diabetic-like vascular injury. In diabetic conditions the study of this 
double action of substrates, thus have an interest. We have examined the 
insulinomimetic activity and effect on indicators of oxidative stress of BzA treatment in 
diabetic rats in the absence or presence of low concentration of vanadate. 
50% increase in AGEs in the serum of diabetic rats after 4 weeks of the disease 
induction was found compared to the control animals. Insulin and BzA+V treatment, 
which was started immediately after the onset of diabetes, reduced the accumulation of 
the glycated proteins. The drop in the amount of AGEs induced by BzA+V treatment 
may be, at least partly, the consequence of the reduction in soluble SSAO activity and 
ROS production (Soltész et al., 2007). Although, BzA alone also reduced 
hyperglycemia, this anti-hyperglycemic effect was not accompanied by the reduction of 
accumulation of AGEs in the serum. 
Endothelial dysfunction, characterised by reduced NO-dependent vasodilatation, 
is the early sign of vascular complications. Reduced effectiveness of NO in diabetes 
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may be the consequence of either its decreased formation, or its increased 
elimination/inactivation. There are contradictory data about the altered expression or 
activity of NO synthase in the diabetic state (Santilli et al., 2004; Tábi et al., 2006). An 
accelerated inactivation of NO is highly probable because of the increased formation of 
reactive oxygen species in the disease. Increased vascular endothelial generation of 
superoxide anions (Hink et al., 2001) has been reported and elevated amounts of 
peroxynitrite in the kidney of diabetic rats have also been shown (Stadler et al., 2003). 
The measurement of the stable end products of the NO metabolism in the tissues allows 
the assessment of the oxidative conversion of NO. In our experiments, decreased nitrite 
level and increased nitrate/nitrite ratio in the diabetic rat kidney was found, indicating a 
reduced biological availability and accelerated oxidative inactivation of NO. Insulin and 
BzA+V treatments both significantly reduced this elevated nitrate/nitrite ratio. No 
increase of the NO production could be observed in the insulin-treated group. This 
contrasts with previous findings, which described increased efflux of nitrate and nitrite 
from aortic strips of insulin treated diabetic rats after acetylcholine stimulation, and 
increased expression of endothelial NO synthase (Kobayashi et al., 2001). However, in 
contrast to insulin, BzA+V treatment increased the nitrite levels, indicating elevated 
production of NO. Both treatments could ameliorate the accelerated oxidative 
inactivation of NO, although mechanisms involved are probably different. In the case of 
insulin, reduction of oxidative stress and consequent decrease of the oxidative metabolic 
transformation of NO are probable, while BzA+V treatment may increase the 
production of NO. 
7.3.3. Effect of oral benzylamine treatment in various 
animal models of insulin resistance  
Though BzA is a synthetic amine it is also present in the plant Moringa oleifera, 
known as the “miracle tree” used in folk medicine as an antidiabetic agent. The glucose 
lowering property of this medicinal plant was certified in a pharmacological survey (Kar 
et al., 2003). This latter finding together with the well-known anti-hyperglycemic effect 
of parenteral BzA administration led us to suppose that BzA might contribute, at least 
partly to the plants’s effect. 
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The demonstration of BzA diffusion across everted gut sacs, and the detection of 
BzA in the urine of BzA-drinking mice show that the intestinal barrier is not 
insurmountable for this amine oxidase substrate. Substantial proportion of ingested BzA 
is thus supposed to be absorbed in the gut, despite of the considerable amine oxidation 
activity in the intestine, supporting the idea that oral administration could result in 
plasma and tissue BzA levels sufficient to exert some of the insulin-like actions 
observed in vitro (Bour, 2006).  
Chronic oral administration of BzA did not totally normalize the relative glucose 
intolerance of VHFD mice, since it could not reduce their slightly increased fasting 
glycemia. Decrease of blood glucose levels was observed only in fed state but did not 
consistently appeared throughout BzA-treatment. This was probably the consequence of 
the highly variable glycemia of fed animals, which unexpectedly remained lower than in 
the fasted state. 
We extended our first observations made in VHFD-fed mice using another 
special diet composition (HFD) containing more carbohydrates to induce insulin 
resistance. A transgenic model of diabetes (db-/- and db-/+) was also accommodated. 
Orally given BzA improved the glucose tolerance in HFD-fed mice, as it did in VHFD 
animals. In addition, BzA slightly reduced fed and fasted glycemia in HFD-fed mice. 
These observations are in perfect agreement with those reported in a preliminary study, 
describing reduced hyperglycaemic response during glucose tolerance tests in non-
obese non-diabetic rats receiving BzA per os (Bour et al., 2005). Such pilot experiment 
also revealed that fasting glycemia was not influenced by BzA in non-obese, non-
diabetic rats, being in complete agreement with our results found in db-/+ mice. 
However, hyperglycemia of db-/- animals was markedly lowered in either fed or fasting 
state by oral BzA supplementation. In other words, BzA supplementation delayed the 
onset of diabetes in this widely recognized model of severe type 2 diabetes. The anti-
hyperglycemic effect of BzA in HFD-fed and db-/- insulin-resistant mice is in complete 
accordance with its beneficial action in streptozotocin-induced type 1 diabetic rats, the 
hyperglycemia of which was not normalized but significantly reduced by repeated s.c. 
administration of BzA alone (see chapter 1.3.2). The BzA-dependent activation of 
glucose transport and de novo lipogenesis in adipocytes should be responsible for such 
beneficial effects (Fontana et al., 2001; Marti et al., 2001).  
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The lack of the effect of BzA on fasting glucose in VHFD-fed animals is 
somehow in discrepancy with the above-mentioned experiments. A possible explanation 
for this is that VHFD mice have a peculiar glucose homeostasis, as they are starved for 
alimentary glucose even under fed conditions, since their diet is devoid of 
carbohydrates. These mice are intolerant to a glucose load although do not display all 
the typical features of type 2 diabetes: they do not exhibit hyperinsulinemia and show 
lower protein glyc(oxid)ation index (AGEs) than normoglycemic mice fed a control 
diet. Therefore, it might be difficult for an agent deemed to improve glucose utilization 
in peripheral tissues to correct the defect of VHFD mice having hepatic gluconeogenesis 
as practically sole source of glucose. This may explain the discrepancy between the 
evident beneficial action of BzA on glucose handling in the presence of a glucose load 
and its inconsistent action on fasting hyperglycemia in VHFD mice. 
BzA treatment diminished water consumption in all studied models of insulin 
resistance. It can be considered as a reduced fluid intake only if spillage and dressing 
can be ruled out. Similar reduction has already been observed in an experiment on non-
diabetic Wistar rats receiving a 0.3% BzA drinking solution for seven weeks (Bour et 
al., 2005). In all conditions, it is difficult to assess whether BzA exerts an aversive 
influence on drinking behaviour or a pharmacological effect on fluid homeostasis. The 
former hypothesis could not be discarded due to the bad smell of BzA solutions, even 
smelling like putrefied fish at much higher concentrations than those given to the mice. 
Unfortunately, in VHFD and HFD-fed mice, it was difficult to assess if there 
was a reduction in calorie intake during BzA-treatment because the very high-fat and 
high-fat chow given to the mice was particularly sticky and could not be accurately 
weighed. Nevertheless BzA was shown to decrease food intake of db-/- as well as that 
of db-/+ mice. This inhibitory effect of BzA on appetite is also supported by previous 
findings, reporting that the amine’s effect is mediated by the Kv1.1 potassium channel 
blockade (Banchelli et al., 2001; Pirisino et al., 2001) and probably the release of 
catecholamines and serotonin in the central nervous system (Banchelli et al., 2001). The 
hypophagic action of BzA is definitively not mediated via its oxidation by SSAO since 
inhibitor of the amine oxidase increased - instead of inhibiting - such effect. 
Surprisingly body weight gain did not show obvious change in the three 
investigated mouse models as water consumption did. In fact, the limitation of fat 
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deposition observed in treated HFD-fed mice is in apparent contradiction with the anti-
lipolytic effect of BzA detected on adipocytes in the presence of vanadate, although it 
could be explained by its central hypophagic action supposed that BzA passes the 
blood-brain barrier. On the contrary, the elevated body weight observed at the end of 
BzA treatment in db-/- mice is in line with the anti-lipolytic effect, although it is in 
contradiction with the experienced reduction in food-intake, which can be considered, 
as a consequence of disrupted leptin anorectic signalling, less important than that 
experienced by HFD mice. Unlike in other two models, BzA did not alter body weight 
gain in VHFD-mice. Conflicting data on body weight gain of the various obesity and 
diabetes models can also be the consequences of different diet composition, genetic 
background and physical activity. 
As far as we know, the hypophagic effects of BzA have been described only in 
acute experiments in behavioural studies on non obese, non diabetic mice (Banchelli et 
al., 2001; Pirisino et al., 2001) and no reduction of body weight after prolonged 
treatment has been reported to date. In earlier studies, only a slight tendency of reduced 
food consumption could be detected in Wistar rats drinking BzA while their water 
intake was significantly reduced at the end of the seven-week treatment period (Bour et 
al., 2005). If such a central hypophagic action of chronically ingested BzA persisted in 
the treated mice, it could be responsible for some of the beneficial effects observed, 
including reduced non-fasting glycemia or body weight gain, but it could not totally 
account for the improved tolerance to a glucose load. This is also supported by the 
results of BzA treatment in VHFD-fed and db-/- mice: the anti-hyperglycemic action of 
BzA was not accompanied by the reduction of body weight gain. 
To better characterise oral BzA’s action in insulin-resistant states several plasma 
markers of the metabolic disease were measured. Immunoreactive insulin was expected 
to be increased by BzA. Albeit, not decreased in the three models, an improvement in 
insulin-sensitivity was found in response to BzA supplementation in HFD-fed mice, as 
they showed a reduced HOMA index, and in db-/- mice, due to a better insulin-
responsiveness of their adipocytes. 
A decrease in plasma FFA was expected, owing to the in vivo anti-lipolytic 
effects of BzA found previously in mouse (Iglesias-Osma et al., 2004) and rat (Bour et 
al., 2005), but did not accur in any of the three models studied. 
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Circulating cholesterol and trigricerides were not expecteded to be altered by the 
treatment. Notwithstanding, oral BzA administration reduced plasma cholesterol levels 
in HFD but not in db-/- or VHFD mice. Although the decrease was mainly observed in 
the non-HDL fraction, there was no rationale of such a beneficial effect. Although it can 
be noted that, in a very recent study, various hydrazine derivatives used as carbonyl 
scavengers, but also known to inhibit SSAO and/or MAO activity, such as hydralazine, 
phenelzine and iproniazid, have been shown to exert anti-atherogenic effects, but 
without lowering circulating cholesterol (Galvani et al., 2008). A putative link between 
amine oxidase activity and cholesterol metabolism deserves to be clarified. We can also 
suggest that the reduction of body weight gain and the ameliorated glucose tolerance, 
together might also contribute to the reduction of total cholesterol.  
A decrease in leptin, adiponectin and resistin was supposed in HFD mice, 
because of the reduced adiposity of the treated animals. After all, only plasma resistin 
was found lower while leptin and adiponectine levels were unaltered in BzA-drinking 
HFD-fed mice. Reduced resistin and the slightly reduced insulin levels are consistent 
with an improvement of insulin sensitivity by BzA-treatment, leading to lowered 
glucose levels, enhanced glucose tolerance.  
An increase in fructosamine was assumed as a consequence of the long-term 
SSAO substrate ingestion, generating H2O2. The glycated plasma protein levels were 
not altered by BzA-treatment in HFD-fed and db-/- mice. 
Elevated plasma uric acid accompanied the onset of metabolic syndrome (db-/- 
vs db-/+, HFD-fed mice vs NC-fed mice) like it did in clinical studies (Yoo et al., 2005). 
BzA decreased the high circulating level of uric acid in both models. Of note, the 
lowered levels of this independent marker of cardiovascular disease risk (Gagliardi et 
al., 2009) could be regarded as protective for cardiac and renal function. Since BzA 
decreased the high circulating level of uric acid in treated HFD and db-/- mice, this 
agent can be endowed with interesting preventive properties. 
In all the treated mice, BzA did not affect the β-adrenergic, dose-dependent 
lipolytic effect of isoprenaline in adipocytes. The effect of insulin in adipocytes of HFD 
and VHFD-fed mice on stimulated lipolysis was not altered by chronic BzA 
administration, but insulin exerted a better anti-lipolytic response in db-/-. 
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Moreover, the long-term oral administration, used in our protocols, may have 
induced desensitisation of members involved in redox regulation. Intriguingly, anti-
lipolytic action of BzA (Visentin et al., 2003b) persisted even after chronic 
administration. Adipocytes of VHFD and HFD-fed mice limited their lipolytic activity 
only when BzA was combined with vanadate. Neither vanadate nor BzA (0.1 mM) 
alone was able to hamper stimulated lipolysis. However, BzA alone was effective in db-
/- mice, probably due to the increased adipose SSAO activity found in this model. This 
in vitro anti-lipolytic action clearly supports the amine’s in vivo effect on body weight. 
Similarly, in db-/- BzA alone could stimulate 2-DG uptake of isolated adipocytes but 
simultaneous presence of vanadate was demanded in adipocytes of HFD or VHFD-fed 
mice. Other examples, in which vanadate is not necessary, are the cultured 
preadipocytes 3T3-F442A (Fontana et al., 2001), 3T3-L1 adipocytes (Subra et al., 2003; 
Visentin et al., 2003a), although these lineages express much less SSAO than db-/- or 
human adipocytes (Carpéné et al., 2001a; Carpéné et al., 2001b; Morin et al., 2001; 
Visentin et al., 2001). The H2O2 generated during amine oxidation is required to be a 
sufficient trigger for the insulin-like effect of BzA, but perhaps its degradation strongly 
differs among the different models, and could be suspected to be very efficient in 
adipocytes of HFD, VHFD-fed mice or rat fat cells (Enrique-Tarancon et al., 1998; 
Figueiredo et al., 1998; Marti et al., 1998). Different oxidation states of vanadate 
(vanadate or vanadyl) or the difference in cellular antioxidant apparatus may be 
hypothesised to influence the in vitro effect. Regarding SSAO, that one may consider as 
porooxidant in view of its ability to produce H2O2, we have never experienced this kind 
of adverse effect: SSAO activity and mRNA expression was unaltered in WAT of BzA-
treated mice (Iffiú-Soltész et al., 2007), so it was for the anti-lipolytic action of BzA+V 
in isolated adipocytes. 
BzA treatment did not alter insulin-responsiveness of adipocytes of HFD-, and 
VHFD-fed mice. However, because BzA acts independently of insulin (Abella et al., 
2003a; Abella et al., 2003b; Zorzano et al., 2003), its effect on glycemia likely have 
delayed the set-up of insulin resistance and of glucotoxicity, at least in adipocytes of 
INWAT of young db-/- mice. 
The decreased nitrite concentrations in the aorta of diabetic db-/- and HFD-fed 
mice is in line with investigations known from the literature, showing decreased 
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acetylcholine-induced relaxation of the aorta in diabetic animals (Miike et al., 2008) and 
also with our results in the kidney of STZ-induced diabetes (chapter 6.3.2). The 
significantly elevated nitrite concentration in BzA-treated groups suggests an increased 
NO production. H2O2 has been reported to increase eNOS expression, and NO release 
of endothelial cells mediated by cooperative effects between PI 3-kinase/PKB-
dependent eNOS serine 1179 phosphorylation and activation of MEK/ERK1/2 (Cai et 
al., 2003; Thomas et al., 2002). However, these latter observations were not confirmed 
in long-term studies (Boulden et al., 2006). Insulin has also been described to increase 
nitrite concentraion in the aorta by inducing eNOS expression, as well. Alternatively, 
the higher aorta nitrite levels can be due to the reduction of hyperglycemia, reducing 
oxidative stress, thus improving local endothelial function. This latter hypothesis is in 
concert with the fact that in non-diabetic (db-/+) and VHFD-fed mice nitrite was 
unchanged by BzA such as plasma glucose at sacrifice. 
The lack of excessive accumulation of nitrate in the aorta of all the three studied 
models of insulin resistance after chronic BzA ingestion indicated that there was no 
increased vascular oxidative stress caused by the treatment. The following markers of 
the anti-oxidant defence systems confirmed that the treatment did not promote clear-cut 
oxidative stress: 
 unchanged SOD2 and catalase expression in the liver of HFD-fed 
mice, or in WAT of VHFD-fed mice receiving BzA 
 unaltered H2O2 production in SCWAT of treated db-/-  
Furthermore, no evident signs of excessive glycation or vascular damage, being 
the possible consequence of excessive activation of soluble or vascular SSAO and 
aldehyde-induced cross-linking (Gubisne-Haberle et al., 2004), were detected after BzA 
administration. Finally, when considering the ratio of tissue nitrate to nitrite as an 
indicator of the conversion of NO to RNS by excessive ROS, there was no indication of 
such oxidative stress in the aorta of db-/- and HFD-fed mice treated with BzA. 
Lowered plasma uric acid and increased nitrite concentration in the aorta of 
HFD-fed and db-/- mice may therefore indicate an improved endothelial function in 
BzA-treated animals instead of the expected damage. The lack of deleterious effects of 
BzA-treatment on vasculature may support the hypothesis that benzaldehyde, the 
product of SSAO -mediated BzA oxidation, is less cytotoxic than formaldehyde 
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produced by methylamine oxidation (Conklin et al., 1998; Gubisne-Haberle et al., 
2004). Therefore, we suggest that among the different possible fates for ingested BzA, a 
competition with methylamine for SSAO-mediated oxidation can occur, and as a result, 
less cytotoxic aldehyde could be generated. In this context, it should be mentioned that 
BzA can also be oxidatively deaminated by reactive aldehydes themselves such as 
methylglyoxal (produced in part by SSAO -dependent aminoacetone oxidation which is 
increased in diabetic plasma) and may limit their toxicity by acting like a scavenger 
(Akagawa et al., 2003). 
We have shown that chronic BzA administration improves glucose homeostasis 
in three models of insulin resistance and in a model of type 1 diabetes. Moreover, these 
mice, prone to develop diabetes and obesity, also reduced levels of several markers of 
the metabolic disease such as plasma cholesterol, resistin (HFD-fed mice) and uric acid 
levels (HFD-fed mice, db-/-) when drinking BzA. The oral amine supplementation 
rather improved (HFD-fed, db-/- mice) or did not affect (VHFD-fed, db-/+ mice) nitric 
oxide bioavailability in the vasculature. Chronic BzA ingestion was therefore 
definitively devoid of adverse effects on markers of oxidative stress, at least under our 
experimental conditions. 
The present findings show that oral amine administration merits testing, and is 
worthy of further investigation. As a matter of fact, the reported anti-hyperglycemic and 
hypocholesterolemic actions warrant future research for selective amine oxidase 
substrates endowed with more powerful anti-hyperglycemic properties and yet devoid 
of adverse effects. In this spirit, we set up an in vitro system to screen SSAO substrates 
as possible future anti-hyperglycemic drug candidates. 
7.4. In vitro tests for screening SSAO substrate drug 
candidates 
In vitro insulin-like effect of BzA has also been confirmed in vivo, so far. 
However some of our results can hardly be extrapolated to humans. Human WAT is 
thus a preferred model to test the SSAO-dependent insulin-like effect of several possible 
anti-hyperglycemic drug candidates, in vitro. 
The very high SSAO activity we found in human SCWAT is in accordance with 
previous findings that AOC3 gene expression dramatically increases during 
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adipogenesis of human pre-adipocytes (Bour et al., 2007a). As a consequence mature 
adipocytes express one of the highest levels of AOC3 mRNAs and SSAO activity found 
in the body (Bour et al., 2007a; Morin et al., 2001) as confirmed by various gene 
expression databases (e.g. SymAtlas from Genomic Institute for the Novartis Research 
Foundation). In our experiments, however, we used WAT homogenates for the 
determination of SSAO activity, since they are more readily availalable than freshly 
preparated adipocytes and since previous reports presented that the SSAO activity found 
in WAT homogenates was mainly due to SSAO activity of adipocytes, not to the stroma 
vascular fraction (Bour et al., 2007a). In keeping with their high SSAO activity, insulin-
like effects of amine oxidation have been described in freshly isolated human 
adipocytes (Carpéné et al., 2001a; Carpéné et al., 2001b; Morin et al., 2001; Visentin et 
al., 2001) but cannot be reproduced on disrupted cells, lacking intact insulin signalling 
pathways.  
The enzyme kinetic parameters we measured and all the above mentioned 
preceding results validated human adipose tissue, as a relevant model for testing anti-
hyperglycemic drug candidates. 
Among the simultaneously tested amines, 4-PBA and 3-MTPPA were already 
known SSAO substrates. Originally, 4-PBA was selected as a better substrate of SSAO 
from an arylalkylamine database as a result of structure activity relationship kinetic 
studies (Yraola et al., 2006). 3-MTPPA was shown to be a good substrate of bovine 
SSAO and MAO-B. 
Most amines inhibited stimulated lipolysis and activated glucose transport. Such 
insulin-like effects and SSAO-dependent H2O2 release were in strong correlation. 
However, in the case of 4-PBA and 3-MTPPA the anti-lipolytic activity was not only 
the consequence of the amine oxidation-dependent H2O2 release as their strong anti-
lipolytic effect was also kept in KO AOC3 mice. 
We suppose that 4-PBA may involve some other possible pathways which are 
independent of SSAO-related H2O2 generation. Some possible mechanisms may be: 
 MAO-dependent  
 other H2O2-generating system 
 antagonism at β-receptor 
 stimulation at α2-receptor. 
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β-receptor antagonism is not involved as the drug remains anti-lipolytic in the 
presence of forskolin which stimulates lipolysis via β-receptor-independent way. 
Furthermore, the drug did not activate glucose uptake better than BzA (not like anti-
lipolysis) as it was reported before in mouse adipocytes (Yraola et al., 2006). 
Such as 4-PBA, 3-MTPPA might also act on different sites. 3-MTPPA is also a 
substrate of MAO-B (Gallardo-Godoy et al., 2004). Nonetheless, this kind of 
characteristic is not likely to be responsible for its anti-lipolytic activity; first of all 
adipocytes do not have high MAO-B activity, second, even if it was the case, glucose 
uptake should be, as well, strongly stimulated. The involvement of β-receptor is also 
discarded, because of the pharmacon’s inhibitory effect on forskolin-stimulated 
lipolysis. 
Our results clearly show that in vitro functional tests are indispensable when 
screening for novel substrates. The measurement of SSAO activity alone does not 
predict all possible effects on adipocyte metabolism. As SSAO substrates are mainly 
monoamines, they are not only substrates for MAOs or SSAOs but they may act on 
biogenic amine receptors such as β or α2 adrenoceptors, histamine, serotonine or trace 
amine receptors, etc. 
During the experiments all substrates had insulin-like effect. Our screening 
method, however, allowed us to eliminate amines acting independently of their SSAO-
dependent H2O2 release (4-PBA, 3-MTPPA and Substrate-A) and resulted substrate-B 
as a novel leader structure for the design of new future SSAO substrates. 
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8. Conclusions 
SSAO substrates have previously been described to exert insulin-like actions in 
vivo and in vitro, thus SSAO has been proposed as a therapeutic target in diabetes.  
Our results revealed a SSAO-dependent H2O2 generation in WAT homogenate 
of mice with addition of benzylamine at 0.01 to 1 mM. A small SSAO activity was also 
detectable without addition of BzA, likely due to the oxidation of endogenous amines. 
SSAO activity was shown to be elevated in SCWAT but not PGWAT or 
PRWAT in our murine HFD-induced and genetic obesity models. 
Experiments on fasting rats unravelled that SSAO activity was spared in spite of 
weight loss. 
Investigation on isolated rodent fat cells elucidated that cells needed vanadate 
for the anti-lipolytic, lipogenic and glucose uptake stimulatory effect, and the genetic 
invalidation of SSAO hampered these BzA + V induced insulin-like properties. 
The single injection of BzA was able to improve glucose tolerance in mice and 
simultaneous administration of vanadate did not further affect this parameter. 
Chronic BzA injection lowered blood glucose in type 1 diabetic rats. Kidney 
endothelial function was only improved in the presence of vanadate. The latter was a 
result of increased NO formation rather than due to a decreased oxidative metabolism of 
NO. 
Oral BzA improved glucose homeostasis in three models of insulin resistance: 
VHFD and HFD-induced obesity and in genetically obese db-/- mice. Such anti-
hyperglycemic effect can be the consequence of: 1.) the oxidation of BzA in adipose 
tissue favouring glucose utilization and 2.) the central hypophagic action of BzA. These 
two, depending on the model may contribute to an in vivo effect in a different way. In 
all cases, BzA was devoid of adverse effects. Moreover, in HFD-fed and db-/- mice 
where BzA treatment lowered fasting glucose it also increased nitrite concentration in 
the aortae suggesting a strong relationship between these two parameters. Obviously, 
BzA can be oxidised in blood and vessels, and in WAT, which is considerably increased 
in overweight rodents and rich in SSAO activity. It is therefore conceivable that direct 
insulin-like actions of orally given BzA can occur in WAT. 
Accordingly, a very high SSAO activity was measured in human SCWAT 
compared to murine. Our test system, based on the correlation between glucose-uptake 
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or anti-lipolysis and SSAO-dependent H2O2 production was able to select Substrate-B, 
as a better SSAO substrate than BzA. The system also showed that several amines can 
also exert SSAO-independent actions on adipocyte metabolism. 
On the basis of the present findings we propose SSAO substrates as possible 
anti-hyperglycemic drug candidates worth for further experimental and clinical 
investigations. 
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Obesity and diabetes are serious public health problems in developed countries 
and considerable efforts are put in the development of drugs improving impaired 
carbohydrate metabolism. Semicarbazide-sensitive amine oxidase (SSAO) may be a 
possible target. The enzyme catalyzes the oxidation of primary amines. SSAO is highly 
expressed in white adipose tissue (WAT) and in the vasculature. It has been found that 
its soluble form in plasma is an independent cardiovascular risk factor in diabetes. 
However, the administration of exogenous SSAO substrates has been shown to reduce 
hyperglycemia in diabetic animals. Hydrogen peroxide formed during the enzyme 
reaction has been proven responsible for such effect. However, this reactive oxygen 
species may contribute to vascular complications of obesity and diabetes, as well. 
Our aim was to explore the implication of SSAO substrates on certain 
parameters of diabetes and obesity. We investigated the influence of WAT extension (in 
obesity and fasting) on its SSAO content. We have analysed the insulin-like actions of 
benzylamine (BzA), an exogenous substrate of SSAO, in vitro and in vivo. Furthermore, 
being aware of the dual action of SSAO in diabetes, we also studied the effect of long-
term BzA treatment on glucose handling and on putative vascular complications. Then, 
we tested SSAO substrate candidates in human adipocytes. 
SSAO activity was higher in subcutaneous WAT of obese than lean mice. BzA 
injection was effective alone to improve glucose homeostasis in type 1 and type 2 
diabetic animals. Chronic BzA injections also improved endothelial function of diabetic 
rats when vanadate was simultaneously administered. Chronic oral administration of 
BzA improved glucose homeostasis in three mouse models of insulin-resistance. In such 
conditions, we did not observe any adverse effect of hydrogen peroxide. Moreover, 
increased aorta nitrite concentration, indicative of NO production, accompanied the 
reduction of fasting plasma glucose levels. In keeping with this, we have set up a 
pharmacological screening, based on human adipocytes, which allowed the detection of 
better SSAO substrates than BzA. The results obtained in obese and diabetic models 
thus confirmed the beneficial metabolic action of BzA and encouraged us to propose 
SSAO substrates as possible anti-hyperglycemic drug candidates. 
106 
Összefoglalás 
PhD doktori értekezés, Készítette: Iffiú-Soltész Zsuzsa 
Gyógyszerhatástani Intézet, Semmelweis Egyetem, Budapest 
INSERM U858, Paul Sabatier Egyetem, Toulouse 
Témavezetők: Prof. Dr. Szökő Éva and Dr. Carpéné Christian 
Az elhízás és a cukorbetegség a fejlett országokat súlyosan sújtja, ezért jelentős 
összegeket fordítanak olyan gyógyszerek fejlesztésére, amelyek a megváltozott 
szénhidrát-metabolizmust célozzák helyreállítani. Az egyik ígéretes célpont a 
szemikarbazid-szenzitív aminoxidáz (SSAO). Az SSAO primer aminokat oxidál és nagy 
mennyiségben található a zsírsejtekben és az erekben. Igazolták, hogy a plazma SSAO 
független kardiovaszkuláris kockázati tényező cukorbetegségben. Ugyanakkor az SSAO 
szubsztrátjaival sikerült csökkenteni a hiperglikémiát diabéteszes állatmodellekben. A 
hatásért a reakció során felszabaduló H2O2-t tartják felelősnek. Másfelől ez a 
szabadgyökök keletkezéséhez vezető anyag hozzájárulhat az elhízás és a cukorbetegség 
vaszkuláris komplikációinak kialakulásához is. 
Célul tűztük ki az SSAO szubsztrátok elhízás és cukorbetegség egyes paraméte-
reire gyakorolt hatásának vizsgálatát. Az elhízás és éhezés hatását vizsgáltuk a különbö-
ző lokalizációjú zsírszövetek SSAO aktivitására. Megvizsgáltuk az SSAO egyik exogén 
szubsztrátjának, a benzilaminnak (BzA) inzulinszerű hatásait in vitro és in vivo. To-
vábbá, tudtában az SSAO kettős hatásának diabéteszben, nyomon követtük a hosszútávú 
BzA kezelés hatásait a glükóz háztartásra, valamint a vaszkuláris komplikációkra. Vé-
gül néhány új SSAO szubsztrát-jelölt molekula hatásait vizsgálatuk emberi zsírsejteken. 
Az elhízott egerek bőr alatti zsírszövete emelkedett SSAO aktivitást mutat. 
Diabéteszes állatok (1-es és 2-es típus) glükóz-háztartásának helyreállításához a s.c. 
BzA kezelés önállóan elegendő. A krónikus s.c. BzA kezelés vanadáttal kombinálva az 
endoteliális funkciót is javítja diabéteszes patkánymodellen. A krónikus per os BzA 
kezelés javítja a glükóz homeosztázist három inzulinrezisztens egérmodellen. Ezen 
körülmények között nem figyeltünk meg semmilyen H2O2-eredetű mellékhatást. 
Ráadásul az éhomi vércukorszint csökkenését az aortában mért emelkedett nitrit-
koncentráció kísérte, amely fokozott nitrogén monoxid termelésre utal. A humán 
zsírsejteken tesztelt vegyületek között egy bizonyult a BzA-nál jobb szubsztrátnak. 
A fenti eredmények megerősítették a BzA-kezelés kedvező hatását a szénhidrát 
anyagcserére, ami arra sarkall bennünket, hogy az SSAO szubsztrátjait lehetséges anti-
hiperglikémiás gyógyszerjelölt molekuláknak tekintsük. 
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L’obésité et le diabète sont de sérieux problèmes de santé dans les pays 
développés. Le développement de médicaments qui pourraient normaliser un 
métabolisme glucidique alteré est donc une grande nécessité actuelle. L’amine oxydase 
sensible au semicarbazide (SSAO) semble être une cible d’intérêt pour améliorer 
l’homéostasie glucidique. Cette enzyme oxyde les amines primaires. Elle est fortement 
exprimée dans le tissu adipeux blanc (WAT) et dans les vaisseaux. Sa forme circulante 
est un facteur indépendant des complications cardiovasculaires du diabète et de 
l’obésité. Cependant, l’administration des substrats exogènes de la SSAO réduit 
l’hyperglycémie des animaux diabétiques. Il a été montré que le peroxyde d’hydrogène 
formé pendant l’oxidation des amines par la SSAO tissulaire est responsable d’un tel 
effet. Pourtant, cette espèce reactive de l’oxygène, à forte dose, peut aussi contribuer 
aux complications de l’obesité et du diabète. 
Nous avons étudié l’influence des substrats de la SSAO sur certains paramètres 
de l’obésité et du diabète. Nous avons d’abord examiné l’influence de la masse du tissu 
adipeux blanc sur sa richesse en SSAO en la faisant varier expérimentalement (obésité 
et jeûne). Nous avons ensuite analysé les actions insulinomimétiques de la benzylamine 
(BzA), un substrat exogène de la SSAO, in vitro et in vivo. De plus, nous avons étudié 
l’effet de traitements à long terme par la BzA sur la tolerance au glucose et les 
éventuelles complications vasculaires. Enfin, nous avons testé des molécules nouvelles, 
substrats potentiels de la SSAO sur des adipocytes humains. 
L’activité de la SSAO augmente dans le WAT sous-cutané de souris obèses. 
L’injection de BzA améliore l’homéostasie glucidique des animaux diabétiques de type 
1 et 2. L’injection chronique de BzA améliore la function endothéliale de rats 
diabétiques si elle est effectuée simultanément avec du vanadate. L’administration 
chronique de BzA par voie orale améliore aussi la tolérance au glucose dans trois 
modèles de souris résistantes à l’insuline dans des conditions où nous n’avons pas 
observé d’effets délétères du peroxyde d’hydrogène. De plus, la concentration des 
nitrites augmente dans l’aorte, indiquant qu’une meilleure biodisponibilité du NO a 
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accompagné la réduction du glucose plasmatique. Ces résultats obtenus sur des rongeurs 
obèses et diabétiques ont confirmé l’action bénéfique de la BzA sur le métabolisme 
glucidique. En utilisant un système de criblage basé sur l’utilisation d’adipocytes 
humains, nous avons caractérisé quelques molécules plus efficaces que la BzA pour 
mimer les effets de l’insuline. L’ensemble de ce travail nous encourage à considérer les 
substrats de la SSAO comme de possibles médicaments antidiabétiques. 
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